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Abstract
No cure exists for Parkinson’s disease (PD), a disease marked by the degeneration of 
dopaminergic neurons of the substantia nigra pars compacta (SNC), a loss of dopamine 
in the dorsal striatum, and resulting motor symptoms. Furthermore, treatment of PD with 
levodopa is oft en complicated by abnormal involuntary movements (levodopa-induced 
dyskinesia, LID). Novel treatment options for PD and LID are thus greatly needed. Nicotinic 
acetylcholine receptors represent one possible novel treatment target, given the complex 
control they exert over dopaminergic neurotransmission, protective eff ects of smoking 
against PD, and extensive preclinical evidence of neuroprotective and antidyskinetic 
eff ects by nicotinic receptor ligands. Nicotinic receptor subtypes essential for nigrostriatal 
dopaminergic neurotransmission include those containing the α5 subunit, which have not 
been previously studied in the context of PD.
In this thesis, further preclinical investigations of the role of nicotinic receptors in PD 
and LID were carried out. An extensive in vivo and ex vivo characterization of the role 
of α5-containing receptors in mouse models of PD was performed. Th e eff ects on LID by 
chronic nicotine treatment in drinking water and other drug treatments were studied in 
vivo utilizing mouse models of both moderate and severe PD and LID. Th e mechanisms 
of action underlying LID and the antidyskinetic eff ects of nicotine were studied by ex vivo 
measurements of striatal dopamine release and corticostriatal brain-derived neurotrophic 
factor (BDNF). In parallel, methods for stereotactic surgery and postoperative care were 
signifi cantly improved. 
Mice lacking α5-containing nicotinic receptors were found to be less susceptible to 
unilateral nigrostriatal neurodegeneration, the resulting interhemispheric motor imbalance, 
and LID. Striatal dopamine uptake measurements suggested reduced dopamine transporter 
function as a possible mechanism of neuroprotection. Nicotine was found to inhibit LID, 
with fi ndings suggesting a role for α6β2* nicotinic receptors. However, neither nicotinic 
receptor agonists nor the clinically used drug amantadine alleviated severe LID associated 
with near-total dopaminergic denervation. Th e fi ndings also confi rmed a correlation 
between striatal BDNF and LID. Th e present fi ndings suggest the potential usability of 
α5-containing nicotinic receptors as a drug target against PD and LID. Th e fi ndings also 
confi rm the preclinical potential of nicotine as an antidyskinetic drug while suggesting 
limited effi  cacy in advanced PD. In addition, the fi ndings expand previous knowledge on 
the possible mechanisms of LID and the antidyskinetic eff ects of nicotine.
VII
Tiivistelmä
Parkinsonin taudin motoriset oireet aiheutuvat mustatumakkeen dopamiinihermosolujen 
rappeutumisesta ja dopamiinin puutoksesta aivojuoviossa. Sairaudelle ei ole löydetty 
parantavaa hoitoa. Lisäksi tahdottomat liikkeet (dyskinesia) vaikeuttavat usein 
sairauden hoitoa levodopa-lääkeaineella. Uusia mahdollisuuksia Parkinsonin taudin 
ja dyskinesian hoitoon siis tarvitaan. Asetyylikoliinin nikotiinireseptorit voisivat 
tarjota yhden mahdollisen uuden lääkevaikutuskohteen, sillä ne säätelevät aivojen 
dopamiinijärjestelmää, tupakoinnin tiedetään suojaavan Parkinsonin taudilta, ja laaja 
prekliininen näyttö viittaa nikotiinireseptoriligandeilla olevan hermosoluja suojaavia ja 
dyskinesiaa lieventäviä vaikutuksia. Dopaminergisen hermovälityksen kannalta oleellisiin 
nikotiinireseptorialatyyppeihin kuuluvat α5-alayksikön sisältävät reseptorit, joiden yhteyttä 
Parkinsonin tautiin ei aiemmin ole tutkittu.
Tässä väitöskirjassa tutkittiin nikotiinireseptorien merkitystä Parkinsonin taudissa ja 
levodopan aiheuttamassa dyskinesiassa. α5-alayksikön sisältävien nikotiinireseptorien 
merkitystä Parkinsonin taudin ja dyskinesian hiirimalleissa tutkittiin kattavin in vivo- ja 
ex vivo-kokein. Juomaveden kautta annetun pitkäkestoisen nikotiinikäsittelyn ja muiden 
lääkehoitojen vaikutuksia tutkittiin sekä kohtalaisen että pitkälle edenneen Parkinsonin 
taudin ja dyskinesian hiirimalleissa. Dyskinesian ja nikotiinin dyskinesiaa lievittävien 
vaikutusten mekanismeja tutkittiin mittaamalla ex vivo dopamiinin vapautumista 
aivojuoviosta sekä aivoperäisen hermokasvutekijän (BDNF) pitoisuuksia aivoissa. 
Samanaikaisesti stereotaktisten leikkausten ja leikkauksen jälkeisen hoidon menetelmiä 
kehitettiin merkittävästi.
α5-poistogeenisten hiirten havaittiin olevan vähemmän herkkiä dopamiinihermojen 
toispuoleiselle tuhoutumiselle, siitä johtuvalle aivopuoliskojen motoriselle epätasapainolle 
sekä levodopan aiheuttamalle dyskinesialle. Dopamiinin soluunottoa aivojuoviossa 
mitanneiden kokeiden perusteella dopamiinin kuljettajaproteiinin heikentynyt toiminta 
saattoi olla yksi hermosoluja suojaava mekanismi. Nikotiinin todettiin lievittävän levodopan 
aiheuttamaa dyskinesiaa, ja α6β2* nikotiinireseptorit voivat olla tärkeitä tämän vaikutuksen 
välittäjiä. Nikotiinireseptorien agonistit tai kliinisesti käytetty lääkeaine amantadiini 
eivät kuitenkaan lievittäneet vakavaa, lähes täydelliseen dopamiinihermokatoon liittyvää 
dyskinesiaa. Tutkimuslöydökset myös vahvistivat yhteyden BDNF:n ja levodopan 
aiheuttaman dyskinesian välillä. Tutkimuksen tulokset viittaavat siihen, että α5-alayksikön 
sisältävät nikotiinireseptorit voisivat olla mahdollinen uusi vaikutuskohde Parkinsonin 
taudin hoidossa. Löydökset myös vahvistavat nikotiinin olevan mahdollinen levodopan 
aiheuttaman dyskinesian hoitomuoto, mutta viittaavat siihen, että hoitovaste pitkälle 
edenneessä Parkinsonin taudissa voi olla heikko. Lisäksi tutkimus laajentaa aiempaa 
tietämystä dyskinesian ja nikotiinin dyskinesiaa lievittävien vaikutusten mahdollisista 
mekanismeista. 
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 1. Introduc  on
Parkinson’s disease (PD) is a progressive neurodegenerative disease aff ecting the 
dopaminergic neurons of the brain nigrostriatal pathway that leads, among other 
symptoms, to progressively worsening diffi  culties in movement (Jankovic, 2008). As 
no treatment aff ecting the progression of the neurodegeneration is available, current 
treatments for Parkinson’s disease can only alleviate its symptoms (Fox et al., 2018). While 
symptomatic treatment with the dopamine precursor levodopa is usually eff ective, long-
term treatment is oft en associated with serious adverse eff ects (Aquino and Fox, 2015). 
Among these adverse eff ects are abnormal involuntary movements, termed levodopa-
induced dyskinesia (LID), which aff ect in some form nearly every patient with long enough 
treatment. Treatment options for LID with strong evidence for effi  cacy are sparse, only 
including pharmacological treatment with amantadine and invasive deep-brain stimulation 
(Fox et al., 2018). Novel options for the treatment of PD and LID are thus sorely needed.
Such novel treatment options have been sought among many other avenues by investigating 
the role of nicotinic acetylcholine receptors (nAChRs) in Parkinson’s disease. nAChRs are 
receptors for the endogenous neurotransmitter acetylcholine and are widely expressed 
throughout the nervous system and the whole body as numerous diff erent subtypes 
(Albuquerque et al., 2009; Millar and Gotti, 2009). Exogenous ligands of nicotinic 
receptors include the prototypical and eponymous non-selective agonist nicotine, the main 
psychoactive component of tobacco, as well as many toxins and investigative drugs. In 
the central nervous system (CNS) nicotinic receptors act primarily as neuromodulators, 
regulating the activity of many neurotransmitter systems and brain areas, including the 
dopaminergic nigrostriatal pathway (Dani and Bertrand, 2007; Quik and Wonnacott, 
2011). Accumulating epidemiological and preclinical evidence suggests potential for 
nAChRs as drug targets for PD, with such fi ndings as decreased risk of PD in users of 
tobacco products, dopaminergic neuroprotection by nAChR agonists in cellular and animal 
models of neurodegeneration, and alleviation of LID by various nAChR ligands (Quik and 
Wonnacott, 2011).
Th e studies comprising this thesis utilized mouse models of PD and LID, and aimed 
at further investigation of the role of nAChRs in PD and LID as well as their potential 
usability as targets in the treatment of the disease. Particular focus was aff orded to nAChRs 
containing the α5 subunit, which have an important role in nigrostriatal dopaminergic 
neurotransmission (Salminen et al., 2004; Exley et al., 2012) but have not been previously 
studied in the context of PD. In the fi rst part of this thesis, the relevant literature will be 
reviewed, with particular attention on levodopa-induced dyskinesia and on nicotinic 
receptors in Parkinson’s disease. Th e subsequent parts contain full descriptions of the 
methods and results of the present studies. Finally, discussion will be presented both 
on methodological issues, including a brief description of the various animal models of 
Parkinson’s disease, and on the results obtained and their implications.
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2.  Review of the literature
2.1.  Basal ganglia and the nigrostriatal dopaminergic pathway
2.1.1.  Anatomy and neurocircuitry of the basal ganglia
Th e cardinal motor symptoms of Parkinson’s disease stem primarily from a selective 
progressive death of neurons in the midbrain region of substantia nigra (SN), in particular 
its subdivision substantia nigra pars compacta (SNC). Th is brain area is located within the 
basal ganglia, a group of subcortical nuclei at the base of the forebrain. Th e basal ganglia 
form an interconnected network of brain areas with many suggested and debated functions, 
including the selection of actions (Cisek and Kalaska, 2010) as well as control over 
movement speed and size, movement error correction, motor learning, and recall of motor 
skills (Turner and Desmurget, 2010). In brief, it is thought that motor information from 
the cortex and the thalamus arrives at the dorsal striatum (caudate-putamen in humans), 
where it is integrated with inputs from other basal ganglia nuclei, including dopaminergic 
input from the SNC, and then transmitted to output nuclei of the basal ganglia and from 
thereon to targets of basal ganglia output (Albin et al., 1989; Smith et al., 1998; Bolam et al., 
2000; Gerfen and Surmeier, 2011). Th e discussion in this thesis will mainly be confi ned to 
basal ganglia regions primarily related to movement control (e.g., the dorsal striatum and 
the SN). Regions that are primarily associated with limbic functions and less aff ected in PD 
(e.g., the ventral striatum and the ventral tegmental area; Joel and Weiner, 2000) will be 
mostly ignored. 
See Figure 1 for a schematic representation of the organization of the basal ganglia. Th e 
striatum is the main input nucleus of the basal ganglia and receives excitatory glutamatergic 
projections from the cortex, with essentially all sensory, motor and associative cortical areas 
sending somatotopically organized projections to the dorsal striatum (Smith et al., 1998; 
Bolam et al., 2000). In addition, the dorsal striatum receives glutamatergic projections from 
the thalamus (Doig et al., 2010). Th e vast majority of all striatal neurons (up to 95 % in 
rodents) consist of medium spiny neurons (MSN), which are inhibitory neurons utilizing 
γ-aminobutyric acid (GABA) that receive the corticostriatal and thalamostriatal inputs 
along with inputs from the midbrain such as from the SNC (Smith et al., 1998; Bolam et 
al., 2000). In turn, MSNs send striatal output to the two output nuclei of the basal ganglia, 
substantia nigra pars reticulata (SNR) and the internal segment of the globus pallidus (GPi), 
via two pathways (Smith et al., 1998; Bolam et al., 2000). Although evidence challenging 
strict segregation exists (e.g.,  Cazorla et al., 2014), these two pathways are regarded as 
largely separate, and termed the direct and indirect pathways according to the route the 
striatal information takes to arrive at the output nuclei (Figure 1). In brief, the direct 
pathway consists of direct inhibitory projections from the striatum to the SNR and the GPi. 
In contrast, the indirect pathway consists of inhibitory projections from the striatum to 
the external segment of the globus pallidus (GPe), followed by inhibitory projections from 
the GPe to not only the SNR and GPi but also to the subthalamic nucleus (STN), which 
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in turn sends excitatory projections to the SNR and the GPi. As the output nuclei SNR 
and GPi are also GABAergic and inhibitory, activation of the inhibitory direct pathway 
results in disinhibition of the target structures of basal ganglia output, while activation of 
the indirect pathway provides excitation to the output nuclei, resulting in inhibition of their 
targets (Smith et al., 1998; Bolam et al., 2000). Besides the above simplifi ed description, 
many additional projections, feedback loops and parallel interconnections are thought to 
exist, including excitatory cortical input to the STN, excitatory projections from the STN to 
the GPe, and inhibitory “bridging” collaterals from striatal direct pathway MSNs to the GPe 
(Smith et al., 1998; Gerfen and Surmeier, 2011; Cazorla et al., 2014; Ko et al., 2014).
Th e target structures of the basal ganglia output nuclei SNR and GPi include subcortical 
“premotor” regions (e.g., the superior colliculus, the pedunculopontine nucleus, and the 
Review of the literature
Figure 1. Basal ganglia organization shown in the mouse brain. Th e striatum receives input 
from the cortex and the thalamus. Th e direct pathway projects directly to the output nuclei, the 
internal segment of the globus pallidus (GPi) and the substantia nigra pars reticulata (SNr). Th e 
indirect pathway projects fi rst to the external segment of the globus pallidus (GPe) and from 
there both to the output nuclei and to the subthalamic nucleus (STN). Th e STN in turn sends 
projections to the output nuclei. Finally, the GPi and the SNR send projections to various target 
regions. Green arrows represent excitatory glutamatergic projections, other arrows represent 
inhibitory GABAergic connections. Th e fi nal outcome of direct and indirect pathway activation 
is disinhibition and inhibition of the target regions, respectively. Dopaminergic pathways are 
not shown and many connections are omitted. PPN = pedunculopontine nucleus. Republished 
with permission from Annual Reviews: Annual Reviews of Neuroscience, Gerfen and Surmeier 
(2011), © Annual Reviews 2011
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reticular formation) and, most importantly, the thalamus with its projections to motor 
and premotor cortical areas (Bolam et al., 2000). Th e classical model of basal ganglia 
neurotransmission suggests that under resting conditions the basal ganglia network 
provides tonic inhibition of the target structures, with signals originating from the cortex 
fi rst eliciting disinhibition of the target structures, mediated by the direct pathway and 
associated with behaviors such as movement, while subsequent inhibition of the target 
structures mediated by the indirect pathway acts to terminate the behavior (Albin et al., 
1989; Smith et al., 1998; Bolam et al., 2000). Further elaborations suggest that the striatum 
may act as an integrator of competing input from diff erent motor systems, with a particular 
behavior selected, and others inhibited, by coordinated activity of the two pathways (Cisek 
and Kalaska, 2010; Gerfen and Surmeier, 2011). Moreover, recent evidence suggests that 
the two pathways are likely to overlap and intertwine, with synaptic plasticity phenomena 
perhaps determining whether MSN activity encodes action initiation or inhibition 
(Calabresi et al., 2014). Based on fi ndings challenging the classical model, such as no 
impairment of movement by lesions of the GP, it has even been suggested that the basal 
ganglia do not in fact have an essential role in moment-to-moment movement control, but 
rather serve higher functions such as motor learning (Obeso et al., 2017).
2.1.2.  Dopaminergic modulation of basal ganglia neurotransmission 
Dopamine (3,4-dihydroxyphenylethylamine) is a catecholamine compound found 
particularly in brain areas involved in motor control such as the SN and the striatum (Joel 
and Weiner, 2000; Björklund and Dunnett, 2007). Neurons within the SNC send projections 
ending in dopamine-releasing synaptic terminals in the dorsal striatum (Joel and Weiner, 
2000; Björklund and Dunnett, 2007). Th ese neurons and their projections are oft en 
termed the nigrostriatal pathway. Figure 2 illustrates the major ascending dopaminergic 
pathways of the midbrain, including not only the nigrostriatal pathway but two other major 
ascending dopaminergic systems. Th e latter arise mainly from the ventral tegmental area 
(VTA) and consist of the mesolimbic pathway, projecting to the ventral striatum (nucleus 
accumbens and olfactory tubercle), and the mesocortical pathway (Joel and Weiner, 2000; 
Björklund and Dunnett, 2007). Note, however, that the common concept of a strict division 
of these dopaminergic projections is an oversimplifi cation; particularly in the primate 
brain, some SNC dopaminergic neurons send projections also to limbic and cortical areas 
and, vice versa, the dorsal striatum receives innervation also from such areas as the VTA 
(Björklund and Dunnett, 2007). Projections from various SNC subdivisions are also at 
least partially segregated according to striatal compartments (patches and matrix; Joel and 
Weiner, 2000; Matsuda et al., 2009). Further subdivisions of brain areas such as the SNC 
have also been described in various species using various nomenclature (see e.g., Björklund 
and Dunnett, 2007; Fu et al., 2012). Finally, note that midbrain dopaminergic neurons 
innervate not only the striatum and the cortex, but also many other basal ganglia nuclei 
(Björklund and Dunnett, 2007). All in all, midbrain dopaminergic systems demonstrate a 
complex organization with numerous components and signifi cant species diff erences (Joel 
and Weiner, 2000; Björklund and Dunnett, 2007).
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Midbrain dopaminergic neurons exhibit both regular spontaneous single spike fi ring 
(tonic activity) and burst fi ring (phasic activity); the latter occurs in response to novel 
external stimuli with behavioral signifi cance, particularly unpredicted rewarding stimuli, 
and has been suggested to contribute to the neural basis of reward prediction and learning 
(Schultz, 2007). Of most relevance to Parkinson’s disease, however, is the critical role that 
nigrostriatal dopaminergic neurons have in modulating basal ganglia activity underlying 
movement control. In the dorsal striatum, nigrostriatal dopaminergic neurons form 
dense, widespread, and highly overlapping axonal arborizations, where in rodents a single 
neuron can cover up to 5 % of the entire target brain area, communicating with tens of 
thousands of striatal neurons, while one striatal MSN can in turn be infl uenced by up to 
200 dopaminergic neurons (Matsuda et al., 2009). Th e main form of dopaminergic control 
of striatal activity is believed to be the modulation of the corticostriatal and possibly 
also thalamo striatal glutamatergic input to the MSN projection neurons (Surmeier et 
al., 2007; Gerfen and Surmeier, 2011). Importantly for dopaminergic modulation, direct 
pathway MSNs (dMSN) and indirect pathway MSNs (iMSN) diff er not only in their 
eff erent projections but their expression of dopamine receptors. More specifi cally, dMSNs 
express dopamine D1 receptors (D1R) while iMSNs express dopamine D2 receptors (D2R; 
Surmeier et al., 2007; Gerfen and Surmeier, 2011). 
Figure 2: Main dopaminergic areas of the ventral midbrain and ascending dopaminergic 
pathways, shown in the mouse brain. Th e nigrostriatal pathway projects from the substantia 
nigra pars compacta (SNC) to the dorsal striatum. Th e mesolimbic pathway projects from the 
ventral tegmental area (VTA) to the ventral striatum, including the nucleus accumbens and 
the olfactory tubercle (OT). Th e mesocortical pathway projects from the VTA to cortical areas. 
Anatomical accuracy approximate only. Information source: Björklund and Dunnett (2007)
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Th rough numerous molecular mechanisms, dopamine activates striatonigral dMSNs 
through D1 receptors, enhancing D1R MSN responsiveness to coordinated glutamatergic 
input, while inhibiting striatopallidal iMSNs through D2 receptors, reducing presynaptic 
glutamate release and D2R MSN responsiveness to glutamate (Surmeier et al., 2007; Gerfen 
and Surmeier, 2011). Th ese mechanisms include the modulation of such phenomena as Ca2+, 
Na+ and K+ ion currents as well as glutamate receptor function and traffi  cking (Surmeier et 
al., 2007; Gerfen and Surmeier, 2011). In addition, dopamine exerts a modulating eff ect on 
activity-dependent plasticity of striatal glutamatergic synapses, possibly mediated in part 
via interneurons, with the magnitude and direction of plasticity (depression or potentiation) 
determined in part by the presence of postsynaptic D1 vs. D2 receptors as well as dopamine 
release kinetics (Surmeier et al., 2007; Wickens, 2009; Gerfen and Surmeier, 2011). On the 
intracellular level, dopamine receptor signaling is very complex. Very briefl y, the main 
signaling pathway for D1R is the Gαs/olf- mediated activation of adenylate cyclase, resulting 
in cyclic adenosine monophosphate (cAMP) elevation and activation of protein kinase A 
(PKA), which then has numerous direct and indirect targets such as the dopamine and 
cAMP-regulated phosphoprotein, 32 kDa (DARPP-32), the extracellular signal-regulated 
kinase (ERK), and glutamatergic ion channels (Beaulieu et al., 2015). Th e main signaling 
pathway for D2R, in contrast, is the Gαi/o-mediated inhibition of adenylate cyclase; both 
receptor types also have numerous other downstream targets (Beaulieu et al., 2015).
Th e dopaminergic modulation of corticostriatal neurotransmission is in turn subject to 
complex modulation by numerous other projections and neurotransmitter systems. Striatal 
dopamine release is presynaptically modulated by D2 autoreceptors as well as numerous 
heteroreceptors such as glutamatergic, GABAergic, and nicotinic acetylcholine receptors 
(Zhang and Sulzer, 2012). In the SNC, dopaminergic neuron fi ring is regulated both by 
inputs from within the basal ganglia, including glutamatergic input from the STN and 
GABAergic input from the striatum, globus pallidus, and SNR, as well as by inputs from 
outside the basal ganglia, including motor and somatosensory cortical areas (Lee and 
Tepper, 2009; Watabe-Uchida et al., 2012). Finally, SNC dopaminergic neurons can also 
release dopamine from their somatodendritic areas, thus modulating both their own 
activity through autoreceptors and GABAergic interneurons as well as the activity of the 
basal ganglia output neurons of the neighboring SNR (Lee and Tepper, 2009; Rice and 
Patel, 2015).
Th e exact nature of how the dopaminergic modulation of corticostriatal neurotransmission 
relates to the postulated action selection function of the basal ganglia remains unclear. 
One suggestion is that the burst activity exhibited by dopaminergic neurons in response to 
rewarding events may be translated to action selection by modulation of the corticostriatal 
glutamatergic signals and striatal output (Gerfen and Surmeier, 2011). Other researchers 
believe that it is the regular tonic release of dopamine that is essential for normal basal 
ganglia function, perhaps by regulating short-term synaptic plasticity (Obeso et al., 2017). 
Nevertheless, the dramatic impact of the loss of striatal dopamine on movement initiation 
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and control, as exhibited for instance in Parkinson’s disease, demonstrates the crucial role 
of the dopaminergic modulation of the basal ganglia. In particular, imbalances between 
direct and indirect pathways may underlie the symptoms of many movement disorders (see 
2.2.2. and Figure 4).
2.1.3.  Striatal interneurons and non-dopaminergic neurotransmission
Although MSNs comprise the vast majority of striatal neurons, various interneurons also 
have signifi cant roles in striatal neurotransmission. Th ese neurons can be broadly divided 
into cholinergic interneurons and two types of GABAergic interneurons (Gittis and 
Kreitzer, 2012). Th e GABAergic interneurons, including fast-spiking interneurons and 
persistent and low-threshold spiking interneurons, comprise 3–4 % of striatal neurons and 
exert a complex regulation of striatal activity, are in turn modulated by nigrostriatal and 
corticostriatal inputs, and are thought to contribute to the pathophysiology of several basal 
ganglia-related movement disorders such as PD (Gittis and Kreitzer, 2012). Th e remaining 
1–3 % of striatal neurons are cholinergic interneurons (ChI), which exhibit widespread 
intrastriatal connectivity, exert a modulatory control on most striatal neurotransmission 
(Aosaki et al., 1994; Oldenburg and Ding, 2011), and are also thought to be involved in a 
number of movement disorders such as PD and LID (see 2.2.2. and 2.3.2.). 
Th e tonically active ChIs are thought to serve as integrators of dopaminergic and 
cholinergic infl uences in the striatum due to showing pauses in the tonic fi ring in 
response to conditioned stimuli (Aosaki et al., 1994). More recently, ChIs have been 
suggested to serve as an integral part of a thalamostriatal circuit regulating corticostriatal 
inputs to MSNs and underlying the cessation of behaviors in response to salient stimuli 
(Ding et al., 2010). Acetylcholine released by ChIs modulates MSN activity directly 
through metabotropic M1 and M4 muscarinic receptors (mAChR) as well as indirectly 
through various mAChRs expressed on corticostriatal glutamate terminals, GABAergic 
interneurons, and ChIs themselves (Oldenburg and Ding, 2011). In addition, acetylcholine 
modulates the striatal release of most neurotransmitters via presynaptic nAChRs; see 2.4.2. 
for a detailed discussion on nAChR-mediated neuromodulation in the basal ganglia. Th us, 
striatal acetylcholine acting through mAChRs and nAChRs serves as a complex modulator 
of glutamatergic neurotransmission, MSN excitability, and striatal output. Note that while 
ChIs were long considered the sole source of striatal acetylcholine, recently also direct 
cholinergic projections from the brainstem to the striatum have been described (Dautan et 
al., 2014).
In addition to those described in the above sections, still a number of other, less 
well characterized striatal inputs exist, including noradrenergic projections from the 
pedunculopontine nucleus and the locus coeruleus as well as glutamatergic projections 
from the amygdala (Parent et al., 1983; Smith et al., 1998). Finally, worth specifi c mentioning 
are serotonergic projections from the medial and dorsal raphe nuclei that innervate both 
the midbrain dopaminergic regions and the striatum (Alex and Pehek, 2007). Numerous 
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serotonin receptor subtypes participate in the regulation of striatal dopamine release (Alex 
and Pehek, 2007), and striatal serotonin terminals are also highly relevant for abnormal 
presynaptic handling of levodopa associated with LID (see 2.3.2.).
2.2.  Parkinson’s disease and dopaminergic neurodegenera  on
2.2.1.  Clinical features and epidemiology of Parkinson’s disease
Th e motor disorder now known as Parkinson’s disease was fi rst systematically described 
in western literature by James Parkinson in his seminal 1817 monograph “An Essay on the 
Shaking palsy” (reprinted as Parkinson, 2002). Th e classical clinical signs of PD include 
motor symptoms such as bradykinesia, akinesia, and hypokinesia (slowness, absence and 
decreased amplitude of movement, respectively); resting tremor; freezing; and rigidity and 
postural instability, with a typically unilateral onset (Jankovic, 2008). Motor abnormalities 
can also be seen in refl exes, speech, swallowing, respiration, and eye movements (Jankovic, 
2008). Th e particular clinical features as well as the severity and course of the disease can 
vary greatly between individuals due to poorly understood reasons (Obeso et al., 2017). 
Th e motor symptoms are typically also accompanied (and oft en preceded) by a wide 
variety of potentially disabling and distressing non-motor symptoms, such as a reduced 
sense of smell, sleep disorders, urinary and sexual dysfunction,  depression, constipation, 
hallucinations, pain, anxiety, and cognitive dysfunction (Schapira et al., 2017).
PD is the second most common neurodegenerative disease (aft er Alzheimer’s disease), 
aff ecting mainly the older population with incidence being low before the age of 50 years 
but increasing rapidly with age from there onwards (Ascherio and Schwarzschild, 2016). 
Recent estimates of the median lifetime risk are 2 % for men and 1.3 % for women aged 
40 years in the United States (Ascherio and Schwarzschild, 2016). Th e estimated annual 
costs of PD reach over 10 billion dollars in the United States alone, and the disease has 
a signifi cant negative impact on the quality of life of both patients and caregivers (Chen, 
2010). Importantly, non-motor symptoms such as cognitive dysfunction and depression 
may have an even greater impact on worsening disability and quality of life than the 
classical motor symptoms (Hely et al., 2008; Chen, 2010). Known and suspected risk and 
protective factors for PD are diverse and numerous, and the interested reader is referred to 
a recent review by Ascherio and Schwarzschild (2016).
2.2.2.  Pathophysiology of Parkinson’s disease
Features, causes and mechanisms of dopaminergic neurodegeneration
As discovered by Oleh Hornykiewicz and others already in the 1960s (Hornykiewicz, 
2006), the main hallmark of PD is the progressive death of nigrostriatal dopaminergic 
neurons with a still fundamentally unclear etiology. Another hallmark of PD diagnosis is 
the presence of intraneuronal protein inclusions termed Lewy bodies; despite not being 
specifi c to PD or strictly necessary for it, “synucleinopathies” of various forms are now 
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thought to be one of the most signifi cant contributors to PD etiology (Michel et al., 2016; 
Obeso et al., 2017).
Th e loss of midbrain dopaminergic neurons in PD is markedly selective, with the greatest 
cell loss occurring in the SNC (Bernheimer et al., 1973; Fearnley and Lees, 1991). Th e 
average magnitude of neurodegeneration observed in post mortem patient studies has 
been approximately 50–90 % of SNC cells lost, depending on the SNC subregion (Fearnley 
and Lees, 1991; Hall et al., 2014), with more than 80 % of dopamine lost in the caudate 
nucleus and 99 % in the putamen (Bernheimer et al., 1973). Compared to normal aging, 
neurodegeneration in PD progresses exponentially and roughly ten times faster (Fearnley 
and Lees, 1991). Parkinsonian neurodegeneration also exhibits a diff erent topography, 
aff ecting primarily the ventrolateral SNC, in contrast to the dorsolateral SNC being aff ected 
in normal aging (Fearnley and Lees, 1991). Th e mesolimbic pathway is also degenerated in 
PD but to a lesser degree (Hall et al., 2014). Remarkably, due to functional compensation 
motor symptoms appear only when cell loss in the SNC reaches approximately 50 %, 
accompanied by a 70–80 % loss of striatal dopamine (Bernheimer et al., 1973; Fearnley and 
Lees, 1991). 
Th e current view of the etiology of PD holds that both genetic factors and environmental 
infl uences contribute to a common pathophysiological process (Obeso et al., 2017). 
Although most cases of PD are sporadic, numerous genetic causes underlying inherited 
PD and risk variants for sporadic PD have been identifi ed (Martin et al., 2011; Ferreira and 
Massano, 2017). Th ese include mutations in genes such as SNCA (encoding the protein 
α-synuclein, the main component of Lewy bodies), LRRK2, VPS35, Parkin, DJ-1, PINK1, 
and many others, oft en encoding proteins of poorly understood function. Th e infl uence 
of the environment is apparent from the numerous known environmental risk factors 
(Ascherio and Schwarzschild, 2016), but no specifi c toxin explaining any but a small 
fraction of cases has been identifi ed (Obeso et al., 2017).
See Figure 3 for a summary of various known pathophysiological mechanisms underlying 
dopaminergic neurodegeneration in PD. Th ese mechanisms include misfolding and 
enhanced aggregation of proteins, particularly α-synuclein, resulting in the disturbance of 
numerous cell processes and possibly spreading via secretory mechanisms (Lashuel et al., 
2013; Michel et al., 2016); disruptions in protein degradation and recycling (autophagy-
lysosome and proteasome systems; Michel et al., 2016); endoplasmic reticulum stress 
(Michel et al., 2016); mitochondrial dysfunction (Michel et al., 2016); oxidative stress, 
possibly caused by dysregulation of intracellular calcium signaling or glutamatergic 
excitotoxicity (Michel et al., 2016); and neuroinfl ammation (Hirsch and Hunot, 
2009). Many of these phenomena are associated with proteins encoded by the various 
PD-associated genes (Ferreira and Massano, 2017) and, in particular, with pathological 
α-synuclein aggregation. Another fundamentally unclear question is the reason for the 
selective vulnerability of nigrostriatal dopaminergic neurons. Suggested explanations 
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include heavy energy demand and protein recycling burden due to highly branched axons, 
elevated basal mitochondrial stress due to calcium-dependent pacemaking, and numerous 
others (Brichta and Greengard, 2014; Obeso et al., 2017).
Consequences of dopaminergic neurodegeneration
Th e classical view of parkinsonian basal ganglia dysfunction is that the loss of striatal 
dopaminergic modulation results in decreased direct pathway activity and increased indirect 
pathway activity, both leading to excessive activity of the inhibitory basal ganglia output 
nuclei (SNR and GPi) and thus to excessive inhibition of their target motor regions (Figure 
4; Albin et al., 1989; DeLong, 1990). Notably, recent rodent evidence suggests that decreased 
fi ring of dMSNs may be the predominant mechanism (Ryan et al., 2018). Alterations in 
synaptic plasticity are also thought to be involved. In the rodent striatum, corticostriatal 
synapses of both dMSNs and iMSNs exhibit bidirectional synaptic plasticity – reversible 
long-term potentiation (LTP) and long-term depression (LTD) – that is controlled by 
dopamine and other neurotransmitters (Shen et al 2008, 2015). Aft er dopamine depletion, 
both LTP and LTD are lost in MSNs (Calabresi et al., 1992; Centonze et al., 1999; Picconi et 
al., 2003; Picconi et al., 2011). Further studies, separately investigating the two MSN classes, 
suggest that the loss of dopamine leads to an imbalance where dMSNs exhibit only LTD, 
while iMSNs exhibit only LTP (Shen et al., 2008; Belujon et al., 2010; Th iele et al., 2014). 
Figure 3. Simplifi ed summary of some of the pathophysiological mechanisms of Parkinson’s 
disease. Among key phenomena are pathological aggregation of proteins (in particular 
α-synuclein) and mitochondrial dysfunction, with numerous possible causes including gene 
mutations (not shown), impaired protein degradation due to dysfunctions in the proteasome 
and lysosome systems, and oxidative stress. Information sources: Hirsch and Hunot (2009), 
Martin et al. (2011), Michel et al. (2016)
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Th ese latter fi ndings appear remarkably in line with the classical model, although note that 
one study observed a similar loss of LTP in both MSN subtypes (Shen et al., 2015).
Th e current view of basal ganglia connectivity has, however, begun to move away from 
the concept of strict pathway segregation (Cazorla et al., 2014). Refl ecting this, changes 
in discharge patterns, rather than simply in neuronal activity rates, have been suggested 
to underlie parkinsonism. More specifi cally, current evidence suggests that dopaminergic 
denervation results in increased fi ring of MSNs, increased coupling between cortical and 
basal ganglia activity, and widespread excessive synchronization and oscillatory activity 
throughout the basal ganglia, where neuronal activity normally is generally asynchronous 
(Hammond et al., 2007; Ko et al., 2014; Cagnan et al., 2015; Neumann et al., 2016). In 
particular, exaggerated synchronized oscillations at the beta frequency band (8–30 Hz), 
generated locally but propagating through the basal ganglia-cortical loop, are correlated 
with parkinsonian motor impairment in both animal models and untreated patients 
Figure 4. Classical model of basal ganglia dysfunction in Parkinson’s disease and hyperkinetic 
disorders as proposed by e.g., DeLong (1990). A: In normal conditions, dopamine released from 
nigrostriatal projections activates the striatal output neurons of the direct pathway and inhibits 
the output neurons of the indirect pathway. A balance is maintained between the opposite 
eff ects of the two pathways on the basal ganglia output nuclei (GPi, SNR) and on basal ganglia 
output. B: In parkinsonism, the loss of nigrostriatal dopamine release results in reduced activity 
of direct pathway neurons and increased activity of indirect pathway neurons. Both alterations 
lead to overactivation of the output nuclei and thus to overinhibition of the target regions. 
C: In hyperkinetic disorders, such as levodopa-induced dyskinesia, uncontrolled striatal 
dopaminergic stimulation overactivates direct pathway neurons and overinhibits indirect 
pathway neurons. Both alterations lead to overinhibition of the output nuclei and to abnormal 
disinhibition of the target regions. Schematic representation of selected basal ganglia projections 
shown. Eff ects of abnormal basal ganglia output on information processing in cortical areas 
are not considered. GPe = external segment of the globus pallidus; GPi = internal segment of 
the globus pallidus; STN = subthalamic nucleus; SNR = substantia nigra pars reticulata; SNC = 
substantia nigra pars compacta
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(Hammond et al., 2007; Neumann et al., 2016). Th e role of dopamine in motor control 
may thus be to dampen excessive synchronization within the basal ganglia and to enable 
dynamic modulation of connectivity (Hammond et al., 2007; Cagnan et al., 2015). Th e loss 
of tonic dopamine release could then result in the striatum becoming unable to fi lter and 
integrate cortical motor command signals, leading to a lack of coordinated activity between 
direct and indirect pathways and an inability to select, initiate, and terminate motor action 
sequences (Hammond et al., 2007; Calabresi et al., 2014; Ko et al., 2014; Cagnan et al., 
2015).
Non-motor and non-dopaminergic pathophysiology
Refl ecting the wide variety of possible non-motor symptoms of PD (Schapira et al., 2017), 
numerous neurodegenerative and other disturbances besides those related to motor 
control have been described, both within and outside of the basal ganglia. Dopaminergic 
neurodegeneration, including not only nigrostriatal degeneration but  also damage and/or 
imbalances in mesolimbic, mesocortical, and other dopaminergic systems, may underlie 
such varied non-motor symptoms as mood and anxiety disorders, cognitive disorders, 
sleep disorders, apathy, fatigue, visual disturbances, and pain (Barone, 2010; Schapira et 
al., 2017). Degeneration of serotonergic neurons in the raphe nuclei and their projections 
to the cortex, the basal ganglia, and other brain areas has been observed in PD patients, 
and may be linked to aff ective disorders, pain, sleep disorders, and fatigue (Barone, 2010; 
Pagano et al., 2017; Schapira et al., 2017). Noradrenergic neurons in the locus coeruleus 
also degenerate in PD patients, possibly contributing to non-motor symptoms (Barone, 
2010; Schapira et al., 2017). Excessively enhanced glutamatergic activity may contribute 
to cognitive impairment and depression (Barone, 2010), while GABAergic dysfunction 
aff ecting both MSNs and interneurons is thought to contribute to aberrant synchronization 
as well as non-motor symptoms (Barone, 2010; Gittis and Kreitzer, 2012).
Th e role of the cholinergic system in PD pathophysiology merits particular mention. A 
classical hypothesis has maintained that a striatal hypercholinergic tone and a resulting 
disturbed striatal dopamine-acetylcholine balance contributes signifi cantly to parkinsonian 
motor symptoms (Barbeau, 1962). While the role of acetylcholine in the striatum has 
subsequently been much revised  (Oldenburg and Ding, 2011; see also 2.4.2.), inhibition 
of cholinergic interneuron activity can alleviate motor dysfunction in parkinsonian animal 
models (Maurice et al., 2015), suggesting that hyperactive cholinergic neurotransmission 
could indeed contribute to parkinsonism. In addition, a loss of cortical cholinergic 
innervation in PD patients has been long recognized, and the resulting depletion of cortical 
acetylcholine has been suggested to contribute to the cognitive impairment commonly 
associated with PD (Barone, 2010; Schapira et al., 2017). Indeed, drugs enhancing 
cholinergic function have long been used for treating PD-associated dementia. Moreover, 
cholinergic dysfunction has been suggested to contribute to various irregularities such 
as gastrointestinal problems, sleep disturbances, and olfactory dysfunction (Barone, 
2010; Schapira et al., 2017). Finally, drugs aff ecting nicotinic acetylcholine receptors 
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can be neuroprotective (see 2.4.4.), suggesting a signifi cant role for nAChR-mediated 
neurotransmission in PD pathophysiology.
2.2.3.  Current treatment of Parkinson’s disease and future perspectives
Th e remarkable symptomatic effi  cacy achieved in PD with the dopamine precursor 
molecule levodopa (L-dopa, L-3,4-dihydroxyphenylalanine) was discovered already in the 
1960s, not long aft er the critical role of dopamine loss became clear (Hornykiewicz, 2006). 
Today, levodopa remains the most eff ective and best-tolerated treatment against the motor 
symptoms of PD (Fox et al., 2018). Levodopa is administered orally, usually along with 
benserazide or carbidopa, inhibitors of aromatic-L-amino-acid decarboxylase (AADC), 
to block peripheral metabolism (Lewitt, 2015). In the brain AADC converts levodopa to 
dopamine, with the therapeutic eff ect stemming in particular from dopamine synthesis 
in the striatum, performed within the remaining dopamine terminals as well as serotonin 
terminals (Lewitt, 2015; see also 2.3.2.). Th e levodopa-derived dopamine acts to replace lost 
endogenous dopamine, relieving motor symptoms at least in part through the suppression 
of excessive basal ganglia-cortex synchrony (Hammond et al., 2007). Treatment with 
levodopa is usually markedly eff ective, particularly in the beginning of the treatment, and 
was at fi rst even hailed as a “miracle” (Hornykiewicz, 2006). However, as soon became 
apparent, long-term treatment with levodopa is oft en associated with a gradual appearance 
of signifi cant motor and non-motor complications (Aquino and Fox, 2015).
Levodopa-induced motor complications include levodopa-induced dyskinesia (discussed 
in detail in the following section) as well as motor fl uctuations, referring to variable or 
unpredictable therapeutic eff ects (Aquino and Fox, 2015). Motor fl uctuations can include 
delayed or even completely failed symptomatic relief; unpredictable or sudden “wearing 
off ”, referring to the re-emergence of parkinsonian motor symptoms; and potentially 
unpredictable “on-off ” fl uctuations between mobile and immobile states (Aquino and Fox, 
2015). Severe on-off  fl uctuations have fortunately become rare due to lower levodopa dosing 
strategies (Aquino and Fox, 2015). Long-term levodopa treatment oft en also results in the 
induction and fl uctuation of non-motor symptoms, with neuropsychiatric, autonomic, and 
sensory symptoms either worsening during periods of wearing off  or, conversely, appearing 
or worsening during periods of motor improvement (Bastide et al., 2015; Aquino and Fox, 
2015). 
To avoid complications, a traditional approach in the treatment of Parkinson’s disease has 
been to delay levodopa treatment as long as possible. However, more recently it has been 
suggested that this represents an unfounded “levodopa phobia” and that early treatment 
with levodopa is more benefi cial (Vlaar et al., 2011; Giannakis et al., 2018; Matarazzo et al., 
2018). More specifi cally, it has been argued that worsening levodopa-induced complications 
are more related to disease progression than the treatment itself; that delaying levodopa 
treatment does in fact not postpone motor fl uctuations; that levodopa is not toxic to 
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dopaminergic neurons contrary to earlier beliefs; and that while LID is common, it is oft en 
not disabling and should be tolerated as long as eff ective motor symptom alleviation is 
achieved (Vlaar et al., 2011; Matarazzo et al., 2018). Levodopa-induced complications can 
also oft en be mitigated by using a lower dose, but typically with the drawback of reduced 
symptomatic effi  cacy (Manson et al., 2012; Matarazzo et al., 2018). 
In addition to levodopa, a number of other pharmacological treatments exist for 
motor symptoms of Parkinson’s disease. Dopamine receptor agonists, catechol-O-
methyltransferase inhibitors and monoamine oxidase (MAO) B inhibitors are oft en used 
and eff ective; other options include anticholinergic drugs and amantadine. Diff erent drugs 
are oft en used in combination, particularly in later stages of treatment; for detailed up-to-
date treatment guidelines see Fox et al. (2018). In addition, a wide range of pharmacological 
treatments can be used to mitigate various non-motor symptoms of the disease (Schapira et 
al., 2017). Finally, deep brain stimulation (DBS) of the GP or the STN has been established 
as a remarkably eff ective treatment for parkinsonian motor symptoms, with the eff ects 
likely mediated by modulation of pathological synchronized oscillations (Fasano et al., 
2012; Guridi and Alegre, 2017).
Despite the variety of options for treating the symptoms of PD, none of them aff ect the 
progression of the disease. While dopaminergic medication can oft en provide adequate 
control of motor symptoms, the treatment of worsening non-motor symptoms such 
as cognitive dysfunction is challenging. Great eff orts have been expended – thus far 
unsuccessfully – in the search of therapies that would signifi cantly slow or stop the 
degeneration of dopaminergic neurons and the worsening clinical status of the patient. 
A plethora of treatments with a wide variety of mechanisms of action have been found 
promising in preclinical studies but clinically ineff ective (AlDakheel et al., 2014; Fox 
et al., 2018). Th e disappointing clinical results may stem in part from issues such as the 
somewhat questionable translational validity of neurotoxin-based animal models of 
PD or the challenges of measuring neuroprotection in living patients (AlDakheel et al., 
2014). Further clinical studies are continuing, and some novel targets being investigated 
include neurotrophic factors, infl ammatory pathways, calcium channels, and α-synuclein 
aggregation (AlDakheel et al., 2014) as well as nicotinic acetylcholine receptors (see 2.4.4.).
2.3.  Levodopa-induced dyskinesia
2.3.1.  Clinical features and epidemiology
Levodopa-induced dyskinesia refers to abnormal involuntary movements that typically 
arise acutely in response to a dose of levodopa. LID can be further classifi ed based on time 
of appearance (Aquino and Fox, 2015; Bastide et al., 2015). Peak-dose dyskinesia, appearing 
at the peak of levodopa action, is the most common form and typically manifests as chorea 
(involuntary, irregular, abrupt, and rapid movements oft en fl owing from one body part 
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to another), dystonia (sustained muscle contractions) or, in severe cases, ballism (large 
limb movements). Other possible forms of peak-dose dyskinesia include involuntary eye 
movements, irregular breathing, and involuntary muscle twitching. Peak-dose dyskinesia is 
the most studied subcategory of LID and also the subject of the present studies. Other types 
of LID include diphasic dyskinesia, appearing just before and at the end of the therapeutic 
eff ect, and off -period dystonia that appears outside of the therapeutic eff ect.
Th e incidence of LID increases with continuing levodopa treatment, and risk factors 
include young age, female sex, and disease duration and severity (Ahlskog and Muenter, 
2001; Manson et al., 2012; Matarazzo et al., 2018). Th e dose and duration of levodopa 
treatment are typically considered particularly signifi cant risk factors (Manson et al., 2012; 
Matarazzo et al., 2018), although interestingly a recent meta-analysis found no evidence of 
a correlation between LID and treatment dose or duration (Giannakis et al., 2018). Genetic 
risk factors include those associated with genetic parkinsonism as well as polymorphisms in 
genes encoding dopamine receptors, opioid receptors, and the brain-derived neurotrophic 
factor (BDNF; Bastide et al., 2015). LID has traditionally been considered a signifi cant 
complication, and levodopa treatment has thus been delayed for as long as possible 
(Ahlskog and Muenter, 2001; but see 2.2.3. above). However, some more recent studies have 
brought into question the traditional views on the clinical signifi cance of LID. Dyskinesia 
was more common during the early levodopa era than in modern use, possibly due to a 
more severe average disease progression at treatment initiation (Ahlskog and Muenter, 
2001). Also in modern treatment LID of some severity seems to aff ect the clear majority of 
patients aft er long enough use, with such reported rates of dyskinesia as every patient aft er 
20 years (Hely et al., 2008), about 90 % of patients aft er 9–15+ years of levodopa treatment 
(Ahlskog and Muenter, 2001), about 80 % of patients aft er 5–10 years (Chapuis et al., 2005), 
and about 80 % of patients aft er 10 years (Hauser et al., 2007). However, also somewhat 
lower incidences, such as 60 % of patients aft er 10 years (Van Gerpen et al., 2006) or only 
35 % of patients aft er 10 years and 60 % aft er 15 years (Sato et al., 2006), have been reported 
in some cohorts.
A more controversial question seems to be the incidence of clinically signifi cant dyskinesia. 
Most earlier studies did not specifi cally investigate the clinical signifi cance of LID (Ahlskog 
and Muenter, 2001), and some modern studies have reported low incidences of signifi cant 
LID. For example, Van Gerpen et al. (2006) reported signifi cant dyskinesia that could 
not be adequately controlled by medication adjustments only in 12 % of patients aft er 10 
treatment years (about 60 % with any LID); Hauser et al. (2007) reported, albeit in a small 
cohort, that only about 25 % of patients showed at least moderately disabling LID aft er 
10 treatment years (about 80 % with any LID); and a number of studies have reported 
no signifi cant impact by LID on diff erent quality of life measures aft er various treatment 
lengths (Marras et al., 2004; Rahman et al., 2008; Winter et al., 2010). On the other hand, 
a number of studies have also reported signifi cant detrimental impacts by LID on quality 
of life measures (Chapuis et al., 2005; Péchevis et al., 2005; Reuther et al., 2007). Recently, 
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a retrospective study undertaken in a large cohort of PD patients aimed at systematically 
investigating the impact of diff erent motor fl uctuations on health-related quality of life 
(Perez-Lloret et al., 2017). In this study, nearly 70 % of patients experienced some degree 
of LID aft er 9+ treatment years, and both LID and other motor fl uctuations were found 
Figure 5. Pathophysiological mechanisms of levodopa-induced dyskinesia. Abnormal presynaptic 
handling of levodopa and hyperactivation of D1 receptor signaling leads to dysfunctional synaptic 
plasticity and abnormal basal ganglia neurotransmission. BDNF = brain-derived neurotrophic 
factor; cAMP = cyclic adenosine monophosphate; D1R = dopamine D1 receptor; ERK = 
extracellular signal-regulated kinase; IEG = immediate early gene; PKA = protein kinase A
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to signifi cantly and independently correlate with quality of life. In addition, it was found 
that the severity of LID (as opposed to LID duration) may be the most important factor 
determining the subjective impact of LID. Th us, it appears that a perhaps smaller than 
previously thought but still signifi cant proportion of PD patients suff er from levodopa-
induced dyskinesia severe enough to detrimentally aff ect quality of life.
2.3.2.  Pathophysiology of peak-dose LID
Th e pathophysiology of levodopa-induced dyskinesia has been extensively studied; for 
a comprehensive and relatively recent review, see Bastide et al. (2015). Th e role of pre- 
and postsynaptic changes in LID has been the subject of great debate during the last few 
decades, but an explosion of evidence during the last ten years or so indicates – perhaps 
in the end unsurprisingly – critical contributions by both. On the most general level, it 
can be stated that LID is thought to develop in response to non-physiological striatal 
release of dopamine and pulsatile stimulation of dopamine receptors that result from the 
repeated administration of exogenous levodopa. Postsynaptic changes in striatal MSNs, in 
particular supersensitization of D1R-mediated signaling, combined with abnormalities in 
various other neurons and neurotransmitter systems, then result in alterations in synaptic 
plasticity and the neuronal fi ring patterns associated with basal ganglia neurotransmission. 
Th e current view of LID pathophysiology is summarized in Figure 5, and the underlying 
evidence will next be reviewed in some detail.
Abnormal presynaptic handling of levodopa
Th e eff ects of levodopa in vivo result from its conversion to dopamine in the brain, as 
demonstrated already in many early fi ndings of increased striatal dopamine release aft er 
levodopa administration (see references in Abercrombie et al., 1990) and inhibition of its 
behavioral eff ects when the conversion is blocked (Ungerstedt, 1971). More recently, many 
in vivo microdialysis studies have shown increased striatal extracellular dopamine levels 
aft er both local and systemic administration of levodopa in intact rats (Abercrombie et al., 
1990; Sarre et al., 1997; Opacka-Juff ry et al., 1998; Shui et al., 2000) as well as in rats with 
unilateral 6-hydroxydopamine (6-OHDA) lesions (Abercrombie et al., 1990; Brannan et al., 
1990; Brannan et al., 1998; Meissner et al., 2006; Buck and Ferger, 2008; Lindgren et al., 
2010). On the other hand, dyskinesia expressed aft er levodopa administration is associated 
with increased plasma and brain levodopa levels in human patients (Olanow et al., 1991), 
monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; Huot et al., 
2012; Porras et al., 2014), and 6-OHDA-lesioned hemiparkinsonian rats (Carta et al., 2006). 
Moreover, in 6-OHDA-lesioned rats LID is associated with increased striatal dopamine 
release (Brannan et al., 1998; Meissner et al., 2006; Buck and Ferger, 2008; Lindgren et 
al., 2010), and blocking the conversion of levodopa to dopamine prevents LID (Buck and 
Ferger, 2008). Similarly, levodopa-induced putaminal dopamine release, measured with 
positron emission tomography (PET) imaging, correlates with LID severity in PD patients 
(Pavese et al., 2006; Politis et al., 2014). Th ese fi ndings strongly suggest that the primary 
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cause of LID is indeed the striatal release of levodopa-derived dopamine. Note, however, a 
contrasting fi nding in MPTP-lesioned monkeys, where levodopa administration produced 
LID but no increased striatal dopamine release (Porras et al., 2014). Some intriguing 
fi ndings also suggest increased central levodopa bioavailability as a possible mechanism for 
LID susceptibility (Carta et al., 2006; Lindgren et al., 2010).
Th e development of LID appears to require conditions of dopaminergic denervation, as 
dyskinesia is not induced by levodopa administration in non-parkinsonian humans (Arts 
et al., 1991), monkeys (except in some rare reports;  Togasaki et al., 2001), or rodents 
(Winkler et al., 2002; Lundblad et al., 2004; Buck and Ferger, 2008; Francardo et al., 2011). 
Th e degree of denervation also aff ects LID severity. Monkeys and rodents suff ering from 
near-total dopaminergic denervation are typically more prone to develop severe LID than 
animals suff ering from a partial lesion (Schneider, 1989; Winkler et al., 2002; Lundblad et 
al., 2004; Francardo et al., 2011; however, see Guigoni, Dovero, et al., 2005 for a contrasting 
fi nding in monkeys). PET studies suggest that the situation is similar in PD patients. 
Dopamine transporter (DAT) activity in the putamen is negatively correlated with LID 
severity (Linazasoro et al., 2004) and lower in dyskinetic than non-dyskinetic patients 
(Hong et al., 2014), suggesting a correlation between dopamine terminal loss and LID.
Importantly, signifi cant changes in the presynaptic handling of levodopa besides the 
simple loss of dopamine terminals appear to underlie LID. In most microdialysis studies 
in 6-OHDA-lesioned rats the levodopa-induced striatal dopamine release was in fact 
much larger in the denervated hemisphere (Abercrombie et al., 1990; Meissner et al., 2006; 
Buck and Ferger, 2008; Lindgren et al., 2010). Similarly, human PET imaging fi ndings 
suggest that levodopa-induced striatal dopamine release increases as PD progresses (de 
la Fuente-Fernández et al., 2004; Pavese et al., 2006). Furthermore, dyskinetic patients 
show larger, but possibly shorter-lived, increases in striatal levels of levodopa-derived 
dopamine than non-dyskinetic patients (de la Fuente-Fernández et al., 2004; Politis et al., 
2014). Th e critical role of the state of the presynaptic dopamine terminals was convincingly 
demonstrated in a study where no LID was observed in rats aft er a functional knockdown 
of dopamine synthesis which left  the dopamine terminals themselves intact (Ulusoy et 
al., 2010). Notably, LID was absent even in rats previously primed for dyskinesia with a 
dopamine agonist, suggesting that if the presynaptic dopamine terminals remain intact, 
levodopa-derived dopamine can be properly stored and released and LID avoided even if 
postsynaptic dyskinesiogenic changes have occurred.
In summary, current evidence suggests that the progressive dopamine terminal loss in PD 
results in increasing abnormalities in the presynaptic handling (transport, storage, and 
release) of levodopa and levodopa-derived dopamine, leading to larger and possibly shorter-
lived transient increases in striatal dopamine release. Th e resulting pulsatile stimulation 
of postsynaptic MSN dopamine receptors is then suggested to lead to increasingly more 
severe LID (Stoessl, 2015). What, then, are the mechanisms of abnormal dopamine release 
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that become progressively more dominant as nigrostriatal dopamine terminals are lost? 
Although reduced dopamine transporter function likely plays a role (Troiano et al., 2009), 
extensive evidence points to a major contribution by striatal 5-hydroxytryptamine (5-HT, 
serotonin) terminals. 
Th e possibility of levodopa being converted to dopamine in non-physiological sites was 
suggested already during the earliest studies, given its eff ects even when dopamine 
terminals are completely lost (see Duvoisin and Mytilineou, 1978 and references therein). 
Serotonin terminals were considered one possibility, since AADC (responsible also for 
5-HT synthesis) was known to be expressed in serotonergic neurons, and indirect evidence 
existed that levodopa might be handled by them (see references in Tison et al., 1991). Later, 
direct immunohistochemical evidence for the presence of levodopa-derived dopamine in 
serotonergic neurons of the raphe nuclei and in striatal serotonin terminals was obtained 
(Tison et al., 1991; Arai et al., 1994; Arai et al., 1995). Further confi rmation was obtained in 
microdialysis studies of 6-OHDA-lesioned rats, where striatal levodopa-induced dopamine 
release was signifi cantly reduced by lesioning of the serotonergic system (Tanaka et al., 
1999) and by stimulation of inhibitory 5-HT1A autoreceptors (Kannari et al., 2001). More 
recent rodent evidence suggests that levodopa-induced dopamine release may partially 
derive from serotonin terminals also in the intact striatum (Nevalainen et al., 2014).
Levodopa-derived dopamine thus appears to be able to act as a “false transmitter”, 
synthesized in and released from serotonin terminals. Th is could certainly have benefi cial 
therapeutic consequences, particularly in late-stage PD where few dopamine terminals 
remain. However, many studies suggest that this non-physiological release of dopamine is 
also critical for LID. Foremost, the induction and expression of LID in 6-OHDA-lesioned 
rats is almost entirely blocked by both non-specifi c lesioning of the serotonergic system 
(Carta et al., 2007) and specifi c lesioning of raphestriatal serotonergic projections (Eskow et 
al., 2009). Further evidence includes fi ndings in many studies that agonists of the inhibitory 
5-HT1A and 5-HT1B autoreceptors can attenuate LID and associated striatal dopamine 
release in 6-OHDA-lesioned rats and MPTP-lesioned monkeys, whether administered 
systemically (e.g., Bibbiani et al., 2001; Carta et al., 2007; Munoz et al., 2008; Lindgren et al., 
2010) or directly to the raphe nuclei or the striatum (Eskow et al., 2009; Bishop et al., 2009). 
Note, however, that in some studies this was associated with a decreased therapeutic eff ect, 
suggesting that serotonin terminals indeed participate also in the benefi cial pro-motor 
eff ects of levodopa (e.g., Iravani et al., 2006; Bezard et al., 2013). Finally, PET imaging 
studies have shown that serotonin terminals in the striatum and the GP and their function 
are relatively more preserved in dyskinetic than non-dyskinetic PD patients, with 5-HT1A 
agonist treatment reducing levodopa-induced dopamine release (Politis et al., 2014; Smith 
et al., 2015).
Considerable evidence thus suggests the release of levodopa-derived dopamine from 
raphestriatal serotonin terminals as an essential mechanism underlying LID. Th is non-
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physiological dopamine release lacks the D2 autoreceptor-mediated feedback control 
exhibited by dopamine terminals and may thus result in large, uncontrolled increases in 
extracellular dopamine (Carta et al., 2007). Note also that besides the striatum, abnormal 
levodopa-induced dopamine release from serotonin terminals occurs also at least in the 
SN, hippocampus, and prefrontal cortex (Navailles et al., 2013). Various 5-HT1 receptor 
agonists, in turn, may suppress this non-physiological dopamine release and LID via the 
activation of various presynaptic and somatodendritic autoreceptors and heteroreceptors 
(Iderberg et al., 2015). Changes in the expression and function of the DAT, the serotonin 
transporter (SERT) and the noradrenaline transporter may also contribute to LID (Conti et 
al., 2016). 
Although PET imaging studies suggest global serotonin terminal degeneration in PD 
(Pagano et al., 2017), local serotonergic hyperinnervation may occur. In rodents, striatal 
serotonergic hyperinnervation has been observed aft er both dopaminergic denervation 
alone (Maeda et al., 2003; Bez et al., 2016) and subsequent levodopa treatment (Maeda et al., 
2005; Rylander et al., 2010). Similarly, increased serotonergic innervation was observed in 
monkeys aft er MPTP lesioning and was further increased by levodopa treatment (Zeng et 
al., 2010). Furthermore, increased SERT binding in post mortem brain tissue was observed 
in dyskinetic rats (striatum and cortex), MPTP-lesioned monkeys (striatum and GP), 
and dyskinetic PD patients (striatum and GP; Rylander et al., 2010). Serotonin terminal 
sprouting in the striatum could thus constitute a mechanism for the increased non-
physiological release of dopamine as LID develops. Interestingly, the levodopa-induced 
SERT upregulation in rats was paralleled by upregulation of Bdnf mRNA, suggesting BDNF-
mediated maladaptive plasticity as a mechanism for the serotonergic hyperinnervation 
(Rylander et al., 2010). In line with this, a recent study found that BDNF overexpression in 
rats increased striatal serotonergic fi ber sprouting and susceptibility to LID (Tronci et al., 
2017). Somewhat in contrast, however, carriers of a Bdnf gene polymorphism associated 
with lower BDNF secretion have a higher risk for developing LID (Foltynie et al., 2009; 
Kusters et al., 2018).
Changes in dopaminergic signaling in striatal medium spiny neurons
Persistently sensitized D1R-mediated signaling in dMSNs is usually considered the most 
critical postsynaptic phenomenon underlying LID, regardless of whether it is thought to 
result primarily from the levodopa-induced pulsatile stimulation (Stoessl, 2015) or already 
from the loss of striatal dopaminergic innervation (Nadjar et al., 2009). While striatal D1R 
numbers are mostly unchanged in PD patients (Hurley et al., 2001), studies in animal 
models suggest that their signaling is enhanced (Aubert et al., 2005). Th is is at least in 
part the result of decreased D1R desensitization due to increased membrane expression 
and reduced internalization (Guigoni et al., 2007; Berthet et al., 2009). In addition, the 
expression patterns of a number of desensitization-regulating kinases and arrestins are 
changed by dopaminergic lesions and subsequent levodopa treatment (Bezard et al., 
2005; Ahmed et al., 2008; Ahmed et al., 2015). Dysregulated lateral diff usion along the 
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cell membrane (Porras et al., 2012) and inhibited proteasomal degradation (Berthet et al., 
2012) have also been indicated as mechanisms of D1R sensitization. Finally, the G-protein 
mediator of D1R activation Gαolf is upregulated in the striatum of PD patients and animal 
models, possibly contributing to the supersensitized signaling (Hervé et al., 1993; Corvol et 
al., 2004; Alcacer et al., 2012). 
Th e intracellular consequences of the supersensitized D1R signaling that are closely 
associated with LID include increased expression of prodynorphin (Cenci et al., 1998) and 
a number of immediate-early gene (IEG) products such as FosB/ΔFosB (Andersson et al., 
1999), Zif-268 (Carta et al., 2005), Arc (Sgambato-Faure et al., 2005), and c-Fos (Santini 
et al., 2007). Th e critical role of ΔFosB overexpression in particular is refl ected in striatal 
ΔFosB overexpression alone resulting in LID-like behavioral sensitization to levodopa (Cao 
et al., 2010). Recent evidence further suggests that ΔFosB accumulation in MSNs results in 
altered electrical properties leading to LID (Engeln et al., 2016). In addition, comprehensive 
gene expression studies in rodents have found levodopa treatment and LID to be associated 
with changes in the expression of hundreds of genes, implicating among other things 
increased transcriptional and synaptic activity (Konradi et al., 2004; El Atifi -Borel et al., 
2009; Heiman et al., 2014).
Rodent studies have elucidated in detail the intracellular pathways, downstream of the 
supersensitized D1 receptors, that are associated with LID. In brief, sequential as well as 
parallel hyperactivation of Gαolf, cAMP production, PKA, DARPP-32, and the extracellular 
signal-regulated protein kinase (ERK) occurs in response to dyskinesia-inducing levodopa 
administration (Gerfen et al., 2002; Picconi et al., 2003; Pavón et al., 2006; Santini et al., 
2007; Westin et al., 2007; Santini, Alcacer, et al., 2009; Alcacer et al., 2012). Th is activation 
cascade results in altered transcription of prodynorphin and the IEGs, at least in part 
through dysregulation of the mitogen- and stress-activated kinase 1 and altered histone 
H3 phosphorylation (Santini et al., 2007; Darmopil et al., 2009; Feyder et al., 2016). Other 
key components modulating the LID-associated D1R-mediated ERK pathway activation 
include the Ras-guanine nucleotide-releasing factor 1 (Fasano et al., 2010) and mGluR5 
glutamate receptors (Fieblinger et al., 2014). ERK-induced activation of the mammalian 
target of rapamycin complex 1 and resulting altered translation also plays a role (Santini, 
Heiman, et al., 2009). Th ese extensive rodent fi ndings have been in part replicated in 
primates: elevated striatal ΔFosB levels are found in PD patients (Tekumalla et al., 2001), 
and LID in MPTP-lesioned monkeys has been associated with increased prodynorphin and 
ΔFosB expression (Berton et al., 2009) as well as increased cAMP/PKA/DARPP-32 and 
ERK signaling (Santini et al., 2010). One fi nal functional result of these alterations may be 
aberrant synaptic plasticity (see 2.3.2.). Finally, ERK hyperactivity appears to not persist 
during long-term levodopa treatment, suggesting that the ERK pathway may be primarily 
involved in sensitization while DARPP-32-mediated signaling may be responsible for LID 
maintenance (Santini et al., 2010; Ahmed et al., 2015). 
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Notably, many of the aforementioned cellular alterations as well as related gene expression 
changes have been found to occur and/or persist specifi cally in D1R-expressing dMSNs 
(Carta et al., 2005; Sgambato-Faure et al., 2005; Darmopil et al., 2009; Santini, Alcacer, et 
al., 2009; Santini et al., 2012; Heiman et al., 2014). Recent optogenetic experiments further 
suggest that although other mechanisms also contribute, LID is primarily associated 
with the activation of a subset of D1R-expressing MSNs in the dorsal striatum, selective 
re-activation of which is suffi  cient to induce dyskinesia in parkinsonian rodents (Hernández 
et al., 2017; Perez et al., 2017; Girasole et al., 2018; Ryan et al., 2018). LID is also associated 
with increased GABA release in the SNR, possibly refl ecting the dMSN hyperactivation 
(Bido et al., 2011). Th e roles of other dopamine receptors in LID pathophysiology have been 
much less studied. Although the expression of D2 receptors is not changed by levodopa 
treatment (Aubert et al., 2005; Guigoni et al., 2007), they are thought to contribute to LID 
given such fi ndings as D2R agonist-induced dyskinesia in animal models (Blanchet et al., 
1993), inhibition of LID by selective iMSN stimulation (Alcacer et al., 2017), and association 
of LID with changes in D2R-specifi c signaling proteins (Gold et al., 2007). D3 receptors 
(D3R) also likely have a role, as LID is associated with increased striatal D3R expression 
in monkeys (Bézard et al., 2003), and selective D3R ligands modulate LID in animal 
models (Bézard et al., 2003; Kumar et al., 2009). Interestingly, D3R-D1R interactions may 
contribute to D1R sensitization and thus LID via regulation of membrane anchoring and 
internalization (Berthet et al., 2009). Furthermore, levodopa administration can increase 
corticostriatal BDNF release and trigger BDNF-mediated D3R overexpression (Guillin et 
al., 2001); BDNF might thus have a role in D1R sensitization. Finally, D4 receptors may also 
contribute to LID (Huot et al., 2015).
Changes in other neurotransmitter systems and brain regions
Acetylcholine released by striatal cholinergic interneurons exerts a complex modulation 
over corticostriatal neurotransmission (see 2.1.3.), and ChIs play a signifi cant role also 
in LID. In rodents, striatal dopamine depletion results in increased acetylcholine release 
(Ding et al., 2006). Subsequent dyskinesia-inducing levodopa treatment was found to 
result in a switch in ERK hyperactivation from MSNs to ChIs, leading to enhanced ChI 
fi ring both basally and in response to dopamine (Ding et al., 2011). Very interestingly, 
selective elimination of striatal ChIs before levodopa treatment almost completely blocked 
the development LID without aff ecting therapeutic effi  cacy (Won et al., 2014). A recent 
optogenetic study by Bordia et al. (2016) further characterized the role of ChIs in LID. 
Short pulse stimulation of ChIs, presumably generating a limited amount of acetylcholine 
release, increased LID via mAChRs and even induced dyskinesia in previously non-
dyskinetic animals. In contrast, longer pulse stimulation, presumably resulting in greater 
acetylcholine release and possibly desensitization of nicotinic receptors, reduced LIDs via 
both mAChRs and nAChRs. In rodents, at least, acetylcholine released by ChIs can thus 
aff ect LID both through mAChRs, expressed directly on MSNs as well as on multiple other 
striatal neuron and terminal types (Oldenburg and Ding, 2011), and through nAChRs. See 
2.4.4. for a detailed discussion on nAChRs and LID.
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Overactivation of glutamatergic neurotransmission in the basal ganglia also contributes 
signifi cantly to LID (Robelet et al., 2004). While dopamine depletion in rodents results in 
a dramatic pruning of corticostriatal synapses, dyskinesiogenic levodopa administration 
induces enlargement of the remaining spines and facilitation of synaptic transmission 
in dMSNs while restoring spines but inhibiting synaptic transmission in iMSNs (Suarez 
et al., 2016). Numerous changes in glutamate receptor composition, localization, and 
activity also occur in association with dopaminergic denervation and LID (Mellone and 
Gardoni, 2018). Other neurotransmitter systems thought to contribute to LID expression 
include the serotonergic system (Navailles et al., 2013; see also 2.3.2.) as well as the opioid, 
endocannabinoid, and noradrenergic systems (Fox and Brotchie, 2014). Interestingly, also 
histaminergic neurons that densely innervate the striatum are able to take up levodopa 
and release levodopa-derived dopamine, suggesting that they could contribute to non-
physiological dopamine release (Yanovsky et al., 2011). Besides the striatum, overactivation 
of other basal ganglia structures may underlie various levodopa-induced non-motor 
complications (Guigoni, Li, et al., 2005). Also many brain areas outside of the basal 
ganglia are involved in LID, with widespread levodopa-induced changes observed in IEG 
expression (Bastide et al., 2014) and monoamine release (Navailles et al., 2013; Engeln et 
al., 2015). Recent studies also indicate the involvement of various cortical areas (see next 
section). Finally, non-neuronal phenomena that may contribute to LID include alterations 
in cerebral blood fl ow, angiogenesis, and blood-brain barrier permeability (Ohlin et al., 
2012).
Alterations in basal ganglia neurotransmission
Th e classical model of hyperkinetic disorders such as LID postulates that excessive 
dopaminergic stimulation of the D1R-expressing dMSNs and, in parallel, excessive 
inhibition of the D2R-expressing iMSNs both lead to overinhibition of the basal ganglia 
output nuclei (GPi/SNR) and thus to pathological disinhibition of the target motor 
regions (Figure 4; DeLong, 1990). Supporting the model are fi ndings of decreased fi ring 
frequency and altered fi ring patterns of single GPi neurons during dopamine receptor-
mediated dyskinesia in parkinsonian monkeys and in PD patients (Papa et al., 1999; 
Boraud et al., 2001; Lee et al., 2007). Also in line is the extensive evidence demonstrating 
supersensitization of D1R-mediated signaling in dMSNs (see 2.3.2.) as well as recent 
optogenetic fi ndings showing that levodopa increases dMSN fi ring while decreasing iMSN 
fi ring in rodents (Ryan et al., 2018).
Aberrant synaptic plasticity at glutamatergic corticostriatal synapses is believed to be a 
particularly critical mechanism underlying LID. As described above (2.2.2.), in rodents 
striatal dopamine depletion results in the loss of bidirectional synaptic plasticity and an 
imbalance where dMSNs exhibit only LTD while iMSNs only show LTP (Th iele et al., 
2014). Subsequent levodopa treatment results in further, potentially maladaptive changes 
in plasticity. In ex vivo electrophysiological studies, the absent plasticity phenomena were 
restored in animals treated chronically with levodopa, possibly refl ecting symptomatic 
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benefi t; however, in dyskinetic animals the restored LTP was resistant to depotentiation 
(reversal) and LTD was not restored (Picconi et al., 2003; Picconi et al., 2008; Picconi et al., 
2011). Th erefore, LID was suggested to be caused by abnormal persistent storage of motor 
information (Picconi et al., 2003). In further ex vivo studies, the situation associated with 
LID was found to be essentially the opposite of the parkinsonian state: dMSNs exhibited 
only LTP, furthermore resistant to depotentiation, while iMSNs exhibited only LTD (Th iele 
et al., 2014; Shen et al., 2015). Notably, these fi ndings are fully consistent with the classical 
model of overactivation of dMSNs and underactivation of iMSNs.
However, also contrasting fi ndings have been reported. An in vivo study in rats found LID 
to be associated with abnormally persistent LTD in dMSNs and LTP that is abnormally 
sensitive to reversal in iMSNs (Belujon et al., 2010), fi ndings that appear quite diffi  cult 
to reconcile with the ex vivo fi ndings or the classical model. Th e relative signifi cance of 
aberrant indirect pathway activity in LID has also been questioned (Ko et al., 2014), and 
recent evidence indeed seems to point to a much more critical role for dMSNs (Girasole 
et al., 2018; Ryan et al., 2018). Nevertheless, at least some form of impaired bidirectional 
plasticity does appear to be associated with rodent LID. Th e cellular mechanisms of altered 
plasticity phenomena have been suggested to include ERK hyperactivation (Cerovic et al., 
2015), hyperphosphorylation of PKA, DARPP-32, and glutamate AMPA receptors (Picconi 
et al., 2003; Santini et al., 2007; Santini et al., 2010), and morphological and receptor-
level alterations in corticostriatal glutamatergic synapses (Suarez et al., 2016; Mellone and 
Gardoni, 2018). Studies in dyskinetic PD patients have provided some evidence of abnormal 
plasticity also in humans, showing e.g., impaired depotentiation of LTP-like synaptic 
facilitation in the motor cortex and the basal ganglia output nuclei (Huang, Rothwell, et al., 
2011; Prescott et al., 2014). 
Finally, as in the case of PD pathophysiology (see 2.2.2.), the focus of studies on basal 
ganglia neurotransmission in LID has begun to turn from activity rates within segregated 
pathways to pathologically synchronized activity. Th is follows in particular from the fact 
that further silencing of the GPi with lesioning does not provoke but alleviates LID in 
PD patients (Fasano et al., 2012) – a fi nding completely in contrast to the classical model. 
Recordings made in PD patients through DBS electrodes in the STN have revealed that LID 
is associated with reduced beta band activity (possibly in part refl ecting the therapeutic 
eff ect) and, notably, increased alpha-theta band (4–10 Hz) oscillations that are coherent 
with cortical motor activity (Alonso-Frech et al., 2006; Rodriguez-Oroz et al., 2011). Th is 
increased synchronization is suggested to allow the release of involuntary motor sequences 
(Ko et al., 2014), and silencing the GPi is thought to result in benefi cial disruption of the 
abnormal synchronicity (Guridi and Alegre, 2017). Furthermore, recent studies in patients 
and animal models have associated LID with neuronal activation, anatomical changes, and 
aberrant high-frequency oscillations in various cortical areas, along with abnormal cortex-
basal ganglia connectivity (Cerasa et al., 2015; Herz et al., 2015; Swann et al., 2016; Girasole 
et al., 2018).
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2.3.3.  Current treatment options for LID and future perspectives
Th e current treatment options for LID remain relatively sparse and with signifi cant 
drawbacks (Fox et al., 2018). Delaying levodopa treatment is a traditional but controversial 
approach (see 2.2.3.). DBS of the STN or the GPi typically results in signifi cant and long-
lasting improvement of both parkinsonism and LID (Moro et al., 2010; Fasano et al., 2012). 
Th e antidyskinetic eff ects of GPi-DBS are direct and acute, while the eff ects of STN-DBS 
are delayed and believed to be mediated through reduced levodopa dosages (Fasano et al., 
2012; Bastide et al., 2015). However, DBS is typically not considered as a fi rst-line treatment 
and may result in adverse eff ects such as cognitive decline or mood disorders (Fasano et al., 
2012).
Th e only pharmacological treatment for LID with reasonably strong evidence for effi  cacy 
is amantadine (Fox et al., 2018). Amantadine is a glutamate NMDA receptor antagonist 
with a wide variety of additional targets (Blanpied et al., 2005; Bido et al., 2011). In 
rodents, amantadine prevents levodopa-induced GABA increases in the SNR (Bido et 
al., 2011), possibly refl ecting inhibition of dMSNs. Some controversy has existed on the 
long-term effi  cacy of amantadine, with one controlled clinical study showing a signifi cant 
antidyskinetic eff ect but a benefi t lasting less than 8 months (Th omas et al., 2004). However, 
other controlled clinical studies have observed effi  cacy lasting for 1 year, albeit in a small 
population (Metman et al., 1999), and that cessation of amantadine aft er 0.5–1 years of 
treatment worsened LID (Wolf et al., 2010; Ory-Magne et al., 2014). Recently, long-
term (up to 2 years) controlled trials of extended-release amantadine showed signifi cant 
antidyskinetic effi  cacy over placebo (Elmer et al., 2018; Isaacson et al., 2018). However, the 
results also suggest that not all patients benefi ted, and furthermore adverse eff ects resulted 
in a discontinuation rate of 20 % (8 % for placebo). Th us, amantadine treatment may not 
suitable or benefi cial for all patients. Amantadine has also been reported to have neurotoxic 
and genotoxic eff ects in mice, albeit only at high doses (Kaefer et al., 2010).
Many preclinically and even some clinically promising future treatment avenues exist 
(Bastide et al., 2015). Delivery of levodopa via continuous intrajejunal infusion, aiming 
at avoiding pulsatile dopamine release, was recently found to provide eff ective symptom 
relief with reduced dyskinesia that lasted for many years (Fernandez et al., 2018). However, 
a high frequency of adverse events such as device failures suggests that further technical 
development may be necessary. Other novel levodopa delivery modes have included 
controlled-release formulations and subcutaneous or intrapulmonary administration 
(Poewe and Antonini, 2015). Th e atypical antipsychotic clozapine may be eff ective against 
LID but has signifi cant safety concerns (Fox et al., 2018). Refl ecting the role of serotonin 
terminals in LID, a 5-HT1A/B autoreceptor agonist showed antidyskinetic eff ects in a small 
controlled clinical trial (Svenningsson et al., 2015). Besides amantadine, other drugs acting 
at glutamate receptors have been studied with mostly confl icting clinical results (Mellone 
and Gardoni, 2018). Some other drugs with preliminarily promising clinical results include 
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MAO-B inhibitors, cannabinoids, and α2 adrenergic receptor antagonists (Bastide et al., 
2015). Finally, preclinical studies suggest nAChR ligands as potential antidyskinetic drugs 
(see 2.4.4.).
2.4.  Nico  nic acetylcholine receptors in Parkinson’s disease
2.4.1.  Nicotinic receptor structure and function 
Cholinergic innervation, utilizing acetylcholine as a neurotransmitter, covers most of the 
mammalian brain (Figure 6; Karczmar, 2007). Th e cholinergic system thus modulates 
neurotransmission in numerous brain areas, including the nigrostriatal dopaminergic 
pathway (Dani and Bertrand, 2007). Cholinergic neurotransmission is critical also in the 
neuromuscular junctions and autonomic ganglions of the peripheral nervous system (Mao 
et al., 2006; Martyn et al., 2009). Furthermore, acetylcholine and its receptors are found on 
numerous non-neuronal cells such as glia, endothelial cells and immune cells (Albuquerque 
et al., 2009). Th e two main types of acetylcholine receptors are the G-protein-coupled 
muscarinic receptors (Scarr, 2012) and nicotinic receptors, ion channel receptors consisting 
of fi ve subunits (Figure 7; Albuquerque et al. 2009).
Figure 6. Cholinergic innervation in the rodent brain. Widespread innervation throughout the 
brain arises from cholinergic neurons located in several nuclei of the basal forebrain as well 
as in the pedunculopontine nucleus (PPN) and the laterodorsal tegmental nucleus (LDT) of 
the brainstem. In addition, local cholinergic interneurons densely innervate the striatum. 
Simplifi ed representation with selected pathways and target areas shown. Anatomical accuracy 
approximate only. IPN = interpeduncular nucleus LC = locus coeruleus; SN = substantia nigra; 
RN = raphe nuclei; VTA = ventral tegmental area. Information sources: Karczmar (2007), 
Dautan et al. (2014)
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Figure 7. Nicotinic acetylcholine receptor structure. A: Schematic of a nicotinic receptor. 
Five transmembrane subunits form a central aqueous pore permeable to specifi c cations. 
Acetylcholine binding sites are located in the extracellular domain. B: Schematic of the 
pentameric structure of a nicotinic receptor. Examples of a homomeric (α7) and a heteromeric 
(α4β2) receptor are shown. Acetylcholine binding sites are formed at subunit interfaces. Adapted 
with permission from Springer Nature: Nature Reviews Neuroscience, Changeux (2010), © 
Springer Nature 2010 
Nicotinic receptors can be either homomeric or heteromeric, with 17 diff erent subunits 
(α1–α10, β1–β4, γ, δ, ε) found in vertebrates (Albuquerque et al., 2009; Millar and Gotti, 
2009). Subunits α1, β1, γ, δ, and ε are expressed only in neuromuscular junctions, while the 
other 12 subtypes (α2–α10, β2–β4) form neuronal nAChRs expressed in the CNS and in 
autonomic ganglions (Albuquerque et al., 2009; Millar and Gotti, 2009). Note that also non-
neuronal cells express the “neuronal” nAChR subtypes (Albuquerque et al., 2009; Millar 
and Gotti, 2009). Although cloned subunits are able to form a vast variety of combinations, 
tightly controlled transcription, assembly, and post-translational modifi cation of native 
nAChRs enables the expression of only certain subunit combinations depending on the 
brain area and cell type (Albuquerque et al., 2009). Nevertheless, for instance Millar and 
Gotti (2009) list as many as 29 diff erent receptor subtypes identifi ed in the vertebrate 
nervous system. nAChR subtypes are usually referred to by their subunit composition, with 
an asterisk denoting the possible inclusion of other subunits (e.g., α4β2*; Millar and Gotti, 
2009). Th e majority of neuronal nAChRs are either homomeric α7 nAChRs or heteromeric 
nAChRs consisting of a single type of α and β subunits, most commonly α4β2 (Millar and 
Gotti, 2009). However, also many diverse subtypes composed of more than two diff erent 
subunits are found in numerous brain areas (Millar and Gotti, 2009). See Figure 8 for a 
depiction of the expression of (some of) the known nAChR subtypes in the rodent nervous 
system. nAChR expression in primates is less extensively studied but known to exhibit 
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comparable diversity, with many similarities but also some species diff erences in subtype 
expression (Zoli et al., 2015).
Acetylcholine binding sites in nAChRs are located at interfaces between an α subunit 
and another subunit (in neuronal nAChRs another α, β2, or β4), while subunits α5, β1, 
and β3 do not directly participate in ligand binding but can aff ect it (Albuquerque et 
al., 2009). Aft er a ligand interacts with a binding site, hydrogen bond reorganization 
generates a rotational movement that propagates to the transmembrane domain and leads 
to channel opening via displacement of pore-blocking residues and widening of the pore 
(Albuquerque et al., 2009). In the neuromuscular junction this results in Na+ infl ux and 
Figure 8. Diversity of neuronal nicotinic receptor expression in rodents. Receptor subtypes were 
collected from studies using knock-out mice and various methods to detect subunit mRNA and 
assembled receptors. Adapted with permission from Elsevier: Neuropharmacology, Millar and 
Gotti (2009), © Elsevier 2008
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muscle depolarization (Martyn et al., 2009). Activation of neuronal nAChRs can also lead 
to Na+ infl ux and fast membrane depolarization; however, changes in intracellular Ca2+, 
through infl ux via nAChRs themselves and through activated voltage-dependent calcium 
channels, as well as through release from intracellular reserves, are considered more 
important (Dajas-Bailador and Wonnacott, 2004; Dani and Bertrand, 2007; Albuquerque et 
al., 2009). Neuronal nAChR stimulation can activate numerous calcium-dependent kinases 
and downstream transcription factors, and nAChR-mediated alterations in intracellular 
calcium signaling are associated with many cellular phenomena such as neurotransmitter 
release, gene expression, neuronal plasticity, and apoptosis (Dajas-Bailador and Wonnacott, 
2004; Albuquerque et al., 2009).
A characteristic property of nAChRs is agonist-induced desensitization, leading to a 
state where the receptor cannot be activated despite still binding ligands with a high 
affi  nity (Picciotto et al., 2008). nAChR agonists and antagonists can therefore have similar 
pharmacological eff ects and, conversely, a nAChR agonist can have variable and even 
simultaneous agonist and antagonist eff ects (Picciotto et al., 2008). Another typical property 
of nAChRs is altered receptor expression (up- or downregulation) in response to chronic 
agonist treatment (Picciotto et al., 2008; Albuquerque et al., 2009). Both desensitization 
kinetics and the amount and direction of expression changes depend on the subunit 
composition of the receptor as well as issues such as ligand concentration and duration of 
exposure (Picciotto et al., 2008). 
Both somatodendritic (postsynaptic) and presynaptic nAChRs exist, and a signifi cant 
part of nAChR-mediated neurotransmission is also suggested to be non-synaptic volume 
transmission (Dani and Bertrand, 2007; Albuquerque et al., 2009). Somatodendritic 
nAChRs mediate fast excitatory neurotransmission mainly in neuromuscular junctions and 
autonomic ganglions (Mao et al., 2006; Martyn et al., 2009), although they are also found in 
restricted CNS locations such as in the hippocampus and the substantia nigra (Albuquerque 
et al., 2009; see also next section). Th e main function of nAChRs in the CNS, however, 
is thought to be the modulation of neurotransmitter release, mediated by presynaptic 
nAChRs located on nerve terminals. Presynaptic nAChRs stimulate or enhance the release 
of neurotransmitters via elevation of the intracellular calcium concentration and calcium-
dependent exocytosis (Dajas-Bailador and Wonnacott, 2004; Albuquerque et al., 2009). 
Note that also axonal and “preterminal” nAChRs that modulate action potential-dependent 
neurotransmission exist (Albuquerque et al., 2009). As cholinergic neurons innervate 
most of the brain, and neuronal nAChRs modulate the release of most neurotransmitters 
(Dani and Bertrand, 2007), disruption of nAChR-mediated neurotransmission has been 
associated with numerous disorders (Taly et al., 2009). Accordingly, nAChR ligands have 
been suggested as possible treatments for many diseases such as Parkinson’s disease, 
Alzheimer’s disease, nicotine addiction, depression, and attention disorders (Taly et al., 
2009).
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2.4.2. Nicotinic receptor-mediated neuromodulation in the basal ganglia
Perhaps the most studied example of nAChR-mediated neuromodulation is the 
regulation of basal ganglia neurotransmission. In particular, the complex regulation of 
midbrain dopaminergic neuron activity and the striatal release of dopamine and other 
neurotransmitters by nAChRs has been extensively studied, and involves numerous 
nAChR subtypes located on diff erent neurons (see Figure 9; Quik and Wonnacott, 
2011). Electrophysiological evidence suggests the expression of somatodendritic α6β2*, 
α4(non-α6)β2*, and α7 nAChRs on dopaminergic neurons of the mouse SNC, with 
some heteromeric receptors possibly also including the α5 subunit (Klink et al., 2001). 
Immunoprecipitation studies in 6-OHDA-lesioned rats further suggest that the heteromeric 
somatodendritic nAChRs may include α4β2, α2α4β2, α4α5β2, α4β2β3, and α4α6β2β3 
subtypes (Gotti et al., 2010). However, the SN and the VTA were not separated, and their 
somatodendritic dopaminergic neuron nAChRs do diff er (Klink et al., 2001; Keath et al., 
2007). Some of these subtypes could also be only destined for traffi  cking to terminal areas.
While there is no evidence of postsynaptic nAChRs on striatal MSNs (Quik and Wonnacott, 
2011), nAChRs located on striatal dopamine terminals indirectly modulate MSN activity. 
Immunoprecipitation experiments in nAChR subunit-knockout mice and 6-OHDA-
lesioned rats suggest the expression of α4β2, α4α5β2, α4β2β3, α6β2β3, and α4α6β2β3 
nAChRs on striatal dopamine terminals (Champtiaux et al., 2003; Gotti et al., 2010). 
Figure 9. Suggested subtypes and neuronal localization of nicotinic receptors contributing to 
neuromodulation in the rodent basal ganglia. nAChR subtypes modulating neurotransmitter 
release and local interneuron activity in the substantia nigra pars compacta (SNC, left ) and the 
striatum (right) are shown. Th e positioning of the fi gure elements does not refl ect anatomical 
proportions. ACh = acetylcholine; DA = dopamine; GABA = γ-aminobutyric acid; GLU = 
glutamate; NA = noradrenaline; STN = subthalamic nucleus; 5-HT = 5-hydroxytryptamine 
(serotonin)
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Knockout mice studies have shown that dopamine release from striatal synaptosomes is 
modulated largely by the same nAChR subtypes, although a role was suggested also for 
α6β2 nAChRs and a contribution by α4β2β3 nAChRs could not be confi rmed (Champtiaux 
et al., 2003; Salminen et al., 2004; Salminen et al., 2007). A particularly noteworthy nAChR 
population are the α6 subunit-containing (α6*) nAChRs, which in rodents are selectively 
expressed in dopaminergic and noradrenergic nuclei (Le Novère et al., 1996) and, in the 
striatum, on dopamine terminals (Quik, Sum, et al., 2003). Th is expression profi le suggests 
that α6* nAChRs might be used for selective targeting of dopaminergic neurons in e.g., 
Parkinson’s disease. Immunoprecipitation and functional studies agree that the α4α6β2β3 
subtype comprises the majority of dopamine terminal α6* nAChRs, and it is also the most 
sensitive to agonist activation (Salminen et al., 2007; Gotti et al., 2010). An invaluable tool 
in the study of α6* nAChRs has been α-conotoxin MII (CtxMII), an α3* and α6* nAChR 
antagonist that in rodent dopaminergic areas can be used to selectively target α6* nAChRs 
(Champtiaux et al., 2002). Another intriguing nAChR population are those containing the 
α5 subunit (α5* nAChRs), which are discussed in more detail below (2.4.3.).
In general, cholinergic input from the mesopontine tegmentum to the SNC (and VTA) has 
been suggested to be a critical regulator of brain dopaminergic systems (Maskos, 2008), 
while striatal dopamine terminal nAChRs have been suggested to act as a presynaptic 
“fi lter” dynamically regulating dopamine release (Exley and Cragg, 2008). Rodent brain 
slice studies suggest that acetylcholine released by cholinergic interneurons not only 
modulates but is essential for striatal dopamine release (Zhou et al., 2001) and can even 
generate dopamine release directly, independently of the activity of the dopaminergic 
neuron (Th relfell et al., 2012). Cholinergic interneurons in turn are engaged in particular by 
thalamostriatal projections, which thus indirectly regulate dopamine release via nAChRs 
and possibly modulate corticostriatal input in response to salient stimuli (Ding et al., 2010; 
Th relfell et al., 2012). Th us, while the fi ring rate and pattern of a nigrostriatal neuron is 
usually considered the primary regulator of striatal dopamine release (Quik and Wonnacott, 
2011), the participation by presynaptic nAChRs is also of signifi cant importance. Findings 
in rodent brain slices also suggest that in conditions where at least some circuit eff ects 
remain intact, α6β2* nAChRs (in particular α4α6β2β3) have a critical role in the ventral 
striatum, while α4α5β2 nAChRs dominate the control of dopamine release in the dorsal 
striatum (Exley and Cragg, 2008; Exley et al., 2012). Note also that at least in brain slice 
preparations exogenous nAChR agonists typically act via desensitization (i.e., similarly as 
antagonists; Zhou et al., 2001).
Besides dopaminergic neurons, nAChRs also modulate the activity and neurotransmitter 
release of many other neurons. In the SNC, functional evidence suggests the existence 
of α7 and non-α7 (possibly β2*) nAChRs on glutamate and GABA terminals as well as 
somatodendritically on GABAergic interneurons, all of which can indirectly modulate the 
activity of dopaminergic neurons (Keath et al., 2007; Quik and Wonnacott, 2011). In the 
striatum, presynaptic α7 nAChRs on glutamate terminals (Kaiser and Wonnacott, 2000), 
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α4β2 and α4α5β2 nAChRs on GABA terminals (McClure-Begley et al., 2009), and nAChRs 
of an unknown subtype (possibly β2*) on raphestriatal serotonin terminals (Schwartz et al., 
1984; Reuben and Clarke, 2000) regulate neurotransmitter release and thus can indirectly 
modulate dopamine release as well as MSN activity. Some striatal GABAergic interneurons 
also express somatodendritic nAChRs of an unknown non-α7 subtype (Koos and Tepper, 
2002). Some studies have also found evidence of somatodendritic nAChRs (possibly α7) on 
cholinergic interneurons (Sandor et al., 1991; Xiao et al., 2009). Finally, nAChR-mediated 
modulation in other basal ganglia areas than those already discussed has been little studied, 
but based on mRNA expression, nAChRs are expressed at least in the globus pallidus and 
the STN (Wada et al., 1989). In addition, somatodendritic nAChRs have been shown to 
modulate the activity of the GABAergic projection neurons of the SNR (Klink et al., 2001).
Th e nAChR subtypes modulating dopaminergic neurotransmission in primates appear 
mostly similar to those in rodents, although some diff erences also exist (see Table 1). 
Studies on the eff ects of MPTP lesioning on mRNA and ligand binding suggest that 
similar to rodents, dopaminergic neurons of the monkey SNC express both α3/α6* and 
non-α3/α6 somatodendritic nAChRs, but unlike rodents α7 nAChRs may be restricted to 
non-dopaminergic neurons (Quik et al., 2000; Quik et al., 2002). Th e nAChR repertoire 
of the monkey striatum has been revealed in more detail in a series of ligand binding, 
immunoprecipitation, and MPTP lesioning studies (Quik et al., 2005). In brief, the 
monkey striatum was found to express α3β2*, α4β2*, α6β2*, α2β2* and α7 nAChRs but 
no α5 or β4 subunits, with evidence further suggesting that α3β2*, α6β2β3, and α4α6β2β3 
nAChRs are located on dopamine terminals, α4β2 nAChRs are located on both dopamine 
terminals and non-dopaminergic neurons, and α2β2* and α7 nAChRs are located only on 
non-dopaminergic neurons. Note the selective localization of α6* nAChRs on dopamine 
terminals, similar to rodents. A notable diff erence to rodents is that α3β2* nAChRs are 
expressed in the monkey striatum and – perhaps consequently – α3/α6* (CtxMII-sensitive) 
receptors make up a much higher proportion of striatal nAChRs (Quik, Sum, et al., 2003) 
and have a more dominant role in the regulation of dopamine release (Mccallum et al., 
2005; Perez et al., 2009).
While high amounts of nAChRs are present in the human SNC (Gotti et al., 1997), their 
composition has not been studied in detail (Zoli et al., 2015). In the human striatum, 
Western blot protein measurements have detected α2–α7 and β2–β3 nAChR subunits, 
but no changes associated with PD (i.e., dopamine terminal loss) were found barring a 
small decrease in α3 in one study (Martin-Ruiz et al., 2002; Guan et al., 2002). In contrast, 
experiments combining ligand binding and immunoprecipitation (refl ecting assembled 
receptors) found only α4, α6, β2, and β3 subunits (i.e., no α3) at levels above the detection 
limit (Gotti et al., 2006; α7 was not studied). Analyses of tissue from PD patients suggest 
that similar to other species, human striatal α6β2* nAChRs (many of which contain also α4 
and/or β3) are selectively expressed on dopamine terminals while α4(non-α6)β2* nAChRs 
are expressed both on dopaminergic and non-dopaminergic sites (Quik et al., 2004; 
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Gotti et al., 2006). Interestingly, the proportion of α3/α6* (CtxMII) binding sites in the 
human striatum resembles that of rodents instead of monkeys (Quik et al., 2004), further 
suggesting that striatal α3* nAChRs may in fact be unique to monkeys.
Table 1. Nicotinic receptor subtypes suggested to be expressed on dopaminergic and other 
neurons in the rodent, monkey and human substantia nigra pars compacta (SNC) and striatum. 





































2.4.3.  α5* nicotinic receptors
A major part of the present studies focused on nAChRs containing the α5 subunit. Cloned 
α5 subunits have been shown to form functional nAChRs but only when co-expressed 
with both a diff erent α subunit and a β subunit (Ramirez-Latorre et al., 1996; Wang et al., 
1996). Unlike other α subunits, the α5 subunit thus does not participate in agonist binding. 
Nevertheless, the presence of an α5 subunit has signifi cant eff ects on ligand binding and 
receptor function. In cloned nAChRs, α5 incorporation results in faster and more extensive 
acute desensitization, increased Ca2+ permeability and, depending on the other subunits, 
either increased or decreased agonist affi  nity (Ramirez-Latorre et al., 1996; Wang et al., 
1996; Gerzanich et al., 1998; Tapia et al., 2007; Kuryatov et al., 2008). Ex vivo rodent studies 
suggest that α5 incorporation into a native nAChR results in increased receptor function 
(Brown et al., 2007), resistance to upregulation (Mao et al., 2008), and a decreased sensitivity 
to short-term desensitization with a faster recovery but no change in desensitization extent 
(Grady et al., 2012); note the complex and in part contradictory eff ects on desensitization 
kinetics in cloned and native nAChRs.
In vertebrates, α5* nAChRs are expressed both in peripheral ganglions and in the CNS 
(Gerzanich et al., 1998). As many as a third of human neocortical α4β2 nAChRs and 20 % 
of rat brain α4β2 nAChRs may contain an α5 subunit (Gerzanich et al., 1998). However, 
α5* nAChRs show a relatively limited localization. In rats, α5 mRNA is expressed at 
relatively high levels in parts of the hippocampus, the interpeduncular nucleus, the 
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SNC, and the VTA, and at moderate levels in brain areas such as the isocortex, olfactory 
nucleus, and a few others (Wada et al., 1990). Immunoprecipitation studies in rodents have 
detected assembled α5* nAChRs in a wider array of brain areas (but always as a minority 
of heteromeric nAChRs): the hippocampus, interpeduncular nucleus, medial habenula, 
hypothalamus, cortex, striatum, thalamus, the olfactory tubercle, and the superior 
colliculus; the SN and the VTA were not studied (Brown et al., 2007; Mao et al., 2008). At 
least in the rat hippocampus, striatum, cortex, and thalamus, virtually all α5* nAChRs are 
of the α4α5β2 subtype (Mao et al., 2008). 
α5* nAChRs have been found to contribute to GABA release in the striatum, cortex, and 
hippocampus (McClure-Begley et al., 2009) and to the activity of serotonergic neurons 
of the dorsal raphe nucleus (Besson et al., 2016). Most importantly for the present thesis, 
α5* nAChRs have a signifi cant role in the modulation dopaminergic neurotransmission, 
at least in rodents. In the SNC, α5 subunit mRNA is expressed in 80 % or more of 
dopaminergic neurons, and their somatodendritic nAChRs may include α5* nAChRs 
(Klink et al., 2001). Immunoprecipitation and dopaminergic lesion studies suggest that 
a third of all heteromeric nAChRs in midbrain dopaminergic neurons consist of α4α5β2 
nAChRs (Gotti et al., 2010), and that in the striatum α4α5β2 nAChRs make up as many 
as 40–50 % of nAChRs on dopamine terminals (Gotti et al., 2010). Similarly, genetic 
deletion of the α5 subunit results in a ca. 60 % decrease in nAChR-mediated dopamine 
release from striatal synaptosomes (Salminen et al., 2004; Grady et al., 2010). As already 
mentioned, nAChR-mediated control of dopamine release in the dorsal striatum was also 
found to critically depend on α4α5β2 nAChRs in brain slice voltammetry studies (Exley et 
al., 2012). Furthermore, in dopaminergic neurons of the ventral midbrain the α5 subunit 
helps maintain α4* nAChR expression and enhances α4*-mediated currents (Chatterjee 
et al., 2013) and is essential for elevation of intracellular Ca2+ concentrations mediated by 
heteromeric nAChRs (Sciaccaluga et al., 2015). However, note that α5* nAChRs are not 
known to be present on striatal dopamine terminals in primates (see the previous section 
and 6.2.2. below).
Mice lacking the α5 subunit do not exhibit obvious physical or neurological defi cits and 
are normal in various measures of autonomic function, behavior, brain anatomy, and 
expression of other nAChR subunits (Wang et al., 2002; Salas et al., 2003). However, they do 
show reduced sensitivity to many eff ects of nicotine (Salas et al., 2003; Jackson et al., 2010), 
including those associated with nicotine addiction. More specifi cally, mice lacking the α5 
subunit exhibit increased nicotine self-administration and reduced somatic signs of nicotine 
withdrawal (Salas et al., 2009; Jackson et al., 2010; Fowler et al., 2011; Morel et al., 2014). As 
their mesolimbic pathway furthermore shows decreased sensitivity to nicotine, the behavioral 
fi ndings have been suggested to refl ect decreased sensitivity to nicotine reward (Morel et 
al., 2014; Besson et al., 2016). α5* nAChRs of the habenulo-interpeduncular pathway have 
also been suggested to be important, and might mediate aversion to nicotine and thus act to 
inhibit nicotine intake (Salas et al., 2009; Fowler et al., 2011; Morton et al., 2018). Importantly, 
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many human studies have associated polymorphisms in the α5 subunit gene CHRNΑ5 with 
nicotine dependence, heavy smoking, and lung cancer (Bierut et al., 2008; Th orgeirsson et 
al., 2008; Weiss et al., 2008; Hung et al., 2008). Rodent studies suggest that the most studied 
variant (D398N) results in a loss of receptor function (Morel et al., 2014; Sciaccaluga et al., 
2015), which has been suggested to lead to increased nicotine consumption either due to 
reduced sensitivity of dopaminergic reward systems (Morel et al., 2014) or due to reduced 
sensitivity to nicotine aversion (Fowler et al., 2011; Morton et al., 2018).
Behavioral studies also suggest α5* nAChRs may have important roles in attention 
(Bailey et al., 2010) and anxiety (Besson et al., 2016). Th e fi ndings of an important role in 
dopaminergic neurotransmission might also give reason to suspect a role for α5* nAChRs 
in Parkinson’s disease and its treatment; however, they have not previously been studied in 
the context of PD.
2.4.4.  Nicotinic receptors as drug targets in Parkinson’s disease
Changes in nicotinic receptors in Parkinson’s disease
Many studies on post mortem tissue from PD patients have found signifi cant reductions in 
nicotinic receptor levels in various brain areas including the SNC, striatum, hippocampus, 
thalamus, and cortex (e.g., Rinne et al., 1991; Aubert et al., 1992; Perry et al., 1995). As 
mentioned above, experiments on human striatal tissue suggest that the nAChR subtypes 
which are preferentially lost in PD (i.e., expressed on dopamine terminals) include both 
α6β2* and α4(non-α6)β2* nAChRs, the former in particular being expressed only on 
dopaminergic neurons (Quik et al., 2004; Gotti et al., 2006). Note, however, also the 
contrasting fi ndings of selectively decreased α3 subunit levels (Guan et al., 2002) or no 
reduction in nAChR subunit levels (Martin-Ruiz et al., 2002). Interestingly, levels of the 
α7 nAChR, not expressed on dopamine terminals, have been reported to be increased in 
the temporal cortex and caudate of PD patients (Guan et al., 2002; Morissette et al., 2016). 
Studies in monkey and rodent models of dopaminergic neurodegeneration have yielded 
similar results, observing near-total striatal losses of α6β2* nAChRs (and/or α3β2* in 
monkeys), less pronounced striatal losses of α4(non-α6)β2* nAChRs, and unaff ected or 
increased striatal α7 nAChR levels (Quik, Sum, et al., 2003; Kulak and Schneider, 2004; 
Quik et al., 2005; Quik, Campos, and Grady, 2013). Animal model studies further suggest 
that the α4α6β2β3 nAChR population may be particularly vulnerable to nigrostriatal 
damage (Bordia et al., 2007). In summary, consistent evidence across species shows that 
the loss of striatal dopamine terminals in PD results in a selective loss of associated nAChR 
populations, in particular those containing the α6 subunit.
Nicotinic receptors and dopaminergic neuroprotection
Evidence for nAChR-mediated benefi cial eff ects includes numerous epidemiological 
studies as well as extensive preclinical investigations both in vitro and in vivo. Here, only 
dopaminergic neuroprotection related to PD will be discussed; for general reviews on 
nAChR-mediated neuroprotection, see e.g., Mudò, Belluardo, and Fuxe (2007), Picciotto 
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and Zoli (2008), or Posadas et al. (2013). Also nAChR-mediated pro-cognitive eff ects and 
protection against Alzheimer’s disease (Mudò, Belluardo, and Fuxe, 2007; Picciotto and 
Zoli, 2008; Quik et al., 2015) should be mentioned, as they may be relevant for instance 
regarding PD-associated cognitive decline.
A negative correlation between tobacco smoking and PD has been observed in dozens of 
epidemiological studies, conducted during the past 50+ years by diff erent investigators in 
diff erent countries. Systematic reviews and meta-analyses have obtained consistent results 
of reduced PD risk, in current smokers as well as less strongly in former smokers, that 
cannot be explained by confounding variables or biases such as selection bias, selective 
mortality of smokers, or changes in smoking behavior aft er diagnosis (Morens et al., 1995; 
Allam et al., 2004; Ritz et al., 2007; Li et al., 2015). Taken together, the risk for PD appears 
to be at least roughly halved in current smokers. Strong evidence for a real, biological 
protective eff ect includes an inverse dose-relationship between smoking and PD risk, with 
a longer and more intensive smoking history associated with a lower PD risk (Gorell et al., 
1999; Th acker et al., 2007; Chen et al., 2010); changes in PD incidence mirroring changes 
in smoking prevalence (Morozova et al., 2008); reduced PD risk in passive smokers (Searles 
Nielsen et al., 2012); twin studies ruling out genetic variability as a confounder (Tanner 
et al., 2002; Wirdefeldt et al., 2005); and fi ndings that the lower PD risk is independent of 
personality traits such as lower sensation seeking or neuroticism (Evans et al., 2006; Sieurin 
et al., 2016). Th e use of cigars, pipes, and chewing tobacco is also inversely associated with 
PD (O’Reilly et al., 2005; Ritz et al., 2007). Note, however, that some contrasting evidence 
does exist; for instance, one study found no association of the progression of parkinsonism, 
cognitive impairment, or mood with cigarette smoking (Alves et al., 2004). A recent study 
also found that PD patients are able to quit smoking more easily than controls, possibly 
suggesting that instead of a neuroprotective eff ect, a reduction in nicotine reward leads 
to easier quitting in individuals at risk for PD (Ritz et al., 2014). In totality, however, the 
evidence for some form of a protective eff ect is convincing and widely accepted. Smoking, 
however, can obviously not be recommended due to its numerous and well-known adverse 
eff ects. Th us, the identifi cation of the protective constituent and its biological targets is of 
paramount importance. MAO-B inhibitors present in tobacco smoke are one possibility 
(Castagnoli and Murugesan, 2004). Another, much more studied possibility is nicotine, the 
primary psychoactive component of tobacco.
Extensive in vitro evidence has shown neuroprotective eff ects by nicotine and other 
nAChR ligands in neuronal cell lines as well as rat and mouse cortical, hippocampal, 
and striatal cultures against diverse neurotoxic insults such as amyloid-β, glutamatergic 
excitotoxicity, kainic acid, growth factor deprivation, oxygen deprivation, and oxidative 
stress (Mudò, Belluardo, and Fuxe, 2007; Picciotto and Zoli, 2008; Quik et al., 2015). 
Furthermore, a number of studies in animal models have described nAChR-mediated 
neuroprotection against ischemic and lesion insults in the hippocampus and the neocortex 
(Mudò, Belluardo, and Fuxe, 2007). In the case of dopaminergic neurons, in vitro studies 
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in rodent dopaminergic neuron cultures have shown nicotine to partially protect against 
neurotoxicity induced by lipopolysaccharide, rotenone, or the toxic MPTP metabolite 
1-methyl-4-phenylpyridinium (MPP+), as well as against spontaneous degeneration 
(Jeyarasasingam et al., 2002; Park et al., 2007; Takeuchi et al., 2009; Toulorge et al., 2011). 
Th e most extensive investigations have focused on in vivo assessment of nigrostriatal 
neuroprotection in parkinsonian animal models. Th e main fi ndings of these studies 
are presented in Table 2. In summary, neuroprotective eff ects by nicotine have been 
demonstrated in a number of monkey and rodent models of dopaminergic denervation and 
in studies utilizing many diff erent routes and regimes of administration. Remarkably, in 
some studies only a few injections given before and aft er 6-OHDA lesioning were found to 
partially block striatal dopamine loss. A few studies have also found neuroprotective eff ects 
by selective α7 nAChR agonists. However, a number of studies in rodents (particularly in 
mice) also observed no eff ect or even increased denervation in nicotine-treated animals. 
Moreover, primate studies are rare and have observed moderate inhibition of striatal 
denervation but no sparing of SNC dopaminergic neurons. Whether neurotoxicity in 
rodents was decreased, unchanged, or increased by nicotine treatment does not appear 
to be clearly related to any single issue such as the lesion model or the method or timing 
of nicotine administration. However, the only study directly comparing pre- and post-
treatments found only pretreatment to be eff ective (Huang et al., 2009). Furthermore, 
one rat study found that neuroprotective eff ects by nicotine were lost when the dosage 
was raised high enough (Ryan et al., 2001). Somewhat surprisingly, while in rats both 
intermittent nicotine injections and continuous treatment via subcutaneous minipumps 
had protective eff ects, in mice two of the three studies utilizing minipump administration 
showed increased neurotoxicity instead.
Both heteromeric (at least α4β2*) and homomeric (α7) nAChRs are involved in hippocampal 
and cortical neuroprotective eff ects of nicotinic agonists (Mudò, Belluardo, and Fuxe, 2007; 
Picciotto and Zoli, 2008; Posadas et al., 2013; Quik et al., 2015), and the same appears to 
be true for dopaminergic neuroprotection. Dopaminergic neuroprotection by nicotine 
was blocked in vivo by a non-selective nAChR antagonist (Costa et al., 2001) and α4 gene 
deletion (Ryan et al., 2001), and in vitro by antagonism of heteromeric nAChRs (Takeuchi 
et al., 2009) but not by α7 nAChR antagonism (Jeyarasasingam et al., 2002), suggesting that 
the neuroprotection was mediated by heteromeric (possibly α4β2*) nAChRs. On the other 
hand, also α7 nAChRs are involved, as demonstrated by neuroprotection by selective α7 
agonists in vivo (Suzuki et al., 2013; Stuckenholz et al., 2013; Bordia, McGregor, Papke, et 
al., 2015) as well as by blockade of neuroprotection by α7 inhibition both in vivo (Liu et al., 
2012; Suzuki et al., 2013) and in vitro (Park et al., 2007; Takeuchi et al., 2009; Toulorge et al., 
2011). Simultaneous activation of both subtypes may be required, as nicotine but neither 
selective α4β2 nor α7 nAChR ligands had a neuroprotective eff ect in one study (Visanji et al., 
2006). Finally, one study in rats observed that striatal α4α6β2* nAChRs were only expressed 
in association with neuroprotection by nicotine, suggesting that they may be an important 
mediator (Huang et al., 2009). Th e possible role of α5* nAChRs has not been studied.
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Th e detailed mechanisms of nAChR-mediated neuroprotection are far from well-
understood. As mentioned above, long-term nicotine treatment in monkeys resulted in 
moderate sparing of striatal markers of dopamine terminal integrity such as the dopamine-
synthesizing enzyme tyrosine hydroxylase (TH), DAT, and dopamine levels (~20 % more 
remaining when compared to control animals), but no sparing of dopaminergic neurons in 
the SNC (Quik, Parameswaran, et al., 2006). However, despite the modest neuroprotective 
eff ects, aberrant striatal functions observed in the MPTP-treated monkeys, such as 
enhanced ex vivo dopamine release and turnover as well as a loss of LTD, were almost 
fully normalized in nicotine-treated animals (Quik, Chen, et al., 2006). Chronic nicotine 
treatment also upregulated striatal α4β2* nAChRs and protected against MPTP-induced 
α4β2* nAChR loss, while downregulating a subset of striatal α6β2* nAChRs but restoring 
a subset that were lost due to MPTP (Bordia et al., 2006). Th us, rather than exerting direct 
protection against nigrostriatal neuron loss, nicotine treatment may allow more effi  cient 
compensation against the resulting striatal dopaminergic dysfunction and nAChR loss. 
Note that many rodent studies also measured only striatal markers (Table 2), such as TH 
or dopamine, making it unclear whether compensation or actual sparing of dopaminergic 
neurons had occurred.
As for actual neuroprotection, alterations in intracellular calcium signaling are oft en 
proposed as a mechanism, given that nAChR activation typically results in Ca2+ infl ux 
and/or mobilization (Mudò, Belluardo, and Fuxe, 2007; Picciotto and Zoli, 2008). nAChR 
activation could lead to modest increases in intracellular calcium that might confer 
protection against larger calcium infl uxes resulting from e.g., excitotoxicity (Picciotto 
and Zoli, 2008). In cultured rat dopaminergic neurons, nicotine-induced protection 
against spontaneous neurodegeneration was indeed found to depend on the elevation of 
cytosolic Ca2+ levels, possibly resulting in the activation of a calcium-mediated prosurvival 
pathway (Toulorge et al., 2011). Other suggested mechanisms relate to oxidative stress 
and mitochondrial dysfunction. Nicotine can both have antioxidant properties and 
induce oxidative stress (Newman et al., 2002), and while some in vitro studies have 
found nicotine to have radical scavenging properties (Ferger et al., 1998), others have not 
observed radical scavenging but rather inhibition of 6-OHDA-induced lipid peroxidation 
(Soto-Otero et al., 2002). Nicotine has also been shown to protect rat brain mitochondria 
against various damaging insults both in vitro and in vivo (Cormier et al., 2003; Xie et al., 
2005). Intriguingly, mitochondria themselves have been shown to express various nAChR 
subtypes (Lykhmus et al., 2014).
Another oft en suggested mechanism for nicotine’s neuroprotective eff ects is nAChR-
mediated stimulation of neuroprotective or neurotrophic growth factors (Mudò, Belluardo, 
and Fuxe, 2007; Picciotto and Zoli, 2008). In rodents, nAChR agonists increase the 
expression of various growth factors such as the nerve growth factor, the fi broblast growth 
factor-2, and the BDNF, along with their tyrosine kinase A and B receptors (Maggio et al., 
1997; French et al., 1999; Belluardo et al., 2000; Jonnala et al., 2002; Formaggio et al., 2010). 
41
Nicotine treatment was also found to enhance neuronal precursor cell proliferation in the 
rat brain (Mudò, Belluardo, Mauro, et al., 2007). nAChRs on non-neuronal cells, such as 
immune cells, could also be involved in neuroprotection. Indeed, neuroprotective eff ects 
by nAChR agonists in rodent models have been found to be associated with modulation of 
the activation of microglia and astrocytes and attenuation of brain infl ammation (Park et 
al., 2007; Liu et al., 2012; Stuckenholz et al., 2013). Finally, an interesting novel hypothesis 
suggests that smoking-induced changes in the gut microbiota could mitigate intestinal 
infl ammation and attenuate α-synuclein misfolding and propagation originating in the 
enteric nervous system (Derkinderen et al., 2014).
Nicotinic receptors and levodopa-induced dyskinesia
Nicotine has been observed to have little or no antiparkinsonian eff ect in preclinical 
monkey and rodent models, although it may potentiate some behavioral eff ects of levodopa 
(Domino et al., 1999; Quik et al., 2007; Bordia et al., 2008; Huang, Grady, and Quik, 
2011). Clinical studies on the treatment of PD motor symptoms with nAChR agonists 
have also been unconvincing (see below). However, preclinical studies suggest that 
nAChR ligands may hold more promise for the treatment of levodopa-induced dyskinesia 
(see Table 3). In summary, the eff ectiveness of long-term treatment with nicotine and 
various other nAChR agonists has been demonstrated in numerous monkey and rodent 
studies using oral administration (monkeys) or both oral and various parenteral routes 
(rodents). Importantly, nAChR agonists can eff ectively alleviate LID both when given as a 
pretreatment and when administered aft er LID has already developed, the latter resembling 
the more probable clinical use scenario, although some studies do suggest a somewhat 
delayed onset of alleviation. Equally importantly, antidyskinetic eff ects by nicotine persist 
for (at least) several months without tolerance developing. Finally, none of the studies 
observed any association of a nAChR agonist treatment with a worsening of parkinsonism 
or a decrease in the antiparkinsonian effi  cacy of levodopa. Th is is a particularly signifi cant 
fi nding, as nicotine is well-known to modulate striatal dopaminergic function and has also 
been found to aff ect levodopa pharmacokinetics in humans (Kyaw et al., 2013). 
Studies using selective nAChR agonists and subunit-knockout mice (see Table 3) suggest 
that the antidyskinetic eff ects are mediated by several nAChR subtypes. Both β2* nAChR 
and α7 nAChR agonists can alleviate LID; however, combined treatment did not result in a 
synergistic eff ect, suggesting a common fi nal mechanism (Zhang, McGregor, et al., 2014). 
Mice lacking β2 and α6 subunits developed less severe LID and LID that spontaneously 
declined over time, respectively, suggesting their involvement in LID pathophysiology 
(Huang, Grady, and Quik, 2011; Quik et al., 2012). Furthermore, no antidyskinetic eff ects 
by nicotine were observed in mice lacking either β2, α6, or α4 nAChR subunits (Huang, 
Grady, and Quik, 2011; Quik et al., 2012; Quik, Campos, and Grady, 2013). As described 
above (2.4.2.), nAChRs composed of these subunits (α6β2* and α4(non-α6)β2* nAChRs) 
are critical regulators of dopaminergic neurotransmission, and thus can be seen as 
prominent candidates for mediators of the antidyskinetic eff ects. Although heteromeric 
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nAChRs on e.g., serotonin terminals (Schwartz et al., 1984; Reuben and Clarke, 2000) 
could also contribute, fi ndings that nicotine and β2* nAChR agonists are less eff ective 
(or even ineff ective) in alleviating LID in severely lesioned animals (Huang, Campos, et 
al., 2011; Huang, Grady, and Quik, 2011; Quik, Campos, and Grady, 2013; Quik, Mallela, 
Chin, McIntosh, et al., 2013) suggest a major role for nAChRs expressed on dopaminergic 
neurons. Th e antidyskinetic eff ects of α7 agonists, on the other hand, are likely to be 
mediated by some other nAChR population(s), given that no evidence has been found 
of α7 expression on striatal dopamine terminals. Th ese could include α7 nAChRs on 
striatal glutamate terminals (Kaiser and Wonnacott, 2000) or somatodendritic α7 nAChRs 
on dopaminergic neurons (Klink et al., 2001), although note that the latter may not be 
expressed in primates (Quik et al., 2000). Also note that in contrast to mice lacking various 
β2* nAChRs, mice lacking α7 nAChRs developed more severe LID but showed normal 
sensitivity to alleviation of LID by nicotine (Quik, Campos, and Grady, 2013). 
In summary, studies in genetically modifi ed mice suggest that at least α6β2* and α7 nAChRs 
are involved in LID pathophysiology, possibly exerting opposite eff ects, while both α4β2* 
and α6β2* nAChRs mediate the antidyskinetic eff ects of nicotine. Th e possible role of α5* 
nAChRs has not been previously studied. Th e mechanisms of the LID-alleviating eff ects 
remain unclear. However, fi ndings that nicotine and the non-selective nAChR antagonist 
mecamylamine can have equal and non-additive inhibiting eff ects on LID suggest receptor 
blockage as a signifi cant mechanism (Bordia et al., 2010; Bordia, McGregor, McIntosh, 
et al., 2015). Th is possibility is supported by fi ndings that chronic nicotine treatment 
reduced dopamine release from remaining striatal terminals in MPTP-lesioned monkeys 
(Quik, Chen, et al., 2006) and that antidyskinetic nicotine treatment was associated with 
reductions in α6β2* nAChR levels and nAChR-mediated dopamine release in rats (Bordia 
et al., 2013). Such a dampening of potentially excessive striatal dopaminergic activity could 
occur via desensitization and/or downregulation in response to chronic agonist treatment. 
Supporting desensitization as a potential mechanism is optogenetic evidence suggesting 
that bursts of large, potentially desensitization-inducing release of acetylcholine from 
striatal cholinergic interneurons attenuate LID (Bordia et al., 2016). Moreover, when mice 
with a hypersensitive α6 mutation were treated with nicotine (at a very low but maximum 
tolerated dose), no LID alleviation was observed; this was suggested to refl ect a failure of 
nicotine to desensitize α6β2* nAChRs (Bordia, McGregor, McIntosh, et al., 2015). Finally, 
interesting fi ndings suggest that also chronic levodopa treatment itself may result in 
changes in striatal α3/α6* nAChRs, although changes were only observed in unlesioned 
monkeys (Quik, Bordia, et al., 2003; Quik et al., 2005).
Extensive preclinical evidence in multiple animal models thus suggests promise for 
nicotinic receptor ligands as drug treatments for LID. However, it should also be noted 
that all of the evidence summarized above has been produced by a single research group, 
with the exception of two monkey studies showing LID alleviation by selective β2* and α7 
nAChR agonists (Johnston et al., 2013; Di Paolo et al., 2014). As for clinical evidence, LID 
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has been associated with increased post mortem α7 nAChR binding in the striatum and the 
GP (Morissette et al., 2016) as well as with increased β2* nAChR density in a brain imaging 
study (Brumberg et al., 2017), suggesting links between nAChRs and LID in humans as 
well. Notably, a history of never smoking was also associated with an increased risk of early 
LID onset in one study (Strong et al., 2006). However, published clinical trials of nicotinic 
agonists have not so far demonstrated antidyskinetic eff ects (see below).
Clinical studies on nicotinic receptor agonists in Parkinson’s disease
To date, a number of clinical studies have investigated the safety and effi  cacy of nAChR 
agonists in the treatment of the symptoms of PD (see Table 4). In summary, although 
nAChR agonists are usually acceptably tolerated and show promising eff ects in uncontrolled 
studies, benefi cial clinical eff ects on motor or non-motor symptoms of PD have not been 
demonstrated in well-controlled trials. Potential shortfalls such as a too short treatment 
time or a too low dosage appear to have been ruled out (Villafane et al., 2018). Signifi cant 
placebo eff ects may be involved, particularly given benefi ts in unblinded but not blinded 
measures in one study (Villafane et al., 2018). Note that all of the controlled studies on the 
eff ects of nicotine included only non-smoking patients. Publication of results from a few 
recent controlled clinical studies is awaited at the time of writing. According to published 
conference abstracts, preliminary results of one study in 65 PD patients suggest reductions 
in falls, freezing of gait, and possibly LID aft er 10 weeks of administration of an oral nicotine 
formulation (Lieberman et al., 2018), while in another study in 163 early PD patients one 
year of transdermal nicotine administration failed to improve motor symptoms (Oertel et 
al., 2018).
Th e lack of effi  cacy against parkinsonian motor symptoms is in fact in line with most 
preclinical results (see above). However, it remains an open question whether nAChR 
agonists might have benefi cial clinical eff ects on some specifi c motor or non-motor 
symptoms or, in particular, motor fl uctuations such as LID. Measures of LID have so far 
been reported in only two published studies. A reduction in troublesome LID by nicotine 
was observed as an unblinded outcome (Villafane et al., 2018), while an α7 agonist 
previously eff ective in a monkey model had no eff ect on LID (Trenkwalder et al., 2016). It 
also remains possible that other selective nAChR agonists than those studied so far might 
show clinical benefi t. As for neuroprotective eff ects by nAChR agonists, while preclinical 
studies strongly suggest potential benefi ts, neuroprotection specifi cally has not been studied 
clinically. Indeed, any neuroprotective eff ects might be diffi  cult to observe in diagnosed 
PD patients, given the signifi cant nigrostriatal damage already at the time of symptom 
appearance (Fearnley and Lees, 1991) as well as a lack of validated biomarkers (AlDakheel 
et al., 2014). Some preclinical studies also suggest signifi cant neuroprotective eff ects by 
nicotine only when the treatment is initiated before the loss of dopaminergic neurons 
(Huang et al., 2009). Here, the question then becomes a need for earlier diagnosis of PD or 
identifi cation of increased disease risk, and the feasibility and safety of pre-treatment with 
nAChR agonists.
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3.  Aims of the studies
As discussed above, the current treatment options for Parkinson’s disease and treatment-
related adverse eff ects such as levodopa-induced dyskinesia remain suboptimal. Th e 
studies comprising this thesis aimed at addressing the need for novel treatment options by 
investigating the role of neuronal nicotinic acetylcholine receptors in Parkinson’s disease 
and levodopa-induced dyskinesia and their potential usability as drug targets. More 
specifi cally, the aims of the present studies were:
1. To study for the fi rst time the role of the α5* nicotinic acetylcholine receptor subtype in 
mouse models of Parkinson’s disease and levodopa-induced dyskinesia (Study I).
2. To study the eff ectiveness of nicotinic receptor agonists in alleviating levodopa-
induced dyskinesia in mouse models of moderate and advanced Parkinson’s disease 
(Studies II–III). 
3. To study the mechanisms of antidyskinetic nicotine treatment by investigating the 
eff ects of chronic nicotine administration on striatal dopamine release (Study II).
4. To study the links between the brain-derived neurotrophic factor, levodopa-induced 
dyskinesia, and the antidyskinetic eff ects of nicotine (Study III).
5. To improve the methods of stereotactic surgery and postoperative care relating to 
near-total unilateral dopaminergic denervation induced by intra-MFB 6-OHDA 
administration in mice (Study IV).
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4.  Materials and methods
Table 5 lists all experimental methods used in the studies and the author’s personal 
contribution.
Table 5. Methods used in each of the original studies and the author’s personal contribution. 
Major contribution = signifi cant contribution to study design and data analysis along with 
signifi cant contribution to hands-on work and/or direct supervision of hands-on work; 
Minor contribution = signifi cant contribution to study design and data analysis and/or minor 







Densitometric analyses I, II, III X
Dopamine HPLC I X
Dopamine receptor qPCR I
Dopamine release assays II X
Dopamine transporter Western 
blotting
I X
Dopamine uptake assays I X
Drug-induced locomotor activity I X
Drug-induced rotametry I X
Immunohistochemistry I, II, III X
Mouse model of levodopa-induced 
dyskinesia
I, II, III X
Mouse strain maintenance and 
genotyping
I X
Stereological cell counting I X
Stereotactic surgeries and 
postoperative care
I, II, III, IV X
4.1.  Drugs
6-hydroxydopamine HCl, amantadine HCl, apomorphine HCl, benserazide HCl, 
desipramine HCl, dopamine HCl, levodopa methyl ester HCl, (–)-nicotine, nicotine 
hydrogen tartrate, nomifensine maleate and pargyline HCl were from Sigma-Aldrich (St. 
Louis, MO, USA). [3H]dopamine was from PerkinElmer (Waltham, MA, USA). α-conotoxin 
MII was a gift  from Dr. J. M. McIntosh (University of Utah, UT, USA). AZD0328 ((2´R)-spiro-
[1-azabicyclo[2.2.2]octane-3,2´(3´H)-furo[2,3-b]pyridine] D-tartrate) was provided free of 
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charge by AstraZeneca (Cambridge, MA, USA). Isofl urane was from Piramal Healthcare 
(Morpeth, UK). Lidocaine and sodium pentobarbital solutions were from Orion Pharma 
(Espoo, Finland), buprenorphine solution was from RB Pharmaceuticals (Berkshire, UK), 
and carprofen solution was from Pfi zer Animal Health (Helsinki, Finland). D-amphetamine 
sulphate was synthesized at the Faculty of Pharmacy (University of Helsinki, Finland). Doses 
of drugs refer to free bases. Drugs were administered in vivo in saline at a volume of 10 ml/
kg.
4.2.  Animals
α5-knockout (α5-KO) C57BL/6J (Salas et al., 2003) and wild-type (WT) mice used in 
Study I were obtained from the Institute for Behavioral Genetics, University of Colorado 
(Boulder, CO, USA), bred at the research site, and genotyped as described by Salminen 
et al. (2004). C57BL/6JRccHsd mice (Envigo, Horst, Netherlands) were used in all other 
studies. See Figure 10 for the age of animals in each experiment. Experimental groups that 
were directly compared were carefully balanced with respect to mean age unless otherwise 
stated. Th e sex distribution in each experiment is given in the Results section. Most studies 
using 6-OHDA injections into the medial forebrain bundle (MFB) included only females 
due to penile prolapse complications aft er a severe lesion (Th iele et al., 2011). Animals were 
group housed in a temperature- and humidity-controlled environment under a 12 h light/
dark cycle. All experiments were authorized by the national Animal Experiment Board of 
Finland (permit number ESAVI/198/04.10.07/2014). In some experiments, the mice were 
habituated to handling prior to any procedures using a progressive handling protocol (see 
Study IV).
4.3.  Stereotac  c 6-OHDA administra  on and postopera  ve care
Unilateral lesioning of the nigrostriatal pathway was induced by stereotactic injections of 
6-OHDA under isofl urane anesthesia. To model moderate and advanced Parkinson’s disease, 
two 6-OHDA models with diff erent sites of injection (striatum and MFB, respectively) were 
used. 6-OHDA was dissolved in 0.02 % ascorbate-saline and injected using a stereotaxic 
frame (Stoelting, Wood Dale, IL, USA) at the coordinates given below, relative to the 
bregma and the dural surface. In the intrastriatal model, two 1 μl injections containing 6 
μg 6-OHDA each were administered into the left  dorsal striatum. In Study I, the sites were 
1: A/P +1.0; L/M +1.9; D/V −2.9, and 2: A/P +0.3; L/M +2.0; D/V −2.9. In Study II, the 
sites were identical except for being slightly more lateral: 1: L/M +2.1; 2: L/M +2.3. In the 
intra-MFB model, one 0.2 μl injection containing 3 μg 6-OHDA was administered into the 
right MFB at A/P -1.2; L/M -1.1; D/V −5.0. In Studies I and II, desipramine (25 mg/kg, 
i.p.) was administered 30 min prior to surgery to inhibit noradrenergic neurodegeneration. 




Th e postoperative care necessary to ensure the survival of operated hemiparkinsonian 
mice was improved throughout the studies, and in its fi nal form was provided for 14 
consequtive days and included daily systematic welfare assessment, warm saline injections 
to prevent dehydration, food pellets soft ened by soaking, additional high-energy diet 
(Bacon Soft ies, Bio-Serv, Flemington, NJ, USA; Nutriplus gel, Virbac, Carros, France), 
feeding by hand, and alleviating hypothermia with heating pads. See Study IV for more 
details on the postoperative care. Postoperative mortality, mostly due to euthanasia, was 
(listed in chronological order) 11 out of 39 (28 %) in Study II (intrastriatal model), 32 out 
of 56 (57 %) in Study I pilot experiments (intra-MFB model), 1 out of 15 (7 %) in Study 
III (intra-MFB), and 2 out of 22 (9 %) and 3 out of 22 (14 %) in Study I main experiments 
(intrastriatal and intra-MFB, respectively).
4.4.  In vivo experiments
4.4.1.  Drug-induced rotametry and locomotor activity (Study I)
Rotation induced by dopaminergic drugs, refl ecting the interhemispheric dopaminergic 
imbalance in unilateral parkinsonism, was measured 2–3 weeks aft er the 6-OHDA 
injections. A Roto-Rat automated rotametry apparatus (Med Associates, St. Albans, VA, 
USA) was used. Mice were administered amphetamine (2.5 mg/kg, i.p.) or apomorphine 
(0.5 mg/kg, i.p.), attached to automatic detectors with cable ties and an iron wire, and 
placed in a plexiglass cylinder (11 x 15 cm). Rotations were measured at 5 min intervals 
and expressed as net ipsi- or contralateral rotations. 
Th e eff ect of amphetamine on locomotion in intact mice was measured using an automated 
infrared activity monitor (Activity Monitor, Med Associates). Mice were placed in a 43 
x 43 cm plexiglass chamber for 30 min, aft er which amphetamine (2.5 mg/kg, i.p.) was 
administered. Th e distance travelled by the animal was measured at 5 min intervals via 
photobeam interruption.
4.4.2.  Drug treatments
To induce dyskinesia, lesioned mice were administered levodopa and the AADC inhibitor 
benserazide daily (Mon-Fri) in a single s.c. injection. Dosages were chosen on the basis of 
literature (Lundblad et al., 2004; Francardo et al., 2011; Th iele et al., 2011). Note that two 
diff erent strategies of levodopa:benserazide dosing were used, where in later studies the 
benserazide dose was lowered to match the 4:1 ratio used clinically (Th iele et al., 2011). In 
Study II, nicotine treatment was initiated simultaneously with the levodopa treatment. In 
all other experiments, other drug treatments were initiated aft er LID had already developed 
to better mimic the potential clinical use scenario. 
See Figure 10 for the time courses of the drug treatments in each experiment. In Studies 
I–III, nicotine was administered in pH-adjusted drinking water with no other source of 
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Figure 10. Summary of the experiments discussed within this thesis. Shown are time course, 
lesion model, sex and age at the time of lesioning, drug treatments, and in vivo and ex vivo 
measurements performed. α5-KO refers to experiments including mice lacking the α5 nicotinic 
receptor subunit. Study order does not refl ect the chronological order of the experiments. 
6-OHDA = 6-hydroxydopamine; AMA = amantadine; BDNF = brain-derived neurotrophic 
factor; HPLC = high-performance liquid chromatography; IHC = immunohistochemistry; 
MFB = medial forebrain bundle; qPCR = quantitative polymerase chain reaction
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fl uid available. Th e nicotine concentration was gradually raised to 300 μg/ml during 2–3 
weeks as previously described (Pekonen et al., 1993; Pietilä et al., 1995). In Studies I and 
III, saccharin (2 %) was added to both nicotine and control solutions to mask the taste 
of nicotine (Huang, Grady, and Quik, 2011). Water consumption was measured every 
2–3 days. In Study III, the α7 nAChR partial agonist AZD0328 (Sydserff  et al., 2009) was 
administered for three weeks at escalating doses of 0.03 mg/kg, 0.1 mg/kg, and 1.0 mg/
kg (s.c.). Each dose was given for fi ve days 30 min prior to levodopa administration, with 
control mice receiving saline injections, and dyskinesia severity was assessed on the fi ft h 
day. Amantadine was administered acutely in an additional series of experiments, following 
chronic administration of a histamine H3 receptor antagonist (not discussed in this thesis) 
and a prolonged washout. First, 60 mg/kg amantadine (i.p.) or saline was administered 60 
min before levodopa. Following a second washout, 60 mg/kg amantadine or saline was 
administered 0 or 100 min before levodopa. Finally, a week later 5 or 15 mg/kg amantadine 
or saline was administered 60 min before levodopa.
4.4.3.  Assessment of dyskinesia severity
Following the levodopa injection, mice were individually video recorded in transparent 
cylinders fl anked by two vertical mirrors using a web camera (HD Pro C920, Logitech, 
Newark, CA, USA). In Study II, mice were recorded every 30 min for 60 s and remained 
in the cylinder throughout. In all other studies, mice were recorded every 20 min for 60 
s and were returned to the home cage in between. Dyskinesia severity was assessed from 
the recordings by a researcher blinded to the experimental group and the time aft er 
levodopa injection. Dyskinesia were classifi ed into three subtypes (axial, orolingual, 
and forelimb dyskinesia) based on topographic distribution and rated on a scale of 0–4 
according to criteria assessing both amplitude and frequency of dyskinetic behaviors 
(Table 6). Th e scoring criteria were developed on the basis of previously published scoring 
methods (Lundblad et al., 2004; Cenci and Lundblad, 2007; Th iele et al., 2011) and the 
video recordings of LID of varying severity obtained in the present studies. See 6.1.2. for 
discussion on the novel scoring method. Some recordings were additionally scored using 
the method of Lundblad et al. (2004). Mice that did not develop dyskinesia (16 % of all 
levodopa-treated mice) were not included in any dataset.
Scores of each dyskinesia subtype (0–4) as well as total dyskinesia scores (sum of the 
subtype scores, 0–12; Lundblad et al., 2004) were analyzed. Integrated weekly scores 
were calculated as the sum or the area under the curve of the scores obtained within one 
recording session (Cenci and Lundblad, 2007). Finally, integrated dyskinesia scores across 
multi-week experiments were calculated as the area under the curve of the weekly scores.
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Table 6. Criteria used for scoring dyskinetic behavior in mice. For axial dyskinesia, the given 





0 Normal physiological motor repertoire.
1 Contralateral deviation of the head and trunk with one or both 
forelimbs contacting the ground. Mouse is steady or moving. 
2 Contralateral deviation of the head and trunk in a bipedal sitting 
position.
3 Contralateral deviation of the head and trunk in a bipedal sitting 
position, causing loss of balance.
4 In a bipedal sitting position, head and trunk fi xed and in a severely 
twisted position followed by a loss of balance.
Orolingual 
dyskinesia
0 Normal physiological motor repertoire.
1 Vacuous chewing movements OR occasional (≤10 times per minute) 
biting of the contralateral side/limbs.
2 Vacuous chewing movements, including tongue protrusions OR 
repeated (11–19 times) biting of the contralateral side/limbs.
3 Sustained (3–5 s) vacuous chewing movements, including tongue 
protrusions, OR frequent (≥20 times) or sustained (3–5 s) biting of 
the contralateral side/limbs. 
4 Prolonged (>5 s) vacuous chewing movements, including tongue 




0 Normal physiological motor repertoire.
1 Isolated jerky movements of the contralateral distal forelimb.
2 Repetitive, small movements (vertical or horizontal) of the 
contralateral forelimb involving the distal and proximal forelimb; <50 
% of time. 
3 Repetitive, small movements of the contralateral forelimb as in 2; 
50–100 % of time. 
4 Repetitive, large movements (vertical or horizontal) of the 




4.5.1.  Tyrosine hydroxylase immunostaining
Dopaminergic denervation was quantifi ed from brain sections stained for the dopaminergic 
neuron-specifi c enzyme TH. Mice were either anesthetized with sodium pentobarbital (100 
mg/kg, i.p.) and perfused intracardially with phosphate-buff ered saline (PBS) followed by 
4 % paraformaldehyde (PFA) in PBS, pH 7.4 (Study I pilot, Study II); or killed by cervical 
dislocation with the posterior part of the brain containing the SN dissected on ice. In both 
cases, the brains were immersed overnight in 4 % PFA in PBS at +4 °C and then stored in 
20 % sucrose in PBS at +4 °C. Subsequently, the brains were frozen in isopentane on dry ice 
and stored at -80 °C. Free-fl oating coronal sections were cut with a Leica CM3050 cryostat 
(Leica Biosystems, Nussloch, Germany) and stored at -20 °C. Sections were cut at 40 μm 
(Study I, intrastriatal model) or 30 μm thickness. 
TH immunostaining followed a previously described protocol (for a detailed description, 
see Mijatovic et al., 2007) with minor variations. In brief, sections were washed in 
PBS and blocked fi rst by H2O2 and then by normal goat serum. Next, the sections were 
incubated overnight at +4 °C with the primary antibody (rabbit anti-TH, 1:2000; AB152, 
Millipore, Bedford, MA, USA). Aft er washing in PBS, the sections were incubated for 1 h 
with either the secondary antibody (biotinylated goat anti-rabbit, 1:500; BA1000, Vector 
Laboratories, Burlingame, CA, USA) or biotinylated protein A (see below). Subsequently, 
the sections were washed in PBS, and the staining was reinforced using the avidin-biotin 
complex method (Vectastain Elite ABC kit, Vector Laboratories) and visualized with 
diaminobenzidine. Th e stained sections were dehydrated in graded ethanols, cleared in 
xylene, and coverslipped with Depex mounting medium (VWR International, Poole, UK).
Th e use of biotinylated protein A was an exception to the previously described protocol. 
Th e reagent was prepared using protein A (MP Biomedicals, Santa Ana, CA, USA) and 
N-hydroxysuccinimido-biotin (Sigma-Aldrich). In brief, protein A was incubated for 1 h 
with N-hydroxysuccinimido-biotin, and the reaction mixture dialyzed overnight at +4 °C 
(membrane cutoff  12–14 kDa, SpectraPor 4, Spectrum Laboratories, Rancho Dominguez, 
CA, USA). Th e mixture was then stored at -20 °C, and used as 1:100 in PBS with 0.5 % 
bovine serum albumin.
4.5.2.  Densitometric and stereological analyses
Both densitometric quantifi cation of immunostaining and stereological counting of stained 
cell bodies were used. For densitometric analyses, stained brain sections were imaged using 
a 3DHISTECH slide scanner (3DHISTECH, Budapest, Hungary). Optical density across 
the SNC (Fu et al., 2012) and/or the dorsal striatum (Franklin and Paxinos, 1997) was 
measured using ImageJ 1.6 (NIH, Bethesda, MD, USA). Optical density of background 
staining was subtracted and the results expressed as percent of intact side. Th e lesion extent 
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in the SNC and the striatum was calculated as the mean of three consecutive sections 
(every 6th section) between −2.9 and −3.4 mm or +0.1 and +1.0 mm from the bregma, 
respectively.
In Study I, the numbers of TH-positive neurons in the dorsal tier (SNCD) and the medial 
cluster (SNCM) of the SNC were estimated by blinded unbiased stereological cell counting. 
Demarcation of brain areas followed published delineations (Franklin and Paxinos, 1997; 
Fu et al., 2012). Th ree consecutive sections (every third section in the striatal model, 
every sixth section in the MFB model) were selected between levels −2.9 and −3.4 mm or 
between −3.1 and −3.6 mm from the bregma for the SNCD and the SNCM, respectively. 
StereoInvestigator (MBF Bioscience, Williston, VT, USA) was used to fi rst outline the 
region at 4x magnifi cation and then count stained cell bodies with an optical fractionator, 
according to optical disector rules (Gundersen et al., 1988), at regular intervals (SNCD: x 
= 80 mm, y = 80 mm; SNCM: x = 60 mm, y = 60 mm) within a counting frame (60 mm x 
60 mm) superimposed on an image obtained using a 60x oil objective (Olympus Plan/Apo, 
Olympus, Tokyo, Japan). Gundersen’s coeffi  cients of error (CE) were ≤0.15 for the intact 
hemisphere. Data were expressed as percentage of the intact hemisphere.
4.6.  Ex vivo assays
4.6.1. Synaptosomal [3H]dopamine uptake (Study I)
To study the eff ects of the lack of α5* nAChRs on DAT function, dopamine uptake into 
synaptosomes was measured using tritiated dopamine as a marker. Intact mice were killed 
by cervical dislocation and samples of the striatum collected on ice using tweezers. Th e 
samples were homogenized by hand using a glass-tefl on homogenizer in 2 ml of ice-cold 
homogenization buff er (0.32 M sucrose, 5 mM HEPES, pH 7.5). A 200 μl aliquot was 
centrifuged at 1000 g for 10 min at +4 °C followed by centrifugation of the fi rst supernatant 
at 12000 g for 20 min at +4 °C. Th e pellet was resuspended in 800 μl of uptake buff er (128 
mM NaCl, 2.4 mM KCl, 3.2 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 10 mM glucose, 1 
mM ascorbic acid, 10 μM pargyline, 25 mM HEPES pH 7.5, 0.1 % bovine serum albumin). 
Th e uptake assay was then performed in a MultiScreen HTS 96-well fi lter-bottomed 
plate (Millipore, Bedford, MA, USA) in a volume of 100 μl uptake buff er containing 25 
μl of the synaptosome suspension and 1 μM dopamine (2 % [3H]dopamine). 200 μM 
nomifensine was used for blank determination. Solutions were incubated for 30 min at 
room temperature before aspiration and washing the fi lters with 6 x 200 μl cold uptake 
buff er. OptiPhase Supermix scintillation cocktail (100 μl/well; PerkinElmer) was added, and 
radioactivity measured with liquid scintillation counting (5 min per well; 1450 MicroBeta 
TriLux; Wallac, Turku, Finland). Th e protein concentrations of synaptosomal suspensions 
were measured using the Bradford method (Bradford Reagent, Sigma-Aldrich). Data were 
expressed as pmol of dopamine taken up per μg of protein.
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4.6.2.  Dopamine transporter Western blotting (Study I)
To study the eff ects of the lack of α5* nAChRs on DAT expression, DAT, phospho (T53)-
DAT (pDAT), and β-actin protein levels were measured using the methods of Julku et al. 
(2018) with some modifi cations. Intact mice were killed by cervical dislocation, and the 
brains were rapidly dissected, frozen in isopentane on dry ice, and stored at -80 °C. Tissue 
samples from the dorsal striatum were collected in a Leica CM3050 cryostat using a sample 
corer (for a detailed description, see Julku et al., 2018). Samples were homogenized using 
ultrasound ( GM35-400, Rinco Ultrasonic, Romanshorn, Switzerland) in fi ve volumes of ice-
cold modifi ed RIPA buff er (50 mM Tris pH 7.4, 1 % NP-40, 0.25 % sodium deoxycholate, 
150 mM NaCl) additionally containing Halt Phosphatase and Protease Inhibitor cocktails 
(Th ermo Fisher Scientifi c, Rockford, IL, USA). Th e homogenates were centrifuged at 16000 
g for 15 min at +4 °C and the supernatants collected. Protein concentrations were measured 
with the BCA method (Pierce BCA Assay Kit, Th ermo Fisher Scientifi c).
Samples were diluted in Laemmli buff er (Bio-Rad, Hercules, CA, USA) containing 
β-mercaptoethanol and boiled for 5 min, aft er which 30 μg of protein was loaded onto 
4–20 % (DAT) or 8–16 % (pDAT) Mini-PROTEAN TGX precast gels (Bio-Rad). Gels were 
ran for 30 min at 200 V in running buff er (25 mM Tris, 190 mM glycine, 0.1 % sodium 
dodecyl sulphate) and transferred to Trans-blot Turbo midi nitrocellulose membranes 
(Bio-Rad) using a Trans-blot Turbo Transfer System (Bio-Rad). Membranes were blocked 
for 1 h at room temperature in 5 % skim milk in 0.05 % Tween-20 in Tris-buff ered saline 
(TTBS), incubated with the primary antibody diluted in 5 % skim milk in TTBS overnight 
at +4 °C, washed in TTBS, and incubated with the secondary antibody diluted in 5 % skim 
milk in TTBS for 2 h at room temperature. Th e following primary antibodies were used: 
DAT, rabbit anti-DAT (1:1000, #PA1-4656, Th ermo Fisher Scientifi c); pDAT, rabbit anti-
phospho(T53)-DAT (1:500, #ab183486, AbCam, Cambridge, UK); β-actin, rabbit anti-
β-actin (1:2000, #ab8227, AbCam). Th e secondary antibody used was goat anti-rabbit 
horseradish peroxidase (1:2000, #31460, Th ermo Fisher Scientifi c). Aft er washing the 
membranes in TTBS and in TBS, they were incubated for 5 min with SuperSignal West Pico 
(DAT, β-actin) or Femto (pDAT) chemiluminescence substrate (Th ermo Fisher Scientifi c 
Scientifi c). Images were captured with a LI-COR C-digit chemiluminescence scanner (LI-
COR, Lincoln, NE, USA). Optical density values were measured using ImageJ 1.6 and 
normalized to loading control (β-actin) optical density values, with the data expressed as 
percentage of wild-type mean.
4.6.3.  Dopamine and metabolite HPLC (Study I)
Th e eff ects of the lack of α5* nAChRs on striatal tissue levels of dopamine and its 
metabolites were studied using high-performance liquid chromatography (HPLC). 
Intact mice were killed by cervical dislocation, and samples of the dorsal striatum were 
collected using a chilled mouse brain matrix and a sample corer (for a detailed description, 
see Airavaara et al., 2004) and stored at -80 °C. Tissue concentrations of dopamine, 
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3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) were measured 
using methods described by Julku et al. (2018). In brief, the samples were homogenized 
using ultrasound (GM35-400, Rinco Ultrasonic) in 0.5 ml of homogenization solution 
consisting of six parts of 0.2 M HClO4 and one part of antioxidant solution (oxalic acid, 
acetic acid, L-cysteine). Th e homogenates were centrifuged at 20800 g for 35 min at +4 
°C. Supernatants were transferred to 0.5 ml Vivaspin fi lter concentrators (10000 MWCO 
PES; Vivascience, Hannover, Germany) and centrifuged at 8600 g for 35 min at +4 °C. Th e 
fi ltrates were then analyzed with HPLC with electrochemical detection. See Julku et al. 
(2018) for a detailed description of the HPLC system. Chromatograms were processed and 
analyte concentrations calculated using CoulArray (ESA Biosciences, Chelmsford, MA, 
USA). Data were expressed as μg of analyte per gram of wet tissue.
4.6.4.  Dopamine receptor qPCR (Study I)
Th e eff ects of the 6-OHDA lesion and the lack of α5* nAChRs on dopamine receptor 
expression were studied by measuring D1R and D2R mRNA with the quantitative 
polymerase chain reaction (qPCR) method. Mice lesioned with intrastriatal 6-OHDA were 
killed by cervical dislocation, and samples of the dorsal striatum of both hemispheres were 
collected using a chilled mouse brain matrix and a sample corer (Airavaara et al., 2004) 
and stored at -80 °C. Tissue from age- and sex-matched control mice (C57BL/6JRccHsd) 
was pooled in two groups to have separate native controls for both hemispheres. RNA 
was isolated using an RNAeasy Mini kit (Qiagen, Hilden, Germany) and DNase digestion 
performed using an RNase-Free Dnase set (Qiagen) as described by the manufacturer. RNA 
was quantifi ed with a NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, 
Wilmington, DE, USA) and converted to cDNA by Super-Script III First-Strand Synthesis 
SuperMix and oligo(dT) primers (Invitrogen, Carlsbad, CA, USA). For qPCR, cDNA 
was diluted with RNase free water, and 4.5 ml of cDNA used per well in a 10 ml reaction 
volume. ABsolute Blue QPCR Mix, ROX (Th ermo Scientifi c, Waltham, MA, USA) was 
mixed with TaqMan primers and hydrolysis probes (Applied Biosystems, Foster City, CA, 
USA; catalogue numbers: Dopamine 1 receptor, Mm02620146_s1; Dopamine 2 receptor, 
Mm00438545_m1). PCR amplifi cation was performed on 384-well plates using a Roche 
LightCycler (Roche Diagnostics, Mannheim, Germany) with 1 cycle of 15 min at 95 °C, 
40 cycles of 15 s at 95 °C, and 40 cycles of 1 min at 60 °C by turns. Expression of target 
genes was normalized to the pooled control with the reference gene GAPDH (TaqMan, 
Mm99999915_g1). Relative mRNA expression was calculated using the 2-ΔΔCt method and 
data expressed as fold change in mRNA levels (Livak and Schmittgen, 2001).
4.6.5.  Synaptosomal [3H]dopamine release (Study II) 
To study the eff ects of the 6-OHDA lesion and chronic nicotine treatment on striatal 
dopamine release, the release of dopamine from synaptosomes was measured using tritiated 
dopamine as a marker. Mice lesioned with intrastriatal 6-OHDA were assayed either aft er 
the lesioning or at the end of chronic drug treatments (see Figure 10). Mice were killed by 
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cervical dislocation 1 h aft er the last levodopa administration, and samples of the dorsal 
and ventral striatum collected using a chilled mouse brain matrix and a sample corer (for 
detailed description see Airavaara et al., 2004). Subsequently, the methods of Salminen et 
al. (2004) were followed with minor modifi cations. Th e samples were homogenized by hand 
using a glass-tefl on homogenizer in 500 μl of ice-cold homogenization buff er (see 4.6.1.). 
Th e homogenate was combined with two 500 μl rinses of the homogenizer and centrifuged 
at 12000 g for 20 min at +4 °C. Th e pellet was resuspended in 800 μl of uptake buff er (see 
4.6.1., not containing bovine serum albumin) and incubated for 10 min at +37 °C. Th en, 
4 μCi of [3H]dopamine (fi nal concentration ~0.1 μM) was added, and the suspension 
incubated for 5 min at +37 °C. Aliquots of 80 μl were distributed to parallel fi lters and 
superfused at room temperature with superfusion buff er (uptake buff er additionally 
containing 1 μM nomifensine, 1 μM atropine and 0.1 % bovine serum albumin) at ~0.8 ml/
min. Aft er 10 min of superfusion to wash off  [3H]dopamine not taken up, the synaptosomes 
were stimulated by switching for 20 s to superfusion buff er containing 10 μM nicotine. To 
determine α4β2*-mediated release, 50 nM α-conotoxin MII was added to the superfusion 
buff er for 3 min before stimulation. Each mouse was assayed with 2–4 parallel replicates. 
Th e superfusate was collected on 96-well plates in 10 s (~130 μl) fractions, OptiPhase 
Supermix scintillation cocktail (100 μl/well) was added, and radioactivity was measured 
with liquid scintillation counting (1 min per well; 1450 MicroBeta TriLux).
[3H]dopamine release data were analyzed using R 2.15.2 (R Core Team). Data were plotted 
as counts per minute (CPM) versus fraction number, and basal release was calculated for 
each fraction by single exponential decay from fractions collected before and aft er the 
stimulated release peak. Fractions exceeding basal release by 15 % or more were summed to 
give the amount of nicotine-stimulated release above baseline. Basal release during the fi rst 
fraction was used as an overall measure of basal release.
4.6.6.  BDNF ELISA (Study III)
To study the eff ects of long-term treatments with levodopa and nicotine on the BDNF, 
BDNF protein levels in the striatum and the prefrontal cortex (PFC) were measured at the 
end of the drug treatments (see Figure 10). Mice were killed by cervical dislocation 4 h aft er 
the last levodopa administration, and samples of the striatum and PFC were dissected on 
ice and stored at -80 °C until use. Extraction of proteins was done essentially as described by 
Rantamäki et al. (2013). A commercial ELISA kit (BDNF Emax® ImmunoAssay; Promega, 
Madison, WI, USA) was used. Th e manufacturer’s instructions were followed except for two 
modifi cations. First, Optacoat™ (ALerCHEK, Springvale, ME, USA) was used as the coating 
buff er, and second, the samples were transiently acidifi ed and neutralized (Rantamäki et al., 
2013) without fi rst diluting them in DPBS, followed by dilution with Block & Sample 1X 




4.7.  Sta  s  cal methods 
All data are represented as mean ± SEM or as box plots with median, quartiles, range, 
and distribution shown. Outliers were removed from all data using the Tukey Box-Plot 
method (Tukey, 1977). Group diff erences were analyzed with unpaired two-tailed Student’s 
t-tests, analyses of variance (ANOVA), or repeated measures ANOVA (RM-ANOVA) as 
appropriate. Th e Bonferroni post hoc correction was used for multiple comparisons aft er 
ANOVA, and multiplicity-adjusted P values are reported. For RM-ANOVA, missing values 
were interpolated with linear regression, and the assumption of sphericity was tested with 
Mauchly’s test and corrected with the Greenhouse-Geisser correction. Pearson’s correlation 
coeffi  cients were calculated for correlation analyses.  Diff erences in postoperative mortality 
and successful lesioning were analyzed with Pearson’s Chi-Square tests. Parallel non-
parametric statistical analyses of integrated dyskinesia scores were performed with 
Mann-Whitney U tests, Kruskal-Wallis ANOVA with Dunn’s post hoc correction, or by 
calculation of Spearman’s correlation coeffi  cients (see 6.1.2. below for the rationale). Th e 
level of statistical signifi cance was set at P < 0.05. Statistical analyses were performed with 
GraphPad Prism 7 (GraphPad Soft ware, La Jolla, CA, USA), with the exception of three-
way RM-ANOVA and all sphericity tests and corrections, which were performed with IBM 




5.1.  Characteriza  on of the 6-OHDA lesion models in wild-type 
mice
See Figure 11 for representative brain sections of mice lesioned with intrastriatal and intra-
MFB 6-OHDA injections. 4–5 weeks aft er 6-OHDA injections into the dorsal striatum, a 
partial loss of TH-positive immunostaining in the dorsal striatum (35 ± 1 % remaining) and 
the SNC (40 ± 10 % remaining) was observed densitometrically, with the ventral striatum 
being less aff ected (Study II, n = 5 female mice). Similarly, stereological counting in the 
SNC showed a partial loss of dopaminergic neurons 3–4 weeks aft er intrastriatal 6-OHDA 
injections, with 17 ± 3 % of cell bodies remaining in the SNCD and 19 ± 3 % in the SNCM 
(Study I, n = 7 mice, 5 female). 
Figure 11: Representative brain sections, immunostained for tyrosine hydroxylase, from 
mice lesioned with stereotactic 6-OHDA injections. Two injections of 6 μg 6-OHDA into 
the dorsal striatum resulted in partial nigrostriatal denervation (Study II). Partial losses of 
immunostaining in the dorsal striatum (A) and the dopaminergic areas of the ventral midbrain 
(B) were observed, the latter being mostly restricted to the substantia nigra. Note that in 
Study I intrastriatal 6-OHDA was administered slightly more medially. One injection of 3 μg 
6-OHDA into the medial forebrain bundle resulted in much more severe nigrostriatal as well 
as mesolimbic denervation (Study I). A practically total loss of immunostaining was observed 
in both the dorsal and ventral striatum (C), along with a marked loss of immunostaining in the 
ventral midbrain (D) that extended also to other dopaminergic areas. Sections were cut at ca. 
+0.8 mm (A, C) or -3.3 mm (B, D) from the bregma.
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In the fi rst experiments with intra-MFB 6-OHDA injections, variable results were obtained 
(see Study I, Supplement), likely refl ecting the challenging procedure. Subsequent studies 
confi rmed that successful intra-MFB 6-OHDA injections resulted in a practically total 
abolishment of TH-positive immunostaining in both the dorsal and the ventral striatum 
(not reliably quantifi able with densitometry), along with a marked loss of immunostaining 
in the SNC (9 ± 2 % remaining 20 weeks aft er the lesion in Study III; n = 10 female mice). 
Similarly, HPLC measurements showed a near-total loss of dopamine in the dorsal striatum 
(1.8 ± 0.4 % remaining 15 weeks lesioning in Study I; n = 5 female mice), and stereological 
counting found a near-total loss of dopaminergic cell bodies in the SNCD (6 ± 1 % 
remaining, Study I; n = 8). Surprisingly, however, neurodegeneration in the SNCM was 
only partial in these mice (45 ± 5 % remaining, n = 8).
5.2.  Eff ects of α5 gene dele  on in mouse models of Parkinson’s 
disease
5.2.1.  Effects of α5 gene deletion on dopaminergic denervation and drug-
induced rotation (Study I)
To study the consequences of the lack of α5* nAChRs in mouse models of PD, the extent of 
the nigrostriatal denervation in 6-OHDA-lesioned α5-KO and WT mice was determined 
by stereological counting of TH-positive cell bodies within the SNCD and the SNCM. Th e 
SNC subdivisions were analyzed separately due to their readily apparent diff erence in lesion 
extent in MFB-lesioned mice. See Study I, Fig. 1 for images of representative brain sections 
and examples of delineations of the SNCD and the SNCM. Measurements of drug-induced 
locomotion were used for behavioral characterization of the dopaminergic lesions as well 
as for assessment of the eff ects of amphetamine in intact animals. Results pertaining to LID 
in α5-KO mice are presented later (5.3.3., Figure 19).
Figure 12 shows the results of stereological cell counting in the intrastriatal 6-OHDA 
lesion model. Both subdivisions of the SNC had suff ered lesions of roughly similar extent. 
Numbers of remaining cells were estimated with CE 0.14–0.39 for SNCD and CE 0.12–
0.28 for SNCM. In the SNCD, no diff erence was found between WT and α5-KO animals in 
TH-positive cells remaining (WT 16.6 ± 2.9 % vs. α5-KO 18.8 ± 2.9 %; two-way ANOVA, 
main eff ect of genotype, F(1,13) = 0.96, P = 0.346; n = 7 WT, 5 female; 10 KO, 7 female). 
SNCD cell loss tended to be more pronounced in male animals (main eff ect of sex, F(1,13) 
= 4.06, P = 0.065). In the SNCM, in contrast, more TH-positive cells remained in α5-KO 
animals (WT 18.5 ± 2.9 % vs. α5-KO 26.9 ± 1.5 %; main eff ect of genotype, F(1,13) = 6.72, 




Figure 12. Attenuated dopaminergic denervation in α5-knockout mice.  α5-knockout (KO) 
and wild-type (WT) mice were lesioned with 6-hydroxydopamine injections into the dorsal 
striatum. Lesion extent was determined 30 days aft er surgery by stereological counting of 
tyrosine hydroxylase (TH)-positive cell bodies in the dorsal tier (SNCD) and the medial cluster 
(SNCM) of the substantia nigra pars compacta. In the SNCM, more TH-positive cells remained 
in α5-KO mice. * P < 0.05, two-way ANOVA. n = 7 WT, 10 KO. 
See Study I, Fig. 2 for the results of drug-induced rotation and locomotion tests in 
intrastriatally lesioned and intact mice. Among intrastriatally lesioned mice, female α5-KO 
mice performed fewer ipsilateral rotations aft er amphetamine administration than female 
WT mice (two-way RM-ANOVA, main eff ect of genotype, F(1,11) = 5.23, P = 0.042; n = 
5 WT, 8 KO), but there was no statistically signifi cant genotype diff erence in contralateral 
rotations aft er apomorphine administration. In contrast, among male animals there was no 
genotype diff erence in amphetamine-induced rotations but α5-KO mice performed more 
apomorphine-induced rotations than WT mice (two-way RM-ANOVA, main eff ect of 
genotype, F(1,5) = 16.1, P = 0.010; n = 3 WT, 4 KO). In intact mice, no genotype diff erence 
was observed in the distance travelled aft er amphetamine administration ( two-way 
RM-ANOVA, main eff ect of genotype, F(1,25) = 0.01, P = 0.930; n = 14 WT, 6 female; 13 
KO, 10 female), with similar results for both sexes (males: F(1,9) = 0.22, P = 0.652; females: 
F(1,14) = 0.39, P = 0.544; data not shown).
See Study I for the immunohistochemical and rotametry results obtained using the intra-
MFB 6-OHDA lesion model. In the pilot experiment (Study I, Supplement; male mice), 
although lesion success was variable and postoperative mortality was high (52 % WT, 63 
% KO), fewer successful severe striatal lesions were observed in surviving α5-KO animals 































WT, 9 KO). Moreover, α5-KO mice tended to perform fewer rotations aft er amphetamine 
administration (two-way RM-ANOVA, main eff ect of genotype, F(1,13) = 4.40, P  = 0.056; 
n = 8 WT, 7 KO). In the main experiment (Study I, Fig. 3; female mice), a rough estimate 
(CE 0.25–0.71) suggested no genotype diff erence in the proportion of TH-positive cells 
remaining in the lesioned SNCD (WT 6.0 ± 0.9 % vs. α5-KO 8.5 ± 2.2 %; two-way ANOVA, 
main eff ect of genotype, F(1,13) = 1.01, P = 0.332; n = 8 WT, 10 KO). In the SNCM, more 
accurate estimates (CE 0.13–0.24) could be obtained due to a markedly less severe cell loss, 
and no signifi cant genotype diff erence was found in cells remaining (WT 45.1 ± 5.2 % vs. 
α5-KO 36.4 ± 3.7 %; main eff ect of genotype, F(1,13) = 2.59, P = 0.131). Th e number of cells 
remaining did not diff er between nicotine-treated and control mice in either area. Results 
of HPLC analyses of striatal dopamine levels are not shown, as a signifi cant number of 
samples were accidentally destroyed, preventing meaningful group comparisons. Female 
α5-KO mice of the intra-MFB model tended to perform fewer amphetamine-induced 
rotations than WT mice (two-way RM-ANOVA, main eff ect of genotype, F(1,18) = 3.70, P 
= 0.070; n = 10 per genotype).
5.2.2.  Effects of α5 gene deletion on striatal markers of dopaminergic 
function (Study I)
Various dopaminergic markers were measured to investigate the eff ects of the lack of α5* 
nAChRs on the dopaminergic system. Uptake of dopamine into striatal synaptosomes 
(Figure 13) was decreased in intact α5-KO mice, suggesting reduced DAT function (main 
eff ect of genotype, F(1,22) = 6.62, P = 0.017; n = 13 WT, 5 female; 13 KO, 4 female). 
Dopamine uptake was larger in male than female animals (main eff ect of sex, F(1,22) = 
6.30, P = 0.020), but the genotype diff erence was similar in both sexes. 
No genotype diff erences were found in other dopaminergic markers (see Study I, Fig. 4). 
When striatal DAT and pDAT protein levels were measured with Western blotting, no 
statistically signifi cant genotype or sex diff erences were found (n = 6 WT, 4 female; 8 KO, 
5 female). Similarly, no statistically signifi cant genotype or sex diff erences were found 
in striatal tissue concentrations of dopamine or its metabolites, measured with HPLC 
from intact mice (n = 9 WT, 5 female; 13 KO, 7 female). Finally, the striatal expression 
of dopamine D1 and D2 receptor mRNA was measured with qPCR from intrastriatally 
lesioned mice. Th e dopaminergic lesion signifi cantly reduced both D1R and D2R mRNA 
expression (three-way ANOVA, main eff ect of hemisphere, D1R: F(1,32) = 25.9, P < 0.001; 
D2R: F(1,32) = 21.2, P < 0.001; n = 8 WT, 5 female; 12 KO, 8 female). However, expression 
did not diff er between genotypes. D1R mRNA expression was larger in male than female 
animals (main eff ect of sex, F(1,32) = 21.2, P < 0.001). Th e lesion-induced decrease in D1R 
and possibly D2R mRNA was greater in male animals (sex × hemisphere interactions, D1R: 
F(1,32) = 14.6, P < 0.001; D2R: F(1,32) = 3.77, P = 0.061).
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Figure 13. Reduced synaptosomal dopamine uptake in α5-knockout (KO) mice when compared 
to wild-type (WT) mice. * P < 0.05, two-way ANOVA. Uptake was larger in male mice (P < 
0.05). n = 13 WT, 13 KO, assayed in triplicate.
5.3.  Levodopa-induced dyskinesia in mouse models of Parkinson’s 
disease
5.3.1.  Characterization of levodopa-induced dyskinesia in mice (Studies 
I–III)
Th e majority of the mice lesioned with 6-OHDA and treated with repeated systemic 
administration of levodopa and benserazide (41 out of 49 mice in total, 84 %) developed 
abnormal involuntary movements, considered to model LID. See Figure 14 for examples 
of such abnormal movements. Th e abnormal movements typically developed within days, 
and breaks in levodopa administration during weekends or washouts had no discernible 
eff ect on their expression. As previously reported (Lundblad et al., 2004; Francardo et al., 
2011), some animals did not develop LID, and mice of the intra-MFB model were much 
more sensitive to levodopa than mice of the intrastriatal model. Th e latter was refl ected by 
lower levodopa doses needed to induce dyskinesia, the dyskinesia being considerably more 
severe, and a smaller proportion of mice remaining non-dyskinetic (3 out of 33 mice, 9 %, 
vs. 5 out of 16 mice, 31 %).
Figure 15 shows baseline dyskinesia scores, obtained using the novel criteria in Table 6, 
in wild-type mice aft er 2–3 weeks of levodopa administration. Note that the data were 
combined from diff erent experiments (see Figure 10) using similar methodology (but 
see below). Figure 15A shows axial, orolingual and forelimb dyskinesia scores as well as 
total dyskinesia scores (a measure of global dyskinesia of an animal) elicited by diff erent 
doses of levodopa in female mice lesioned with intra-MFB 6-OHDA injections (3 mg/kg, 
Study I; 4.5 mg/kg, amantadine study; 6 mg/kg, Study III; n = 8–17 per group). Figure 15B 
shows, for comparison, dyskinesia scores elicited by 30 mg/kg levodopa in mice lesioned 





























with levodopa expressed all dyskinesia subtypes in a time-dependent manner (2-way 
RM-ANOVA, main eff ect of time, axial: F(3.0,103.3) = 20.0, P < 0.001; orolingual: F(4,136) 
= 15.1, P < 0.001; forelimb: F(3.1,105.6) = 8.34, P < 0.001; total: F(3.1,105.5) = 26.2, P < 
0.001). Maximal dyskinesia appeared within 20 minutes and continued for approximately 
one hour before gradually disappearing. 
Dyskinesia scores also exhibited some dose-dependency (Figure 15A). Orolingual, 
forelimb, and total dyskinesia scores were statistically signifi cantly aff ected by the levodopa 
dose (2-way RM-ANOVA, main eff ect of dose, orolingual: F(2,34) = 6.38, P = 0.005; 
forelimb: F(2,34) = 24.2, P < 0.001; total: F(2,34) = 11.0, P < 0.001). Post hoc tests show that 
the dose of 6 mg/kg elicited higher orolingual, forelimb and total dyskinesia scores than the 
Figure 14. Representative images of levodopa-induced abnormal involuntary movements.
Images were captured from video recordings of mice lesioned with intra-MFB 6-OHDA
injections. A: Moderate axial dyskinesia (2 points), deviation of the head/trunk in a sitting
position. B: Severe axial dyskinesia (4 points), severe twisting of the head/trunk followed by a
loss of balance. C: Orolingual dyskinesia, purposeless chewing motions and tongue protrusion.
Orolingual dyskinesia can also manifest as repeated biting of the contralateral side/limbs.
D: Severe forelimb dyskinesia (4 points), repetitive large swings of the contralateral forelimb.




doses of 4.5 mg/kg (orolingual, P = 0.005; forelimb, P < 0.001; total, P < 0.001) or 3 mg/kg 
(orolingual, P = 0.039; forelimb, P = 0.001; total, tendency P = 0.065). In contrast, similar 
or even lower orolingual and forelimb dyskinesia scores were elicited by the dose of 4.5 mg/
Figure 15. Levodopa-induced dyskinesia in wild-type mice. Mice were lesioned with intra-
MFB (A) or intrastriatal (B) 6-OHDA and administered levodopa and benserazide (s.c.) for 2–3 
weeks. Th e severity of axial, orolingual, and forelimb dyskinesia aft er levodopa administration 
was then assessed. Total dyskinesia refers to the sum of the subtype scores. Line graphs show 
mean scores ± SEM. Box plots show integrated dyskinesia scores (area under the curve). 
A: Considerable dyskinesia was observed in MFB-lesioned mice. Orolingual and forelimb 
dyskinesia induced by 6 mg/kg levodopa was assessed as more severe than that induced by 
lower doses, but the doses of 3 and 4.5 mg/kg did not diff er, possibly due to methodological 
discrepancies (see text for details). All doses induced similar axial dyskinesia. n = 12 (6 mg/
kg), 17 (4.5 mg/kg), 8 (3 mg/kg). B: Markedly less severe dyskinesia was observed in striatally 
lesioned mice (n =  5). * P < 0.05, ** P < 0.01, *** P < 0.001 compared to 4.5 mg/kg, # P < 0.05, 
### P < 0.001 compared to 3 mg/kg, two-way RM-ANOVA with Bonferroni’s post hoc tests; 
§ P < 0.05, §§§ P < 0.001 compared to 4.5 mg/kg, Kruskall-Wallis ANOVA with Dunn’s post hoc 
tests.
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kg compared to 3 mg/kg. Note, however, some methodological discrepancies at the dose of 
3 mg/kg (see 6.1.2.). High axial dyskinesia scores were elicited by all levodopa doses, with 
no diff erences between doses (2-way RM-ANOVA, main eff ect of dose, F(2,34) = 2.59, P 
= 0.090). Non-parametric statistical analysis confi rmed that the dose of levodopa had a 
statistically signifi cant eff ect on orolingual, forelimb, and total dyskinesia scores but not on 
axial dyskinesia scores (Kruskal-Wallis ANOVA, axial: H = 3.45, P = 0.178; orolingual: H = 
8.74, P = 0.013; forelimb: H = 21.7, P < 0.001; total: H = 15.3, P < 0.001). 
Th e fi nal recordings of Studies II and III were scored with both the novel criteria and the 
criteria of Lundblad et al. (2004), using a truncated version in Study III as interruptibility 
was not assessed. In both cases, scores obtained with the diff erent methods were highly 
correlated (Study II: Pearson’s r = 0.96, P < 0.001; Spearman’s r = 0.92, P < 0.01; n = 11; 
Study III: Pearson’s r = 0.89, P < 0.001; Spearman’s r = 0.78, P < 0.01; n = 12).
5.3.2.  Effects of drug treatments on levodopa-induced dyskinesia (Studies 
II–III)
Figure 16 shows the development of dyskinesia scores in mice lesioned with intrastriatal 
6-OHDA (Study II) and treated chronically with levodopa and either nicotine-containing 
or normal drinking water (initiated simultaneously). Average nicotine intake at 300 μg/
ml was 36 ± 10 mg/kg/day. Th e nicotine treatment inhibited the development of all LID 
subtypes, particularly aft er the treatment had been continuing for several weeks. At the time 
of the fi nal measurements, mean dyskinesia scores were considerably lower in nicotine-
treated animals (ca. −50% for axial dyskinesia, −80% for orolingual dyskinesia, −70% for 
forelimb dyskinesia). 
In statistical analysis, total dyskinesia only had a tendency to be attenuated in nicotine-
treated animals (2-way RM-ANOVA, main eff ect of treatment, F(1,9) = 4.55, P = 0.062, n 
=  5 control mice, 3 female; 6 nicotine-treated mice, 4 female). However, subtype-specifi c 
analyses revealed statistically signifi cant eff ects. Forelimb dyskinesia was signifi cantly 
attenuated (main eff ect of treatment, F(1,9) = 7.99, P = 0.020). While the main eff ect of 
treatment was not signifi cant for the other subtypes (axial: F(1,9) = 2.56, P = 0.144; 
orolingual: F(1,9) = 3.00, P = 0.117), a signifi cant treatment × time interaction shows 
that there was a diff erence between the treatment groups in how axial dyskinesia scores 
changed over time (F(4,36) = 3.15, P = 0.026). Although no post hoc comparisons reached 
signifi cance, the data quite clearly suggest inhibition of axial LID by the nicotine treatment. 
A tendency along similar lines was observed for orolingual dyskinesia scores (treatment 
× time interaction, F(2.2,20.0) = 2.91, P = 0.073). While no group diff erences reached 
signifi cance in non-parametric statistical analyses, tendencies suggest attenuation of 
orolingual (Mann-Whitney U test, U = 5.0, P = 0.076) and forelimb (U= 5.5, P = 0.089) 
dyskinesia as well as total dyskinesia (U = 5.0, P = 0.082) in nicotine-treated animals but no 
group diff erence in axial dyskinesia (U = 9.0, P = 0.329). 
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Figure 16. Nicotine treatment inhibited the development of levodopa-induced dyskinesia in 
mice lesioned with intrastriatal 6-OHDA injections. Th e mice were chronically administered 
levodopa (30 mg/kg) and benserazide (12 mg/kg) (s.c.) and nicotine (up to 300 μg/ml) in 
drinking water. Both treatments were initiated simultaneously. Dyskinesia severity was assessed 
weekly. Line graphs show mean weekly dyskinesia scores ± SEM. Two-way RM-ANOVA: Axial 
dyskinesia, treatment × time interaction P < 0.05; Orolingual dyskinesia, interaction P = 0.07; 
Forelimb dyskinesia, main eff ect of nicotine P < 0.05; Total dyskinesia, main eff ect of nicotine P 
= 0.06. Box plots show integrated dyskinesia scores for the entire experiment. Mann-Whitney U 
test: Orolingual dyskinesia, P = 0.08; Forelimb dyskinesia, P = 0.09; Total dyskinesia, P = 0.08. 
n = 5–6 per group.
Figure 17 shows dyskinesia scores in female mice lesioned with intra-MFB 6-OHDA 
(Study III) and treated chronically with levodopa and nAChR agonists. Th e mice were 
rendered dyskinetic with 2 weeks of levodopa treatment and then administered (s.c.) 
either escalating doses of AZD0328 or saline. AZD0328 treatment had no eff ect on total 
dyskinesia scores (Figure 17A and Study III, Figure 3), with no statistically signifi cant 
fi ndings (n = 6 per group). Subtype-specifi c analyses revealed only one signifi cant fi nding, 
where axial dyskinesia was reduced by the lowest dose of AZD0328 (0.03 mg/kg) 100 min 
aft er levodopa injection (2-way RM-ANOVA, treatment × time interaction, F(4,40) = 3.37, 
P = 0.018; data not shown). However, the control group appeared to exhibit aberrantly 
long-lasting axial dyskinesia at that particular date.
Aft er a washout, the mice of Study III were randomly re-assigned to two groups and 
chronic treatment with either nicotine or vehicle (saccharin-sweetened drinking water) 
was initiated. Average nicotine intake at 300 μg/ml was 35 ± 10 mg/kg/day. Total dyskinesia 
scores (Figure 17B) and subtype-specifi c dyskinesia scores (Study III, Figure 3) were not 
Results


































































































































































lower in nicotine-treated animals. However, while no treatment main eff ects reached 
statistical signifi cance, there was a diff erence between the treatment groups in how total, 
axial, and possibly forelimb dyskinesia scores changed over time (2-way RM-ANOVA, 
treatment × time interactions, total: F(8,80) = 2.97, P = 0.006; axial: F(8,80) = 3.04, P = 
0.005; forelimb: F(8,80) = 1.93, P = 0.067; n = 6 per group). While no post hoc tests reached 
statistical signifi cance, a possible interpretation is that LID severity was fi rst transiently 
increased in nicotine-treated animals and then returned to control levels. Non-parametric 
statistical analysis found no statistically signifi cant group diff erences. Finally, instances 
of severe axial dyskinesia (losses of balance) per minute were separately counted, and no 
diff erences between treatment groups were observed (data not shown).
Figure 17. No attenuation of levodopa-induced dyskinesia by nAChR agonists in mice lesioned 
with intra-MFB 6-OHDA injections. Dyskinesia was pre-established by two weeks of levodopa 
treatment (6 mg/kg, s.c.). A: Th e α7 receptor partial agonist AZD0328 was administered (s.c.) 30 
min before levodopa for 5 days per dose, and dyskinesia severity was assessed on the fi ft h day. 
No diff erences in total dyskinesia between treatment groups were found. B: Aft er a washout, 
chronic levodopa treatment was continued and nicotine treatment in drinking water (up to 
300 μg/ml) initiated. Dyskinesia severity was assessed weekly. Nicotine treatment may have 
transiently increased dyskinesia severity. Two-way RM-ANOVA, treatment × time interaction 
P < 0.01.  Shown are integrated total dyskinesia scores for the recording session (A) or mean 
total dyskinesia scores ± SEM along with integrated scores for the entire experiment (B). n = 6 
per group.
Figure 18 shows dyskinesia scores in female mice lesioned with intra-MFB 6-OHDA and 
treated chronically with levodopa and acutely with amantadine (additional study). Doses 
of 5, 15, and 60 mg/kg amantadine, administered (i.p.) 60 min before levodopa, failed to 
attenuate LID, with no statistically signifi cant treatment main eff ects at any dose. Moreover, 
amantadine pretreatment prolonged dyskinetic behaviors, an eff ect readily apparent during 
the recording session. Statistically signifi cant eff ects on LID were observed at the dose of 60 
mg/kg (Figure 18A; 2-way RM-ANOVA, treatment × time interactions, axial: F(2.7,43.3) 
= 6.56, P = 0.001; forelimb: F(5,80) = 3.31, P = 0.009; orolingual: F(2.5,40.4) = 2.66, P = 
0.070; total: F(2.8,44.7) = 4.52, P = 0.009; n = 9 per group). Again, however, no post hoc 
Results






































































Figure 18. Unattenuated and prolonged levodopa-induced dyskinesia aft er acute amantadine 
treatment in mice lesioned with intra-MFB 6-OHDA injections. A: Th e mice were administered 
levodopa (4.5 mg/kg) for two weeks. At the last day, amantadine (60 mg/kg, i.p.) was 
administered 60 min before levodopa, and dyskinesia severity was assessed. Amantadine 
pretreatment failed to reduce dyskinesia and, instead, markedly prolonged dyskinetic behaviors. 
Two-way RM-ANOVA,  treatment × time interactions: Axial dyskinesia, P = 0.001; Orolingual 
dyskinesia, P = 0.07; Forelimb dyskinesia, P < 0.01; Total dyskinesia, P < 0.01. B: Aft er a 
washout and further three weeks of levodopa administration, amantadine (5 or 15 mg/kg, i.p.) 
was administered 60 min before levodopa, and dyskinesia severity was assessed. Lower dose 
amantadine pretreatment also failed to reduce dyskinesia scores. Th e dose of 15 mg/kg had 
modest prolonging eff ects. Two-way RM-ANOVA, treatment × time interaction: Forelimb 
dyskinesia, P < 0.05. Line graphs show mean dyskinesia scores ± SEM. Box plots show integrated 
weekly dyskinesia scores. n = 9 (A) or 6 (B) per group.
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comparisons reached signifi cance. When lower doses of amantadine were tested, the dose 
of 15 mg/kg had shorter-lasting but still clearly discernible prolonging eff ects (Figure 18B), 
although only the eff ect on forelimb LID was signifi cant (treatment × time interaction, 
F(5,75) = 2.20, P = 0.026; n = 6 per group). Non-parametric statistical analysis found no 
signifi cant group diff erences in integrated dyskinesia scores. Administration of 60 mg/kg 
amantadine 0 and 100 min before levodopa was also tested, with very similar results of 
prolonged and unattenuated LID (data not shown).
5.3.3.  Levodopa-induced dyskinesia in α5-knockout mice (Study I)
Figure 19 shows dyskinesia scores in female α5-KO and WT mice lesioned with intra-MFB 
6-OHDA (Study I). Th e mice were rendered dyskinetic with 3 weeks of levodopa treatment, 
aft er which chronic treatment with either nicotine or vehicle (saccharin-sweetened 
drinking water) was initiated. Th e average intake of nicotine at 300 μg/ml was 31 ± 6 mg/
kg/day. Total dyskinesia scores were lower in α5-KO mice than in WT mice (three-way 
RM-ANOVA, main eff ect of genotype, F(1,14) = 12.3, P = 0.004; n = 4–5 per genotype and 
treatment). Non-parametric statistical analysis confi rmed the lower dyskinesia scores in 
α5-KO mice (Mann-Whitney U test, U = 9.0, P = 0.004). In addition, there was a diff erence 
between nicotine-treated α5-KO and WT mice in how dyskinesia scores changed over time 
(genotype × treatment × time interaction, F(3.5,48.5) = 3.14, P = 0.028; genotype × time 
interaction only in nicotine-treated animals, F(3.2,22.3) = 4.73, P = 0.010). Although no 
post hoc comparisons reached statistical signifi cance, a possible interpretation is that LID 
severity decreased over time in nicotine-treated WT but not α5-KO mice. Th e eff ect of 
nicotine treatment was not signifi cant in non-parametric statistical analysis.
Figure 19. Levodopa-induced dyskinesia in α5-knockout (KO) and wild-type (WT) mice. 
Mice lacking α5* nicotinic receptors developed less severe LID than wild-type mice (three-way 
RM-ANOVA, P < 0.01, n = 8 WT, 10 KO, female). In nicotine-treated mice, dyskinesia severity 
may have been reduced over time in WT but not α5-KO mice (genotype × treatment × time 
interaction, P < 0.05; genotype × time interaction in nicotine-treated animals, P = 0.01; n = 4–5 
per group). Line graph shows mean weekly dyskinesia scores ± SEM. Box plots show integrated 
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5.3.4.  Effects of antidyskinetic nicotine treatment on striatal dopamine 
release (Study II)
To determine the eff ects of dopaminergic denervation and chronic nicotine treatment 
on dopaminergic nerve terminals and their presynaptic nAChRs, basal and nicotine-
stimulated [3H]dopamine release was measured from striatal synaptosomes. Synaptosomes 
were separately prepared from the dorsal and ventral striatum of both hemispheres of 
mice lesioned with intrastriatal 6-OHDA. Nicotine-stimulated release was separated to 
α4( non-α6)β2*-mediated and α6β2*-mediated release with CtxMII and normalized to 
basal release.
See Study II, Fig. 3 for the full results. Basal [3H]dopamine release from samples of the 
lesioned dorsal striatum was reduced 4–5 weeks aft er lesioning to 37 ± 5% of the intact 
side (t-test, t(10) = 8.15, P < 0.001; n = 6, all female). In animals assayed aft er 7–8 weeks of 
chronic treatment with levodopa and either nicotine or water (15–16 weeks aft er lesioning), 
basal release from samples of the lesioned dorsal striatum remained signifi cantly reduced 
(74 ± 10% of the intact side; two-way ANOVA, main eff ect of hemisphere, F(1,17) = 5.24, 
P = 0.035; n = 5 control mice, 3 female; 6 nicotine-treated mice, 4 female). In samples of 
the lesioned ventral striatum, 4–5 weeks aft er lesioning basal [3H]dopamine release was 
reduced to 61 ± 9% of the intact side (t(10) = 3.25, P = 0.009). In animals assayed aft er 
the chronic drug treatments, basal release from the lesioned ventral striatum was no 
longer signifi cantly reduced (main eff ect of hemisphere, F(1,18) = 2.75, P = 0.115). In 
particular, in nicotine-treated animals basal release from the lesioned ventral striatum 
was comparable to the intact hemisphere (main eff ect of treatment, F(1,18) = 7.93, P = 
Figure 20. Chronic nicotine treatment reduced synaptosomal [3H]dopamine release mediated 
by  α6β2* nicotinic receptors. Mice were lesioned with intrastriatal 6-OHDA injections and 
administered levodopa and either nicotine-containing or normal drinking water for 7–8 weeks. 
α6β2*-mediated release was calculated as the diff erence between total and α-conotoxin MII-
resistant release. ** P < 0.01, diff erence to control, # P < 0.05, main eff ect of treatment, two-way 
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0.011; treatment × hemisphere interaction, F(1,18) = 3.60, P = 0.074). nAChR-mediated 
normalized [3H]dopamine release was not aff ected by the dopaminergic lesion. Th e chronic 
nicotine treatment had no statistically signifi cant eff ect on α4(non-α6)β2*-mediated release 
in either brain area. However, as shown in Figure 20, nicotine treatment signifi cantly 
decreased α6β2*-mediated [3H]dopamine release in the lesioned dorsal striatum (main 
eff ect of treatment, F(1,17) = 6.61, P = 0.020; treatment × hemisphere interaction, F(1,17) 
= 5.39, P = 0.033) and in both the intact and the lesioned ventral striatum (main eff ect 
of treatment, F(1,18) = 7.93, P = 0.028). When non-normalized nAChR-mediated [3H]
dopamine release was analyzed, release was diminished in the lesioned hemisphere, but the 
nicotine treatment had no statistically signifi cant eff ects (data not shown). 
5.3.5.  Effects of levodopa and nicotine treatments on BDNF levels (Study 
III)
BDNF protein levels in the striatum and the PFC (Figure 21) were measured from female 
mice lesioned with intra-MFB 6-OHDA and treated with levodopa and nAChR agonists. 
No diff erence in BDNF levels between the lesioned and intact hemispheres was observed 
in either brain area. Nicotine treatment had no eff ect on striatal BDNF, but BDNF levels 
in the PFC were decreased in nicotine-treated animals (two-way ANOVA, main eff ect of 
treatment, F(1,20) = 9.06, P = 0.007; n = 6 per group). For analysis of correlation between 
striatal BDNF and dyskinesia severity, control and nicotine groups were combined as 
neither dyskinesia severity nor striatal BDNF levels diff ered between groups. BDNF levels 
Figure 21. Brain-derived neurotrophic factor (BDNF) protein levels in chronically drug-
treated mice previously lesioned with intra-MFB 6-OHDA. A: No interhemispheric diff erences 
in BDNF protein levels of the striatum and the prefrontal cortex aft er 15 weeks of levodopa 
administration. Aft er 10 weeks of chronic nicotine administration BDNF levels were reduced 
in the prefrontal cortex. B: BDNF levels of the lesioned striatum were positively correlated with 
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in the lesioned striatum had a positive linear correlation with weekly total dyskinesia scores 
at the time of the last dyskinesia measurement (Pearson’s r = 0.58, P = 0.047, n = 12). Non-
parametric  Spearman’s correlation was not statistically signifi cant (r = 0.40, P = 0.198). No 
other statistically signifi cant correlations between dyskinesia scores and BDNF levels were 
found (data not shown).
5.4.  Impacts of pre-experimental handling and improved postoper-
a  ve care (Study IV)
Th e gradual handling protocol led to what appeared to be obvious and signifi cant reductions 
in aggressive and escape behaviors. Th e handled mice exhibited a marked lack of aversion 
towards the researcher and accepted restraint much more easily than unhandled mice of 
the same strain. Th is led to the facilitation of many experimental procedures such as hand 
feeding during postoperative care, drug administration by injection, euthanasia by cervical 
dislocation, and handling in general. It is also very likely that this led to a concurrent 
reduction in animal stress (see Discussion of Study IV). However, the eff ects of the pre-
experimental handling were not studied in a systematic and controlled manner.
Average postoperative mortality was greatly reduced, decreasing from 71 % to 14 % 
(Pearson Chi-Square test, χ2(1) = 27.8, P < 0.001), aft er the introduction of the systematic 
welfare scoring along with the majority of the other refi nements described in Study IV. 
Concurrently, improvements in surgical procedures increased the average rate of successful 
abundant lesions from 46% to 81% (χ2(1) = 7.45, P = 0.006). Note that these fi gures include 
only wild-type animals and that unsuccessfully lesioned animals were not included in the 
mortality fi gures. See Study IV for more details on the postoperative mortality and lesion 




6.1.  Methodological considera  ons
6.1.1.  Mouse models of Parkinson’s disease
Th e methods for modeling PD in mice can be broadly divided into genetic and neurotoxin 
models. Genetic models include knockout and transgenic mutations in various 
PD-associated genes, and although in the future they might replace neurotoxin models 
particularly in neuroprotection studies, they have been hampered by a lack of dopaminergic 
neurodegeneration (Dawson et al., 2010). Neurotoxin models are based on toxins such 
as 6-OHDA, MPTP, rotenone, or paraquat that are relatively selective in destroying 
dopaminergic neurons (Bové and Perier, 2012). Th e three latter toxins can be administered 
systemically to induce bilateral parkinsonism. Th e metabolite of MPTP, MPP+, inhibits the 
mitochondrial complex I and results in e.g., the generation of reactive oxygen species and 
activation of apoptotic pathways (Bové and Perier, 2012). In mice, acute and chronic MPTP 
administration can be used to induce severe or partial neurodegeneration, respectively, 
while in non-human primates chronic administration regimes can be tailored to induce 
neurodegeneration of required degree. Rotenone is another mitochondrial toxin which 
also impairs microtubule formation, while paraquat toxicity is mediated by reactive oxygen 
species formation (Bové and Perier, 2012). Th e latter two are less commonly used, but may 
have some advantages such as α-synuclein aggregation that is not seen in the 6-OHDA 
or acute MPTP mouse models (Bové and Perier, 2012). 6-OHDA crosses the blood-brain 
barrier poorly and is administered directly into the nigrostriatal pathway, either into the 
SNC, the MFB, or the striatum (Bové and Perier, 2012). In the present studies, the intra-
MFB and intrastriatal models were used. 
6-OHDA is thought to enter catecholaminergic neurons through the DAT, there produce 
reactive oxygen species via MAO activity and/or auto-oxidation, and thus induce toxic 
oxidative stress (Blum et al., 2001). Unilateral administration to induce hemiparkinsonism 
is almost always used due to very poor survival aft er bilateral administration. Striatal 
6-OHDA administration results in delayed retrograde neurodegeneration within 1–3 weeks, 
while administration into the MFB results in prompt neurodegeneration within a few days, 
although in both cases full cell loss can take several weeks (Bové and Perier, 2012). While 
nigrostriatal neurodegeneration is partial and dose-dependent in the intrastriatal model, 
neurodegeneration in the intra-MFB model is usually near-total and, furthermore, not 
restricted to the nigrostriatal pathway. See Figure 11 for examples from the present studies 
contrasting the relatively restricted nigrostriatal denervation in the intrastriatal model 
with the near-total loss of both nigrostriatal and mesolimbic innervation in the intra-MFB 
model. Both lesion models result in quantifi able unilateral motor defi cits such as rotation 
induced by dopaminergic drugs and impaired contralateral limb use (Bové and Perier, 
2012). Th e intrastriatal model has several practical advantages, including the possibility of 
controlling the lesion by adjusting the 6-OHDA dose and injection site(s) and much better 
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postoperative survival. However, the intra-MFB model also confers substantial advantages, 
including more pronounced motor defi cits and a higher sensitivity to levodopa-induced 
dyskinesia (Bové and Perier, 2012).
Th e challenges of the intra-MFB 6-OHDA model are strikingly demonstrated by the 
outcomes of the fi rst intra-MFB lesions performed during the present studies (Study 
I pilot). First, many unsuccessful lesions were observed in surviving animals. Moreover, 
postoperative mortality was very high, with 52 % of all operated animals and as many 
as 71 % of successfully lesioned animals lost (only wild-types included), mainly due to 
euthanasia in response to severe weight loss. Th ese unsatisfactory outcomes refl ect both 
the challenges of targeting a small brain area and, most importantly, the major impact on 
eating, drinking, and general wellbeing by the near-total dopaminergic denervation, even 
when applied unilaterally. However, both of these challenges were successfully resolved. In 
subsequent studies, improved stereotactic protocols, along with accumulating experience of 
the researcher performing and supervising the surgeries, led to a much higher proportion 
of successfully lesioned animals. Concurrently, extensively improved postoperative care 
dramatically reduced postoperative mortality (14 % across all subsequent studies in wild-
type mice). Th e pre-operative gradual handling of the mice performed in some studies also 
greatly facilitated postoperative care procedures such as feeding by hand (and, in general, 
all experimental procedures). Besides the refi nement of animal wellbeing, these outcomes 
demonstrate that acceptable postoperative survival aft er intra-MFB 6-OHDA lesioning is 
achievable but requires the expending of considerable eff ort.
A separate and more complex question is the relative suitability of the two 6-OHDA 
models as models of human PD. On one hand, the symptoms of PD appear and a diagnosis 
can be made when already roughly 50 % of SNC dopaminergic neurons and 70–80 % of 
striatal dopamine are lost (Bernheimer et al., 1973; Fearnley and Lees, 1991). In late-stage 
patients up to 90 % of dopaminergic cells in parts of the SNC and 99 % of dopamine in 
the putamen can be lost (Bernheimer et al., 1973; Fearnley and Lees, 1991; Hall et al., 
2014). Th us, intrastriatal 6-OHDA administration arguably models early or moderate PD, 
while intra-MFB 6-OHDA administration could be considered to model late-stage PD. On 
the other hand, even in advanced PD the near-total losses are restricted to certain areas 
of the SNC and the dorsal striatum, and denervation within the mesolimbic pathway 
is much less extensive (Bernheimer et al., 1973; Fearnley and Lees, 1991; Hall et al., 
2014). Unfortunately, the contributions of mesolimbic or region-specifi c denervation to 
parkinsonian pathophysiology are not well-understood.
While both 6-OHDA models have been extensively used in preclinical research, they may 
have diff ering applications. For instance, Bové and Perier (2012) suggest that the intra-MFB 
model is more suitable for studying the consequences of denervation and symptomatic 
treatments, while the intrastriatal model can be used to study PD pathogenesis and 
neuroprotective treatments. However, it should be noted that the intra-MFB model may in 
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fact not be suitable for the study of all potential symptomatic treatments. Using the intra-
MFB model to study treatments that could be mediated in signifi cant part by the remaining 
striatal dopamine terminals could lead to discarding some that would be eff ective in early 
PD. An example could be nAChR agonists, which likely exert their antidyskinetic eff ects in 
part through dopamine terminal nAChRs and indeed appear to be less eff ective in conditions 
of severe dopaminergic denervation, as seen here as well as in a number of previous studies 
(see 6.3.1. below). Finally, another separate but potentially highly signifi cant question is the 
overall translational validity of a neurotoxin rodent model of PD characterized by rapid 
unilateral neurodegeneration, given that human PD is slowly progressing, bilateral, and 
only attributable to exogenous toxins in a very limited proportion of cases (although a few 
intriguing fi ndings do suggest the presence of endogenous 6-OHDA in humans; see Bové 
and Perier, 2012). Th is issue will not be further discussed here, but see 6.2.2. below for 
some considerations based on the present fi ndings.
6.1.2.  Mouse model of levodopa-induced dyskinesia
Th e mouse model of LID, building on the unilateral 6-OHDA model of PD, was originally 
described by the Cenci laboratory (Lundblad et al., 2004; Lundblad et al., 2005; Cenci and 
Lundblad, 2007; Francardo et al., 2011). Lesioning with either intrastriatal or intra-MFB 
6-OHDA can be used, but intra-SNC 6-OHDA was found unsuitable (Francardo et al., 
2011). Further developments in MFB injection coordinates and levodopa and benserazide 
dosing that were followed in the present studies were described by Th iele et al. (2011). As 
expected, clearly abnormal unilateral movements, considered to model human LID, were 
rapidly induced in most 6-OHDA-lesioned animals by repeated levodopa administration. 
Pauses in levodopa administration in primed animals had no eff ect on LID, in line with the 
literature (Nadjar et al., 2009). 
Th e mouse model of LID was applied as previously described, with the major exception 
that the dyskinetic behaviors were quantifi ed with a modifi ed scoring method. Th e 
modifi ed scoring method was developed due to observations that the previously published 
methods (Lundblad et al., 2004; Th iele et al., 2011) appeared not entirely suitable for 
quantifying severe dyskinesia exhibited by MFB-lesioned mice from video recordings. Th e 
original and most widely used scoring method, developed for rats and validated also for 
mice, assesses dyskinetic behaviors on the basis of frequency (as a proportion of time) and 
interruptibility (Winkler et al., 2002; Lundblad et al., 2004; Lundblad et al., 2005). However, 
in the present studies the axial dyskinesia exhibited by the majority of MFB-lesioned mice 
was continuous and non-interruptible while still showing individual diff erences in spatial 
severity (“amplitude”). Various additional criteria for dyskinesia amplitude have been used 
by diff erent researchers (Cenci and Lundblad, 2007; Huang, Grady, and Quik, 2011), but at 
the initiation of the present studies only the frequency-based method had been validated 
for mice. Th e present scoring method can be seen as measuring both the frequency 
and the amplitude of orolingual and forelimb dyskinesia, but mainly the amplitude of 
axial dyskinesia due to the aforementioned propensity for continuous axial dyskinesia. 
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Interruptibility was not measured due to axial dyskinesia being, if anything, exacerbated by 
sudden noises or movements. Contralateral rotations, considered “locomotive dyskinesia” 
in earlier rodent studies, were not included as they are now thought to not reliably refl ect 
dyskinesia (Cenci and Lundblad, 2007).
As mentioned, video recording instead of live assessment was utilized in the present studies. 
Th e vast majority of studies utilizing the original scoring method, including those where 
they were established and validated (Lundblad et al., 2004; Lundblad et al., 2005), have 
relied on live rating. Th is might in part explain the challenges in adapting the previously 
published scoring criteria to the present experiments. Video recording has the advantages 
of better documented data and the possibility for more detailed (e.g., slow-motion) analysis 
and reanalysis. On the other hand, video recording has the disadvantage of a static viewing 
angle, which was here partially mitigated by the presence of fl anking mirrors. In particular, 
it was found that reliable assessment of orolingual and forelimb dyskinesia from video 
recordings using the original scoring method was hampered by issues such as the fast 
movements exhibited by mice, challenges in obtaining 360° video coverage, and the video 
quality yielded by aff ordable recording hardware.
Importantly, a recent study by the Cenci laboratory, utilizing both live assessment and 
video recordings, described and pharmacologically validated a detailed method for 
scoring LID amplitude in mice (Sebastianutto et al., 2016). Furthermore, it was found that 
the frequency and amplitude dimensions of LID can be diff erentially responsive to drug 
treatments (Sebastianutto et al., 2016). Th e present studies were already ongoing at the 
time of this advancement. Future mouse studies, however, might be best served to adopt a 
scoring method which separately assesses both the frequency and amplitude of dyskinetic 
behaviors, such as the now available validated method of Sebastianutto et al. (2016), and 
to subject these dimensions to data analysis both separately and as a combined measure of 
dyskinesia.
Th e accuracy and validity of the present LID quantifi cation method is an obvious 
methodological question. A number of fi ndings suggest that the present method measures 
essentially the same phenomenon as previously described methods. Foremost, dyskinesia 
scores obtained with the present method and the original method of Lundblad et al. 
(2004) were found to be highly correlated. Note, however, that for MFB-lesioned animals 
only a truncated version of the original method could be used, as interruptibility was not 
measured. Findings in line with the previous literature included similar LID time courses 
as previously described (Lundblad et al., 2004; Francardo et al., 2011), more severe LID 
being exhibited by mice with near-total vs. partial nigrostriatal lesions (Lundblad et al., 
2004; Francardo et al., 2011), alleviation of LID by nicotine in Study II (Huang, Grady, 
and Quik, 2011), and a very similar correlation between striatal BDNF levels and LID as 
was previously found between striatal Bdnf mRNA and LID in 6-OHDA-lesioned rats 
(Rylander et al., 2010).
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A partial dose-response relationship between levodopa and dyskinesia scores was observed 
when data from several studies were combined (see Figure 15A). Th e lowest dose of 
levodopa (3 mg/kg) did not induce lower dyskinesia scores, preventing a conclusion 
of a full dose-response relationship. However, this may be explained by a number of 
methodological diff erences, including a diff erent C57/BL6J substrain (α5-WT vs. RccHsd), 
younger mice (10–20 weeks vs. 28–30 weeks), the use of desipramine during lesioning, a 
diff erent levodopa:benserazide ratio (1:5 vs. 4:1), and a longer levodopa treatment before 
assessment (3 vs. 2 weeks). High mean axial dyskinesia scores were induced by all doses in 
MFB-lesioned mice, and although consistently severe axial dyskinesia appeared a hallmark 
of the present MFB model, a lack of sensitivity in quantifi cation cannot be entirely ruled out. 
Note that the separation of mild axial LID from levodopa-induced rotation (not considered 
dyskinesia) was at times diffi  cult. Finally, pharmacological validation of the scoring method 
was not consistently achieved. While nicotine reduced LID in intrastriatally lesioned mice, 
the eff ects of nicotine on LID in MFB-lesioned mice were unclear (see 6.3.1.). Moreover, 
treatment with the known antidyskinetic drug amantadine failed to reduce LID scores in 
MFB-lesioned animals (see 6.3.2.). Th e readily apparent and entirely aberrant prolonging 
of dyskinesia by amantadine suggests, however, that the observed lack of effi  cacy was not 
due to a lack of sensitivity in quantifi cation. In summary, available evidence suggests that 
the dyskinesia scores obtained using the present scoring method accurately refl ect the 
time course and severity of mouse LID, although in hindsight some additional control 
experiments could have been performed. Th ese could have included administration of 
amantadine to intrastriatally lesioned dyskinetic animals as well as direct comparisons of 
diff erent levodopa doses.
Finally, statistical analysis of dyskinesia scores should be briefl y discussed. As dyskinesia 
scoring scales used in the literature are mostly ordinal by nature, using parametric statistics 
(and, in fact, calculating such measures as sums or means) is in the strict sense inappropriate 
(Forrest and Andersen, 1986; Munzel and Langer, 2004). However, it is common and, 
argued by some statisticians, even fully acceptable practice to utilize parametric statistical 
analysis on ordinal scores or their summations (Forrest and Andersen, 1986; Munzel and 
Langer, 2004; Norman, 2010). Moreover, in the case of the original LID scoring method 
it has been argued that parametric analysis allows for remarkable descriptive power and 
is acceptable given that the scoring scale has some properties of a ratio scale and that its 
output is correlated with biochemical markers (Cenci and Lundblad, 2007). Parametric 
tests indeed allow more detailed analysis, particularly as a non-parametric test for 
analyzing two-way repeated measures data (a very common form of data in LID studies) is 
not readily available. As for the present scoring method, the linear correlation of LID with 
striatal BDNF arguably satisfi es the latter condition. Nevertheless, as suggested by Cenci 
and Lundblad (2007), in the present thesis non-parametric tests were used in parallel with 
parametric tests. Th e results were generally along the same lines. However, in some cases 
group diff erences did not quite reach statistical signifi cance with non-parametric analysis 
(see Figure 16). In other cases more complex eff ects, such as group diff erences appearing 
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only during some part of the experiment, could not be confi rmed (see Figures 17–18). Th e 
latter is not surprising given the loss of information when integrating a data series into 
one value. In the end, the results of parametric statistical analysis were used as the primary 
results on which conclusions were based. Th is follows the large majority of previous studies 
by many laboratories which have only used parametric statistics in the analysis of data 
obtained with similar LID scoring methods (e.g., Santini et al., 2007; Buck and Ferger, 2008; 
Darmopil et al., 2009; Bido et al., 2011; Francardo et al., 2011; Th iele et al., 2011; Quik et al., 
2012).
6.2.  α5* nico  nic receptors in mouse models of Parkinson’s 
disease
6.2.1.  Attenuated dopaminergic neurodegeneration and motor 
dysfunction in mice lacking α5* nAChRs
Nicotinic receptors containing the α5 subunit could have a role in Parkinson’s disease 
and LID or their animal models, given the critical role of α5* nAChRs in the regulation 
of dopamine release in the dorsal striatum at least in mice (Salminen et al., 2004; Exley et 
al., 2012). To study this possibility, an extensive series of experiments utilizing α5 subunit-
knockout mice was undertaken in order to characterize the role of α5* nAChRs in mouse 
models of PD and LID as well as the eff ects of the lack of α5* nAChRs on the dopaminergic 
system. Th ese studies represent the fi rst investigation of α5* nAChRs in the context of PD, 
and the fi ndings of attenuated dopaminergic neurodegeneration and motor dysfunction in 
α5-KO mice raise intriguing possibilities for the use of α5 nAChRs as a drug target. Striatal 
markers of the dopaminergic system were unaff ected, with the notable exception of reduced 
dopamine transporter function observed in α5-KO mice.
Th e primary fi nding was that the death of dopaminergic neurons induced by intrastriatal 
injections of 6-OHDA was attenuated in α5-KO mice, specifi cally within the medial cluster 
of the SNC. Th is neuroprotective eff ect was paralleled by attenuation of amphetamine-
induced rotation, a widely-used test where rotational behavior relates to the degree of 
dopaminergic denervation (Iancu et al., 2005; Bové and Perier, 2012). Th e latter fi nding 
suggests that the neuroprotection was signifi cant enough to be refl ected in motor behavior. 
Importantly, no genotype diff erence in locomotor activity was found aft er amphetamine 
administration in intact animals, suggesting that the observed attenuation of rotational 
behavior was indeed linked to the lessened neurodegeneration. Th e present fi nding is 
also in line with a previous study, utilizing electrically lesioned rats, where damage to the 
medial but not the lateral substantia nigra was linked to amphetamine-induced ipsilateral 
rotational behavior (Vaccarino and Franklin, 1982). Th is further suggests that the less 
pronounced ipsilateral rotation observed in the present experiments was the result of 
attenuated neurodegeneration in the SNCM.
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In female animals lesioned with intra-MFB 6-OHDA injections, lesion extent in the SNC 
did not diff er between wild-type and α5-KO mice. Nevertheless, attenuated dopaminergic 
motor dysfunction was observed also in these α5-KO animals, as evidenced by a tendency 
for attenuated amphetamine-induced rotation as well as less severe LID. Th e contrasting 
SNC immunohistochemical results from the two experiments utilizing diff erent lesion 
models could be explained by their diff erent time courses. When utilizing the intrastriatal 
model, lesion extent was assessed 1–2 weeks aft er the rotametry experiments, capturing 
the state of the midbrain soon aft er the behavioral assays. In contrast, when utilizing the 
intra-MFB model, several months of chronic treatment with levodopa, benserazide, 
and either nicotine or vehicle interceded between the rotametry measurements and 
immunohistochemistry. Possible confounding phenomena include eff ects of levodopa, 
able to induce a TH-positive phenotype in at least striatal neurons (Darmopil et al., 2008; 
Francardo et al., 2011), or spontaneous neuronal recovery, reported in 6-OHDA-lesioned 
mice at least in the striatum (Bez et al., 2016). Alternatively, it is possible that the more severe 
dopaminergic neurotoxicity induced in the intra-MFB model resulted in the masking of 
any protective eff ect by α5-KO; note the suggested lesser suitability of the intra-MFB model 
for neuroprotection studies in general (Bové and Perier, 2012). In that case, the tendency 
for attenuated rotational behavior could suggest more effi  cient functional compensation in 
α5-KO mice. Finally, in a pilot experiment fewer successful intra-MFB lesions, as well as 
a tendency for attenuated amphetamine-induced rotation, were observed in male α5-KO 
mice. Th ese fi ndings further suggest attenuated dopaminergic neurodegeneration and 
motor dysfunction in mice lacking α5* nAChRs.
As mentioned, female α5-KO mice lesioned with intra-MFB 6-OHDA developed less 
severe LID. Th e attenuated LID could be explained by less severe denervation (Lundblad et 
al., 2004; Francardo et al., 2011), but no genotype diff erence in lesion extent was observed 
in these mice. Although the long period of chronic drug treatments may explain the lack of 
a diff erence in lesion extent (see above), the attenuated dyskinesia in α5-KO animals may 
also have been the result of some other mechanism. Th is mechanism could be analogous to 
similar fi ndings in mice lacking the α6 nAChR subunit (Quik et al., 2012), and the fi nding 
suggests the involvement of α5* nAChRs in LID pathophysiology. Th e important role of 
α5* nAChRs in the regulation of striatal dopamine release (Salminen et al., 2004; Exley et 
al., 2012) and the decreased striatal DAT function in α5-KO mice suggest at fi rst glance 
that the attenuated LID could be the result of altered release and/or uptake of levodopa-
derived dopamine. However, given the near-total loss of striatal dopaminergic innervation 
observed in MFB-lesioned mice in the present studies, these explanations are unlikely. 
Other α5* nAChR populations that could be involved include those regulating serotonergic 
neurotransmission in the dorsal raphe nucleus (Besson et al., 2016), given the importance 
of raphestriatal serotonergic projections for LID (see 2.3.2.), or those modulating striatal 
GABA release (McClure-Begley et al., 2009). α5* nAChR disruption with e.g., selective 
antagonists or agonists (via desensitization) could thus represent a novel treatment avenue 
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for LID. See also below (6.3.1.) for related discussion on the eff ects of nicotine on LID in 
α5-KO mice.
Interestingly, while dopaminergic cell loss in the SNCD was more severe in the intra-
MFB model than in the intrastriatal model (as expected), cell loss in the SNCM was in 
fact less severe in the intra-MFB model. Th is suggests that spontaneous or drug-induced 
recovery may indeed have occurred and perhaps been more pronounced within the SNCM. 
Alternatively, the relatively well-spared SNCM could be due to a presence of projections 
from the SNCM to the dorsal striatum that do not pass through the MFB coordinates 
where 6-OHDA was injected. In the rat, projections of the SNC exhibit a relatively distinct 
topographic segregation, with medial parts projecting to the dorsomedial striatum (and 
partly to the ventral striatum) and lateral parts projecting to the dorsolateral striatum (Joel 
and Weiner, 2000). Th is suggests that there may also exist anatomical diff erences in the 
projections of the SNCM and the SNCD in mice (note that varying terminology across and 
even within species complicates comparisons; see e.g., Fu et al., 2012). In the intrastriatal 
model, the 6-OHDA injections were targeted approximately at the center of the striatum on 
the lateromedial axis and resulted in similar lesions in the SNCD and the SNCM. Finally, 
chronic nicotine treatment had no eff ect on the lesion extent of MFB-lesioned animals. 
Th is fi nding is in line with a previous study showing no neurorestoration by post-lesion 
chronic nicotine treatment in 6-OHDA-lesioned rats or MPTP-lesioned primates (Huang 
et al., 2009).
Surprisingly, male mice lesioned with intrastriatal 6-OHDA injections exhibited a 
contrasting pattern of genotype diff erences in rotational behavior. As no sex or genotype 
diff erences were found in intact animals’ motor response to amphetamine, and in the 
intra-MFB model both male and female α5-KO mice showed a tendency for attenuation 
of amphetamine-induced rotation, this sex diff erence appears to be linked specifi cally 
to the intrastriatal 6-OHDA model. While little is known about possible sex diff erences 
related to α5* nAChRs, the female sex hormone progesterone has been shown to upregulate 
α5* expression (Gangitano et al., 2009). Th e lack of signifi cant attenuation of rotational 
behavior in response to α5 deletion in male mice could therefore have been the result 
of lower α5* nAChR expression already in wild-type animals. Th e lack of a similar sex 
diff erence in the intra-MFB model could, then, be related to the near-total loss of striatal 
α5-expressing dopamine terminals. Th e contrasting behavioral fi ndings in male mice could 
also be related to the sex diff erences observed in some biomarkers of the dopaminergic 
system. More effi  cient dopamine uptake in male mice could explain the shorter duration 
of amphetamine’s eff ects seen in intrastriatally lesioned male animals, although no such 
sex diff erence was observed in intact or MFB-lesioned animals. Furthermore, a relatively 
larger lesion-induced reduction in D1 and possibly D2 receptor mRNA was observed in 
the intrastriatally lesioned male animals when compared to female animals. A greater 
decrease in dopamine receptors in male animals could result in greater sensitization of the 
remaining receptors and thus aff ect in particular the eff ects of the direct dopamine agonist 
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apomorphine. However, the explanation for the more pronounced apomorphine-induced 
rotation observed specifi cally in male α5-KO mice remains unclear.
6.2.2.  Potential mechanisms and implications of attenuated 
neurodegeneration
Th e dopaminergic neuroprotection observed in α5-KO animals may be linked to their 
reduced striatal DAT function. 6-OHDA is thought to enter dopaminergic neurons in vivo 
through the DAT (Blum et al., 2001), and the reduced DAT function may thus have led to 
attenuated neurotoxicity. Supporting this hypothesis are previous fi ndings in rats, linking 
diff erences in DAT protein levels to the diff erential vulnerability of midbrain dopaminergic 
neuron populations to 6-OHDA (González-Hernández et al., 2004). Notably, acute nAChR 
activation has previously been found to increase dopamine clearance in the striatum and 
DAT cell surface expression in the PFC (Middleton et al., 2004; Zhu et al., 2009), showing 
that nAChR signaling can indeed modulate DAT function. As no genotype diff erence in 
striatal DAT protein levels was found in the present study, the reduced dopamine uptake 
observed in α5-KO animals seems to be mainly the result of reduced DAT activity. DAT 
activity and membrane expression is regulated by phosphorylation (Vaughan et al., 
1997; Morón et al., 2003), and the phosphorylation site T53 has a major role in activity 
modulation (Foster et al., 2012). However, no genotype diff erence in striatal phospho 
(T53)-DAT levels was found, suggesting that the decreased activity was mediated by other 
mechanisms. Finally, DAT measurements were performed only in the striatum. Th us, it 
remains an open question whether also the function of the dopamine transporters localized 
on axon fi bers in the MFB (Ciliax et al., 1995) was reduced and whether this might in part 
explain the lack of neuroprotection in the intra-MFB model.
It should be noted, however, that a number of in vitro studies have not been able to 
demonstrate the DAT-dependence of 6-OHDA cytotoxicity (Blum et al., 2001; Storch et al., 
2004). Another explanation for the attenuated dopaminergic denervation in animals lacking 
α5* nAChRs could be reduced calcium infl ux and consequently reduced oxidative stress. 
Incorporation of the α5 subunit into a nAChR results in increased calcium permeability 
(Tapia et al., 2007), and α5* nAChRs have an essential role in nAChR-mediated calcium 
fl uxes in at least some dopaminergic neurons of the ventral midbrain (Sciaccaluga et al., 
2015). On the other hand, the neurotoxic eff ects of 6-OHDA are suggested to be caused by 
oxidative stress and amplifi ed by cytoplasmic free calcium (Blum et al., 2001). Supporting 
this suggestion is a fi nding of increased striatal intracellular calcium in 6-OHDA-lesioned 
rats (Kumar et al., 1995). Interestingly, cytosolic reactive oxygen species are able to inactivate 
nAChRs, possibly as a protective mechanism against excess calcium infl ux (Campanucci et 
al., 2008; Krishnaswamy and Cooper, 2012). Conversely, this suggests that calcium infl ux 
through nAChRs can indeed be a signifi cant cause of oxidative stress and, thus, that its 
dampening as a result of a lack of α5* nAChRs could have protective consequences.
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It is unclear why a neuroprotective eff ect mediated by either reduced DAT function or 
reduced calcium infl ux would manifest specifi cally in neurons of the SNCM. Diff erent SN 
subdivisions express dopaminergic neurons of various phenotypes; it may be of relevance 
that when compared to dopaminergic neurons of SNCD, a much higher proportion of 
dopaminergic neurons in the mouse SNCM express the calcium-binding protein calbindin 
(Fu et al., 2012), suggesting that they may be more resistant to calcium-linked toxicity. 
Indeed, low calbindin expression has previously been suggested as one explanation for the 
selective vulnerability of SNC dopaminergic neurons in PD (Brichta and Greengard, 2014). 
On the other hand, no diff erence in DAT expression in dopaminergic neurons was found 
between mouse SNCD and SNCM (Fu et al., 2012). It remains to be determined whether 
dopaminergic neurons of the diff erent mouse SNC regions diff er in other aspects of calcium 
signaling or their expression of α5* nAChRs. Note that while the lateral SNC is more 
aff ected than the medial SNC in human PD, both are signifi cantly degenerated (Fearnley 
and Lees, 1991). It is diffi  cult, however, to draw any conclusions on the signifi cance of 
the SNCM-specifi city of the neuroprotection for human PD, given marked diff erences in 
nigrostriatal anatomy between rodents and primates (Joel and Weiner, 2000).
It is notable that calcium-linked oxidative stress in particular, but also the DAT, have been 
suggested to be of major importance in the pathophysiology of human PD. Oxidative 
stress caused by disturbances in intracellular calcium homeostasis has been suggested as 
an important inducer of mitochondrial dysfunction in PD, and the selective vulnerability 
of nigrostriatal dopaminergic neurons has been linked for example to their reliance on 
membrane L-type calcium channels for autonomic pacemaking (Brichta and Greengard, 
2014; Michel et al., 2016). It is quite conceivable that the highly calcium-permeable α5* 
nAChRs could act as one mediator of calcium overload in PD pathogenesis. On the other 
hand, also DAT expression has been suggested to play a role in selective vulnerability. 
DAT expression has been linked to the sensitivity of dopaminergic neurons to various 
neurotoxins in animal models, and also suggested to account for the region-specifi city of 
dopaminergic denervation in human PD (González-Hernández et al., 2004; Storch et al., 
2004). Th us, previous literature supports an argument that the neuroprotection resulting 
from the lack of α5* nAChRs in mice could have clinical signifi cance for the human disease. 
As such, the present results could represent a signifi cant fi nding in the fi eld of dopaminergic 
neuroprotection, suggesting potential for α5* nAChR disruption as a novel avenue for the 
treatment of PD. Further studies are needed to more clearly elucidate the mechanisms 
of the attenuated denervation and motor dysfunction. Such studies could for example 
investigate the eff ects of α5 gene deletion in genetic mouse models of Parkinson’s disease or 
on other measures of parkinsonism than drug-induced rotational behavior. Further studies 
could also investigate the contribution of α5* nAChRs to the neuroprotection and more 
effi  cient functional compensation observed in animals treated chronically with nAChR 
agonists (see 2.4.4.). Agonist-induced chronic desensitization and genetic deletion of α5* 
nAChRs could conceivably have partially similar outcomes, resulting in neuroprotection 
and attenuated motor dysfunction.
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On the other hand, the possibility that the observed neuroprotective eff ect is specifi c 
to the 6-OHDA model must also be acknowledged. Th is may be true particularly if the 
attenuated neurodegeneration was indeed the result of reduced DAT function and 
diminished 6-OHDA uptake. A potentially highly relevant question that follows is whether 
alterations of DAT function have been ruled out in previous studies on nAChR-mediated 
neuroprotection utilizing 6-OHDA models. Moreover, also MPTP exerts its neurotoxicity 
via the DAT (Storch et al., 2004). Given that DAT function can be aff ected both by nAChR 
activation (Middleton et al., 2004; Zhu et al., 2009) and by changes in nAChR subtype 
distribution (present fi ndings), an essential control experiment could be missing from 
much of the literature. It is consoling to note, however, that at least one study has found 
DAT expression and function in the mouse striatum to be mostly resistant to chronic 
nicotine treatment (Marks et al., 2014). Th e neuroprotective eff ects of smoking have also 
been extensively demonstrated in humans (see 2.4.4.), showing that nAChR-mediated 
neuroprotection as a whole is unlikely to be an artefact. Nevertheless, this intriguing and 
somewhat alarming question deserves further study.
Another important question regarding the potential clinical implications of the present 
fi ndings is whether human nigrostriatal neurons express α5* nAChRs. α5 subunit mRNA 
was detected in the monkey SNC (Han et al., 2000) but only weakly in most human 
brain areas, including the SN and the caudate-putamen (Flora et al., 2000). Furthermore, 
in immunoprecipitation experiments no α5 subunit protein was reliably detected in the 
monkey or human striatum (Quik et al., 2005; Gotti et al., 2006). Th us, the present fi ndings 
could be applicable only to rodents. However, it is possible that the α5 antibodies used in 
the mentioned immunoprecipitation experiments were not able to detect some (or any) 
portion of human α5* nAChRs. Advances in antibody design might hopefully enable the 
conducting of additional studies on this issue. Furthermore, the subunit composition 
of nAChRs of the human SNC remains unknown (Zoli et al., 2015), leaving open the 
possibility that α5* nAChRs could be expressed somatodendritically. Finally, the links 
between CHRNA5 gene variants and nicotine addiction (Bierut et al., 2008; Hung et al., 
2008; Th orgeirsson et al., 2008; Weiss et al., 2008) suggest that α5* nAChRs do have an 
important role at least within the mesolimbic dopaminergic pathway of humans.
6.3.  Nico  nic receptors in mouse models of levodopa-induced dys-
kinesia
6.3.1.  Alleviation of moderate but not severe LID by chronic nicotine 
treatment
Th e second main research avenue of the present studies was the further investigation of the 
antidyskinetic eff ects of long-term nicotine treatment, previously described in a number of 
animal models of LID by Quik and colleagues (see 2.4.4.). Data from Study II suggest that 
chronic nicotine treatment in drinking water inhibited the development of LID in mice 
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suff ering from partial dopaminergic denervation. In addition, data from synaptosomal 
[3H]dopamine release experiments suggest that the the antidyskinetic eff ects may have 
been mediated by downregulation of striatal presynaptic α6β2* nAChRs (see 6.3.3.). Th e 
results are in line with the previous preclinical fi ndings and represent the fi rst independent 
replication of the antidyskinetic potential of nicotine published in peer-reviewed form. 
Th us, the present fi ndings give additional support to the hypothesis that long-term nicotine 
treatment may have benefi cial eff ects on dyskinesia associated with the treatment of 
Parkinson’s disease with levodopa. Th e results of a recently fi nished clinical trial studying 
the eff ects of oral nicotine on LID (Lieberman et al., 2018) should, when published, shed 
more light on the implications of these preclinical fi ndings for human PD.
An important question when considering dyskinesia-alleviating eff ects is whether these 
eff ects refl ect a reduction in LID specifi cally. A treatment that reduces the eff ects of 
levodopa generally would inhibit LID but be undesirable due to the simultaneous inhibition 
of benefi cial antiparkinsonian eff ects. In the present studies, the eff ects of the nicotine 
treatment on the antiparkinsonian effi  cacy of levodopa were not investigated. Note, 
however, that a similar nicotine treatment in drinking water increased locomotion and 
striatal dopamine release in mice (Gäddnäs et al., 2001), suggesting that at least a general 
motor-depressant eff ect can be ruled out. Moreover, Quik and colleagues have routinely 
investigated parkinsonism and levodopa’s antiparkinsonian eff ects in their extensive 
studies, and have reported no change by nAChR agonist treatment in any animal model. 
Th is suggests that the LID alleviation seen in nicotine-treated animals is not the result of 
generally reduced levodopa effi  cacy.
In subsequent experiments, the eff ects of chronic nicotine treatment in drinking water 
were studied in mice of the intra-MFB model suff ering from near-total dopaminergic 
denervation (Studies I and III). While statistical analyses of the data show that the nicotine 
treatments did aff ect LID, unlike in Study II clear antidyskinetic eff ects and lower dyskinesia 
scores than in control animals were not observed. On the contrary, in Study III LID may 
have been transiently exacerbated by the nicotine treatment. In Study I the nicotine 
treatment may have reduced LID over time in wild-type animals, but other interpretations 
of the data are also possible.
An arguably very plausible explanation for the lack of similarly robust antidyskinetic effi  cacy 
by nicotine in MFB-lesioned mice is the much more extensive dopaminergic lesion. Th e 
extent of the lesion may be particularly important in determining treatment eff ectiveness 
in the case of drugs (such as nicotine) which aff ect the presynaptic receptors of striatal 
dopamine terminals, as in a severe lesion these receptors are mostly lost. Th e fi nding of no 
clear LID alleviation in near-totally lesioned mice is partially in line with previous rodent 
and monkey studies, where the most severely lesioned animals were typically found to 
be less responsive or even completely unresponsive to antidyskinetic nicotine treatment 
(Huang, Campos, et al., 2011; Huang, Grady, and Quik, 2011; Quik, Campos, and Grady, 
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2013; Quik, Mallela, Chin, McIntosh, et al., 2013). Th ese fi ndings suggest that a partially 
intact nigrostriatal pathway may be required or at least highly conducive for the treatment 
of LID with nicotine. Th e potential treatment of LID with nAChR agonists in PD patients 
could thus lose eff ectiveness as the disease progresses. 
On the other hand, the present fi ndings are also partially in contrast with previous studies, 
where nicotine treatment in drinking water did inhibit LID in severely lesioned mice and 
rats with as little as less than 1 % of striatal dopaminergic innervation remaining (Huang, 
Campos, et al., 2011; Huang, Grady, and Quik, 2011; Quik et al., 2012; Quik, Campos, 
Bordia, et al., 2013; Quik, Campos, and Grady, 2013). Th e reasons for this discrepancy 
are unclear, but note that the methods of lesioning, LID induction, and chronic nicotine 
treatment were similar to the previous mouse studies (Huang, Grady, and Quik, 2011; Quik 
et al., 2012; Quik, Campos, and Grady, 2013). Although nicotine intake was not measured 
on the individual level, average nicotine intake was very similar in both the intrastriatally 
lesioned mice, where an antidyskinetic eff ect was observed, and in the MFB-lesioned mice. 
Moreover, plasma and brain nicotine concentrations during administration in drinking 
water were determined in previous studies at the research site (Pekonen et al., 1993; Pietilä 
et al., 1995; Gäddnäs et al., 2001), and found to reach similar or higher levels than those 
reported in heavy smokers, suffi  cient to induce the nAChR desensitization that is thought 
to underlie LID alleviation (plasma 33–144 ng/ml, brain 243–329 ng/g, depending on the 
time of day). Also note that the sex and exact age of the mice were not reported in the 
previous studies, making comparison on that basis impossible (Huang, Grady, and Quik, 
2011; Quik et al., 2012; Quik, Campos, and Grady, 2013).
Th e timing of antidyskinetic drug administration could also aff ect its effi  cacy. Here, 
attenuation of LID by nicotine was observed when the chronic drug treatments were initiated 
simultaneously, while no clear antidyskinetic eff ects were observed when treating pre-
established LID with nicotine. Previous mouse studies have reported robust antidyskinetic 
eff ects also on pre-established LID (Huang, Grady, and Quik, 2011; Quik et al., 2012; Quik, 
Campos, and Grady, 2013). However, the dose of levodopa used in the present Study III 
(6 mg/kg) was higher than in most of the previous studies, where dyskinesia induced by 6 
mg/kg levodopa was studied (and found to be alleviated by nicotine) only using nicotine 
pretreatment (Huang, Grady, and Quik, 2011). In addition, at least axial LID may have 
been in general more severe in the present studies utilizing MFB lesions than than in 
those of Quik and colleagues. Observations indirectly suggesting this include continuous 
axial dyskinesia replacing most normal behaviors, which would certainly have prevented 
the use of some methods successfully used in the previous studies, primarily the forelimb 
use asymmetry test (Huang, Grady, and Quik, 2011). Direct comparison of LID severity is 
diffi  cult, however, due to the previous studies utilizing their own modifi cation of the LID 
scoring method (Huang, Grady, and Quik, 2011). All in all, it is possible that particularly 
in Study III the combination of a near-total lesion, high levodopa dose, and pre-existing 
sensitization to levodopa resulted in dyskinesia that was too severe and ingrained to yield 
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to attenuation by the nicotine treatment. Th is situation could be comparable to starting 
nicotine treatment in advanced PD associated with a high levodopa dose regime and 
severe LID. Th us, it may turn out to be necessary to begin potential clinical antidyskinetic 
treatments with nAChR agonists as early as possible, perhaps even before signifi cant LID 
has developed.
A notable diff erence between the various present studies was that desipramine pretreatment 
was used to inhibit noradrenergic neurodegeneration only in the studies where clear (Study 
II) or possible (Study I) attenuation of LID was observed. In rats lesioned with intra-
MFB 6-OHDA injections, desipramine pretreatment has resulted in both decreased and 
increased LID (Fulceri et al., 2007; Barnum et al., 2012). Th us, it is unclear what role the 
desipramine pretreatment may have had in the expression of LID in the present studies. 
However, as none of the previous rodent studies on antidyskinetic eff ects of nAChR agonists 
used desipramine (Bordia et al., 2008; Huang, Campos, et al., 2011; Huang, Grady, and 
Quik, 2011; Quik et al., 2012; Quik, Campos, and Grady, 2013), it is unlikely that the lack 
of desipramine pretreatment would fully explain the lack of effi  cacy of nicotine in Study III.
A fi nal potential explanation for the partially diff ering results between the present studies 
utilizing MFB-lesioned mice and the studies of Quik et al. is the use of a diff erent LID 
scoring method. As diff erent dimensions of LID can be diff erentially responsive to drug 
treatment (Sebastianutto et al., 2016), diff erent scoring methods could conceivably result in 
diff erent apparent treatment outcomes. For instance, nicotine might decrease the frequency 
but not amplitude of dyskinesia in severely dyskinetic mice. To investigate this possibility, 
in Study III the number of instances of severe axial dyskinesia per minute was adopted as 
a frequency measurement to complement the mainly amplitude-based scoring criteria for 
axial LID. However, nicotine had no eff ect on this measure, suggesting that this potential 
explanation is also unlikely to account for the negative results.
Notwithstanding the above discussion, it should be stressed that statistical analyses 
show that the nicotine treatments did aff ect LID also in MFB-lesioned mice. Whether 
these eff ects were alleviating or not, an interesting question is the identity of the nAChR 
populations that mediate presumably dopamine-related motor eff ects in conditions of 
near-total nigrostriatal denervation. Note, again, that such eff ects were observed not only 
in the present studies but in a number of previous rodent studies (Huang, Campos, et al., 
2011; Huang, Grady, and Quik, 2011; Quik, Campos, Bordia, et al., 2013). Th us, it appears 
reasonably certain that other nAChR populations than those expressed on nigrostriatal 
neurons of the lesioned hemisphere also contribute to the modulation of LID by nAChR 
ligands. Th e identity of these receptor populations has not so far been directly investigated, 
but they could be potential drug targets in the treatment of LID associated with advanced 
PD. As there is no evidence of nAChRs on striatal MSNs (Quik and Wonnacott, 2011), 
potentially involved receptor populations could include presynaptic nAChRs expressed 
on striatal serotonin or glutamate terminals (Schwartz et al., 1984; Kaiser and Wonnacott, 
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2000; Reuben and Clarke, 2000), both of which are implicated in LID pathophysiology (see 
2.3.2.). As serotonergic terminals are particularly critical for LID, being responsible for the 
non-physiological release of levodopa-derived dopamine, it is unfortunate that very little is 
known about their presynaptic nAChRs. Moreover, any of the diverse nAChR populations 
that are expressed widely across the entire brain could in principle contribute. Some drug 
eff ects might conceivably also be mediated by nigrostriatal nAChRs of the intact brain 
hemisphere, even though LID in the rodent model is predominantly expressed on the 
contralateral side that is controlled by the lesioned hemisphere.
Finally, the contribution of α5* nAChRs to nicotine’s eff ects on LID was investigated in 
Study I. Th e chronic nicotine treatment had diff ering eff ects on LID in wild-type and 
α5-KO mice; more specifi cally, LID appeared to be attenuated over time in wild-type but 
not α5-KO mice, although statistical analyses did not defi nitively confi rm this particular 
interpretation. Nevertheless, the genotype diff erence suggests that α5* nAChRs are 
involved in the modulation of LID by nicotine. Th is would not be entirely surprising, given 
the fi nding of attenuated LID in α5-KO mice that suggests the involvement of α5* nAChRs 
in LID pathophysiology (see above). Th us, the α4β2* nAChRs shown to mediate nicotine’s 
eff ects on LID in mice (Huang, Grady, and Quik, 2011; Quik, Campos, and Grady, 2013) 
could very well include α4α5β2 nAChRs. Again, the presence of a signifi cant eff ect in 
near-totally lesioned animals suggests the involvement of other nAChRs than those on 
dopaminergic neurons. α5-containing nAChRs exhibit altered desensitization kinetics 
(Tapia et al., 2007; Grady et al., 2012), suggesting that the manipulation of α5* nAChRs 
could have particularly signifi cant eff ects on the postulated desensitization-based eff ects 
of nicotine on LID (Bordia et al., 2010; Bordia et al., 2016). α5* nAChRs could, as already 
proposed above, thus be a potential target for more selective antidyskinetic treatments. 
However, additional studies more clearly demonstrating the nature of the α5*-mediated 
pharmacological eff ects on LID are necessary.
6.3.2.  No alleviation of severe LID by α7 nAChR agonist and amantadine 
treatments
In Study III, chronic administration of the selective α7 nAChR partial agonist AZD0328 
had no eff ect on pre-established LID in MFB-lesioned mice. While α7 nAChRs are not 
expressed on striatal dopamine terminals (Salminen et al., 2004), somatodendritic α7 
nAChRs modulate the activity of SNC dopaminergic neurons in rodents (Klink et al., 
2001). Th us, the near-total nigrostriatal denervation could have eliminated potential 
sites of action also in this case. While in primates benefi cial eff ects of α7 agonists on LID 
have been reported also in severely lesioned animals, the loss of striatal innervation was 
not total (Zhang et al., 2015). A too short treatment time or too low dosages are unlikely 
explanations for the lack of effi  cacy. Monkey studies have shown signifi cant eff ects by α7 
agonists already within 1–2 weeks (Di Paolo et al., 2014; Zhang, McGregor, et al., 2014; 
Zhang et al., 2015), and comparable AZD0328 doses were shown in mice to result in various 
behavioral eff ects, changes in dopamine release, and (at the highest dose) maximal brain α7 
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receptor occupancy (Sydserff  et al., 2009; Werkheiser et al., 2011). It is, again, also possible 
that the pre-established LID exhibited in the present studies was in general too severe for 
alleviation by nAChR agonists. However, as no previous studies on selective α7 nAChR 
agonists in dyskinetic rodents have been published, it may also be that α7 agonism is not 
antidyskinetic in the mouse. Although α7-knockout mice exhibit more severe dyskinesia, 
they respond to antidyskinetic nicotine treatment similarly or even better than wild-type 
mice (Quik, Campos, and Grady, 2013). Th us, in mice α7 agonism does not appear to have 
a major role in nicotine’s antidyskinetic eff ect either. Note also that a recent clinical study 
observed no reduction in LID by α7 nAChR agonist treatment (Trenkwalder et al., 2016).
Th e eff ects of acute treatments with amantadine on LID were investigated in an additional 
study. Surprisingly, the treatment of MFB-lesioned mice with amantadine failed to decrease 
LID severity. Th is fi nding is in contrast to previous mouse studies, which have reported 
robust reductions of pre-established LID using similar amantadine and levodopa dosages 
and timing of administration (Lundblad et al., 2005; Bido et al., 2011; Sebastianutto et al., 
2016). Moreover, amantadine consistently prolonged LID duration in the present study, an 
observation not reported previously. Th e prolonging of LID was clear and readily apparent 
at the time of the experiments. Moreover, lower doses of amantadine did not have as clear 
LID-prolonging eff ects, suggesting a dose-response relationship. While amantadine’s 
targets are numerous and its mechanisms of action are not completely understood (Bido 
et al., 2011), interestingly it is an antagonist of both α7 and β2* nAChRs (Albuquerque et 
al., 1998). Th us, the antidyskinetic eff ects of amantadine could conceivably be mediated by 
nAChRs on dopaminergic neurons and be lost in conditions of near-total dopaminergic 
denervation. On the other hand, a previous study reported eff ective alleviation of LID 
by amantadine also in MFB-lesioned mice, although biochemical characterization of the 
lesions was not carried out (Sebastianutto et al., 2016). All in all, the unusual behavioral 
eff ects of the known antidyskinetic drug amantadine suggest that the unresponsiveness to 
antidyskinetic drug treatment observed in the severely dyskinetic MFB-lesioned mice may 
have been more general instead of specifi c to nAChR agonists. Care should be taken in 
future studies to investigate potential antidyskinetic drugs using diff erent severity stages of 
dopaminergic denervation and LID. Eff ects may be blunted or even paradoxical in severe 
conditions, and treatments potentially useful in earlier disease could be unnecessarily 
discarded.
6.3.3.  Effects of antidyskinetic nicotine treatment on striatal dopamine 
release
Th e eff ects of 6-OHDA lesioning and chronic nicotine treatment on striatal dopamine 
release were investigated in Study II by measuring both basal and nicotine-stimulated 
release of [3H]dopamine from synaptosomes. α6β2* and α4(non-α6)β2* nAChRs may 
diff erentially regulate dopamine release in the dorsal and ventral striatum (Exley et al., 
2012), and are diff erentially aff ected by nigrostriatal denervation (Bordia et al., 2007) 
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and chronic nicotine treatment (Lai et al., 2005; Marks et al., 2014). Th erefore, the dorsal 
and ventral striatum were studied separately, and α6β2*-mediated and α4(non-α6)β2*-
mediated release was separated using CtxMII.
Interestingly, no diff erence was found in the proportions of [3H]dopamine release mediated 
by α6β2* versus α4(non-α6)β2* nAChRs, in contrast to voltammetry studies in mouse 
brain slices (Exley et al., 2012) but in line with previous synaptosomal release studies 
(Grady et al., 2002; Salminen et al., 2007). Note that the synaptosome technique uses 
continuous superfusion that is thought to largely abolish indirect eff ects mediated by the 
release of other neurotransmitters. Th ese studies thus strongly suggest that such indirect 
eff ects signifi cantly contribute to nAChR-mediated regulation of dopamine release. Th e 
nigrostriatal 6-OHDA lesion had no eff ect on nAChR-mediated [3H]dopamine release 
when normalized to basal release, suggesting that despite the signifi cant loss of dopamine 
terminals the remaining presynaptic nAChRs functioned with normal effi  ciency. Non-
normalized basal release was reduced by the lesion, as expected. Th e lesion also did not 
change the relative contribution of α6β2* and α4(non-α6)β2* nAChRs to [3H]dopamine 
release, largely in line with a previous voltammetric study in rats (Perez et al., 2010). 
Ligand binding studies have shown a preferential loss of α6β2* nAChRs aft er dopaminergic 
denervation (Bordia et al., 2007; Perez et al., 2010), but this likely refl ects their preferential 
expression on dopamine terminals in the striatum.
In animals treated chronically with levodopa and either nicotine or vehicle, a partial 
recovery of basal [3H]dopamine release in the lesioned dorsal striatum was observed 
irrespective of treatment group, possibly representing spontaneous recovery as reported in 
some previous mouse studies (Stanic et al., 2003; Bez et al., 2016). Note, however, possible 
confounding eff ects by the diff erent sex distribution in the related experimental groups. 
Intriguingly, the chronic nicotine treatment appeared to restore basal [3H]dopamine release 
in the lesioned ventral striatum up to intact levels. Although neurorestoration by post-lesion 
nicotine treatment has been observed in some studies (Janson, Fuxe, Agnati, et al., 1988; 
Fuxe et al., 1990; Janson and Møller, 1993), most studies reporting neuroprotective eff ects 
have included a pretreatment period (see Table 2), and a study directly comparing pre- and 
post-treatments found no neurorestoration (Huang et al., 2009). Th us, the present result 
may represent functional compensation rather than a regrowth of dopamine terminals.
While the chronic nicotine treatment had no eff ect on α4(non-α6)β2*-mediated [3H]
dopamine release, α6β2*-mediated release was signifi cantly reduced in nicotine-treated 
animals in the lesioned dorsal striatum and in both the intact and lesioned ventral 
striatum. Th e reduction in α6β2*-mediated release could refl ect downregulation and/or 
desensitization. A number of previous fi ndings in mice suggest that downregulation is the 
more likely explanation. Previous synaptosome studies utilizing the same technique suggest 
that nAChRs would have mostly recovered from any acute desensitization by the time of 
measurement (Grady et al., 1994; Grady et al., 2012). Furthermore, previous studies have 
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reported α6β2* downregulation in the mouse striatum aft er chronic nicotine treatment 
(Lai et al., 2005; Marks et al., 2014). Moreover, antidyskinetic chronic nicotine treatment 
was associated with α6β2* downregulation also in rats (Bordia et al., 2010; Bordia et al., 
2013). Although in the former study this was observed only in the unlesioned hemisphere, 
α6β2* nAChR levels of the lesioned hemisphere were so low that diff erences in expression 
may have been impossible to detect. Note also that in these studies α4(non-α6)β2* nAChRs 
were upregulated or unchanged and in general found to be less sensitive to regulation, in 
line with the present results (Lai et al., 2005; Bordia et al., 2010; Bordia et al., 2013; Marks 
et al., 2014).
Th e present fi nding of reduced α6β2*-mediated release is also in line with further rodent 
fi ndings suggesting that α6* nAChRs have a signifi cant role in the antidyskinetic eff ects 
of nicotine (Quik et al., 2012) and that the eff ects are mediated by downregulation or 
desensitization of striatal presynaptic nAChRs and dampening of dopaminergic activity 
(Bordia et al., 2010; Bordia et al., 2013). Th us, the present results further support a role 
for α6β2* nAChRs as an important mediator of dyskinesia-alleviating eff ects of nAChR 
agonists and as a possible drug target in the treatment of LID. Notably, within the basal 
ganglia α6β2* nAChRs are selectively expressed on dopaminergic neurons across species 
(Quik, Sum, et al., 2003; Quik et al., 2005; Gotti et al., 2006), suggesting that they may 
hold promise for more selective targeting than can be achieved with non-selective drugs 
such as nicotine. However, selective targeting of specifi cally striatal α6* nAChRs could be 
complicated by their expression also outside of the basal ganglia (Le Novere et al., 1996). 
Furthermore, the expression of α3/α6* nAChRs is more widespread in the human than the 
rodent or monkey brain (Quik et al., 2004; Bohr et al., 2005), although it is unclear what 
proportion of those consist specifi cally of α6* nAChRs. 
In contrast to the present study, a previous study in rats found that antidyskinetic 
nicotine treatment was associated with a decrease also in α4(non-α6)β2*-mediated [3H]
dopamine release from striatal synaptosomes (Bordia et al., 2013). Th e explanation for the 
discrepancy is unclear, but could be the result of a diff erent species or a diff erent lesion 
model (intrastriatal vs. intra-MFB 6-OHDA). Note also that unlike in the previous study, 
in the present study nicotine-stimulated dopamine release was normalized to basal release 
to investigate the functioning of remaining nAChRs independently of the release-reducing 
eff ects of the lesion. Th e previous result of decreased α4(non-α6)β2*-mediated dopamine 
release is also diffi  cult to reconcile with the simultaneously observed upregulation of the 
same nAChR subtype (Bordia et al., 2013), perhaps suggesting that upregulation could there 
have selectively aff ected nAChRs not located on dopamine terminals or that desensitization 
kinetics in the synaptosome assay (see above) could be diff erent in rats than in mice.
Studies in α4-KO mice do suggest that nicotine’s antidyskinetic eff ects are mediated also 
by α4* nAChRs (Quik, Campos, and Grady, 2013). Presynaptic α4α6β2β3 nAChRs are 
particularly sensitive to nicotine (Salminen et al., 2007), are suggested to be important 
Discussion
93
mediators of the antidyskinetic eff ects (Quik, Campos, and Grady, 2013), and are blocked 
by CtxMII. Th e loss of antidyskinetic eff ects by nicotine in α4-KO mice could thus be 
explained by the loss of this specifi c nAChR subtype, while its downregulation would not 
aff ect α4(non-α6)β2*-mediated [3H]dopamine release. Both the present and the previous 
results in mice are therefore fully compatible with the hypothesis of α4α6β2β3 nAChRs as 
a critical mediator of LID alleviation. Alternatively, it should be noted that α4(non-α6)β2* 
nAChRs are the most widely expressed nAChR subtype (Millar and Gotti, 2009). It is thus 
very possible that other α4* nAChR populations and/or mechanisms than those related 
to striatal dopamine release would contribute to the antidyskinetic eff ects of nicotine 
– particularly when again considering the antidyskinetic eff ects previously observed in 
rodents suff ering from practically total nigrostriatal denervation (see 6.3.1. above).
6.3.4.  Effects of levodopa and nicotine treatments on BDNF
LID is associated with aberrant synaptic plasticity (Picconi et al., 2003; Th iele et al., 2014; 
see 2.3.2.). Th e BDNF, as an important regulator of plasticity (Bramham and Messaoudi, 
2005), may be involved. In particular, levodopa treatment has been suggested to result in 
elevated BDNF in corticostriatal neurons and increased striatal BDNF release (Guillin et 
al., 2001). Th e increased striatal BDNF levels may then lead to such phenomena as D3R 
overexpression (Guillin et al., 2001) or serotonergic hyperinnervation (Rylander et al., 
2010; Tronci et al., 2017). To further investigate the association of BDNF and LID, BDNF 
protein levels were measured from the striatum and the PFC of the mice of Study III that 
were treated chronically with levodopa and either nicotine or vehicle. 
BDNF protein levels in the lesioned striatum and LID severity were positively correlated, 
similar to a previously reported correlation between striatal Bdnf mRNA and LID severity 
in rats (Rylander et al., 2010). Th e observed correlation further supports a role for BDNF in 
LID pathophysiology, demonstrating that the previously reported mRNA level correlation 
is present also when measuring the protein, a relationship which is not always predictable in 
the case of BDNF (McAllister et al., 1999). However, no diff erences in BDNF protein levels 
between the intact and lesioned hemispheres were observed, in contrast to earlier fi ndings 
on Bdnf mRNA in rats (Guillin et al., 2001; Rylander et al., 2010). Th us, the present fi ndings 
do not directly support the hypothesis of Guillin et al. (2001) that LID is caused by a 
levodopa-induced elevation of corticostriatal BDNF that is further enhanced in conditions 
of dopaminergic denervation. However, the contrasting results could be explained by the 
considerably longer duration of levodopa treatment (months vs. days/weeks). Th e elevated 
corticostriatal BDNF could be related to the early phase of sensitization to levodopa in 
the lesioned hemisphere and thus be undetectable aft er a longer treatment. Note also that 
while striatal BDNF protein is mainly derived from corticostriatal glutamatergic aff erents, 
nigrostriatal dopamine terminals do represent a minor source of striatal BDNF (Altar et al., 
1997). Unlike in the present study, a near-total depletion of striatal dopamine in 6-OHDA-
lesioned rats was associated with a modest (14 %) decrease in striatal BDNF protein levels 
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(Altar et al., 1997). While the reason for this discrepancy is unclear, opposite changes in 
striatal BDNF by the nigrostriatal lesion and the levodopa treatment may in principle have 
occurred.
In the present study, chronic nicotine treatment had no eff ect on striatal BDNF levels, in line 
with a previous study on long-term nicotine administration in drinking water (Kivinummi 
et al., 2011). Other studies have, however, reported both increases and decreases in striatal 
BDNF aft er chronic nicotine administration via various routes (Yeom et al., 2005; Correll 
et al., 2009; Ortega et al., 2013). In the present study, the nicotine treatment signifi cantly 
decreased BDNF levels in the PFC, similarly as in a previous study on rat frontal cortex 
utilizing repeated nicotine injections (Brown et al., 2006). While the previous study 
suggested that the nicotine-induced BDNF decrease was related to a withdrawal stress 
response, the present study included no withdrawal period, making this explanation 
unlikely. Note also a contrasting report of a nicotine-induced increase in cortical BDNF in 
another rat study (Czubak et al., 2009). All in all, eff ects of chronic nicotine treatment on 
BDNF appear highly variable. It is also unclear whether the nicotine-induced decrease in 
BDNF levels in the PFC was related to the changes in LID observed in the present studies. 
Mice in each study were treated with similar nicotine administration regimes and showed 
a similar average daily nicotine intake, but as the eff ects on LID varied from study to study, 
clear conclusions cannot be drawn.
Finally, it should be noted that contrary to rodent studies, in primates lesioned bilaterally 
with MPTP no diff erence in striatal BDNF protein levels between dyskinetic and non-
dyskinetic animals was found aft er four weeks of levodopa treatment, and striatal BDNF 
protein levels were decreased when compared to saline-treated animals (Samadi et al., 
2010). Similarly, PD patients carrying a genetic polymorphism associated with lower 
activity-dependent secretion of BDNF were found to be at higher risk of early development 
of LID (Foltynie et al., 2009; Kusters et al., 2018). In primates, it could thus in fact be 
decreased levels of BDNF that lead to impaired plasticity and development of dyskinesia.
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7.  Summary and conclusions
In this thesis, the role of neuronal nicotinic acetylcholine receptors in mouse models of 
Parkinson’s disease and levodopa-induced dyskinesia was investigated. Th e main fi ndings 
and conclusions of the studies can be summarized as follows:
1. Hemiparkinsonian mice lacking α5* nAChRs showed attenuated dopaminergic 
neurodegeneration in the medial substantia nigra, attenuated amphetamine-induced 
rotational behavior, and less severe LID. Reduced dopamine transporter activity was 
observed in intact α5-knockout mice. Th ese fi ndings may be of signifi cant relevance to 
human Parkinson’s disease, and the potential of α5* nAChRs as a novel drug target for 
the treatment of the disease warrants further study. Th e fi ndings also more generally 
support the signifi cant involvement of nAChRs in Parkinson’s disease and their drug 
target potential.
2. LID was reduced by chronic nicotine treatment in drinking water in hemiparkinsonian 
mice suff ering from partial dopaminergic denervation. Th is fi nding supports a role 
for nAChRs as drug targets for alleviating dyskinesia associated with the treatment 
of Parkinson’s disease with levodopa. However, severe LID in hemiparkinsonian mice 
suff ering from near-total dopaminergic denervation was not alleviated by treatment 
with nAChR agonists. Th ese fi ndings suggest that a partially intact nigrostriatal 
pathway may be essential for optimal nAChR-mediated antidyskinetic effi  cacy. 
Potential clinical treatment of LID with nAChR agonists may thus lose its eff ectiveness 
as the disease progresses.
3. Synaptosomal dopamine release experiments suggest that in conditions of partial 
denervation, dampening of dopaminergic activity via downregulation of striatal 
presynaptic α6β2* nAChRs may have a signifi cant role in mediating the antidyskinetic 
eff ects of chronic nicotine treatment. In particular, presynaptic α4α6β2β3 nAChRs 
could be an important mediator and a possible drug target for clinical applications. α5* 
nAChRs may also be involved in nicotine’s eff ects on LID.
4. BDNF protein levels of the lesioned striatum were correlated with LID severity, 
confi rming previous results measuring Bdnf mRNA and representing further evidence 
for a link between BDNF and LID. A levodopa-induced elevation in corticostriatal 
BDNF of the lesioned hemisphere, reported in previous short-term studies, was not 
observed aft er a long-term levodopa treatment. Th e previously reported elevation may 
thus refl ect early sensitization.
5. Th e methods of stereotactic surgery and postoperative care were signifi cantly improved. 
Intensive postoperative care was found to increase wellbeing and dramatically reduce 
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